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patient education models for adults with Type 2
diabetes.
Data sources: Electronic databases were searched
from 2002 to January 2007.
Review methods: A systematic review of the
literature on educational interventions in diabetes was
undertaken. This was an update of a previous
systematic review.
Results: Including studies identified in the previous
systematic review, there were 13 published studies.
Eight studies of education on multiple aspects of
diabetes self-management were identified that provided
education that was focused on a particular aspect of
self-management. The quality of reporting and
methodology of the studies was variable. Studies of
multi-component educational interventions yielded
mixed results. Some trials reported significant
improvements on measures of diabetic control but
others did not. Positive effects may be attributable to
longer-term interventions with a shorter duration
between the end of the intervention and the follow-up
evaluation point. There may also be an effect of having
a multi-professional team delivering the educational
programme. Studies of focused educational
interventions did not yield consistent results. Some
effects were shown on measures of diabetic control in
studies that focused on diet or exercise alone. Although
the effects shown were generally small, those that
were present did appear to be relatively long-lasting.
This update review does not substantially alter the
conclusions of the previous systematic review; for each
outcome, the proportion of studies that demonstrated
significant effects of education was similar.
Conclusions: Based on the evidence, it would seem
that education delivered by a team of educators, with
some degree of reinforcement of that education made
at additional points of contact, may provide the best
opportunity for improvements in patient outcomes.
Educators need to have time and resources to fulfil the
needs of any structured educational programme. There
is also a need for education to have a clear programme
at the outset. From the evidence reported it is unclear
what resources would need to be directed at the
educators themselves to ensure that they can deliver
programmes successfully. Any future research should
consider patient education within the context of overall
diabetes care and as such follow guidelines for the
development and evaluation of complex interventions.
Good-quality, longer-term studies would be desirable,
but these would require careful consideration around
the nature of any control group. Information is needed
to clarify the sensitivity of diabetes education
programmes to the performance of the diabetes
educators, in order to ensure success and cost-
effectiveness of education programmes.
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Background
Diabetes is a chronic and progressive disorder that
has an impact on almost every aspect of life. 
Type 2 diabetes is characterised by insulin
resistance and relative insulin deficiency. It is
commonly linked to being overweight or obese,
and to physical inactivity. Type 2 diabetes
primarily affects people over the age of 40 years
and is becoming more common. 
The basic targets in the treatment of diabetes are
the normalisation of blood glucose levels, blood
pressure control and lipid management, and
studies have shown that good diabetic control is
associated with a significant reduction in the risk
of a number of complications. Control of diabetes
is affected by both lifestyle factors and by
pharmacological treatments and the management
of diabetes is largely the responsibility of those
affected. Supporting self-care is a crucial aspect of
any diabetes service, and national guidance
recommends structured education as fundamental
to this. 
The aim of patient education is to empower
patients by improving knowledge, skills and
confidence, enabling them to take increasing
control of their condition. Structured educational
programmes for diabetes self-management are
often multifaceted interventions providing
information and also management skills around
diet, exercise, self-monitoring and medication use. 
This review is an update of a previous systematic
review which concluded that the diversity of the
educational programmes for Type 2 diabetes did
not yield consistent results. Some of the included
trials reported significant improvements in
metabolic control and/or quality of life or other
psychological outcomes; however, many others did
not report significant effects of educational
interventions.
Objective
The objective was to examine the clinical
effectiveness of patient-education models for
adults with Type 2 diabetes.
Methods
A systematic review of the literature on educational
methods in diabetes was undertaken. This was an
update of a previous systematic review.
Data sources
Electronic databases (including Cochrane Library,
MEDLINE, PsychINFO) were searched from 2002
to January 2007. Bibliographies of included
studies and related papers were checked for
relevant studies. Experts were contacted for advice
and peer review, and to identify additional studies. 
Study selection
A total of 1696 titles and abstracts were screened
for eligibility by one reviewer and checked by a
second. Inclusion criteria were applied to the full
text of selected papers by two reviewers, with
differences resolved through discussion. Studies
were included if they fulfilled the following criteria:
● Interventions: educational interventions
compared with usual care or another
educational intervention.
● Participants: adults with Type 2 diabetes mellitus.
● Outcomes: must report glycated haemoglobin,
hypoglycaemic episodes, diabetic complications,
or quality of life. Other reported outcomes from
included studies were discussed.
● Evaluation of outcomes 12 months from
inception of intervention.
● Design: randomised controlled trials (RCTs)
and controlled clinical trials (CCTs) with a
concurrent control were included.
● Reporting: studies were only included if they
reported sufficient detail of the intervention to
be reproducible (e.g. topics covered, who
provided the education, how many sessions
were available).
Studies in non-English languages or available only
as abstracts were excluded.
Data extraction and quality assessment
Data extraction and quality assessment were
undertaken by one reviewer and checked by a
second, with differences resolved through
discussion. The quality of included studies was
assessed using criteria set by the NHS Centre for
Reviews and Dissemination.
Executive summaryx
Data synthesis
The clinical effectiveness data were synthesised
through a narrative review with full tabulation of
results. Meta-analysis was not undertaken due to
differences in study populations and comparators.
Results
Number and quality of studies 
Including studies identified in the previous
systematic review, 13 published studies (11 RCTs,
two CCTs) were identified that provided education
on multiple aspects of diabetes self-management
and eight studies (seven RCTs, one CCT) were
identified that provided education that was
focused on a particular aspect of self-management.
The quality of reporting and methodology of the
studies was variable.
Summary of benefits
Studies of multi-component educational
interventions yielded mixed results. Some trials
reported significant improvements on measures of
diabetic control but others did not. Positive effects
may be attributable to longer-term interventions
with a shorter duration between the end of the
intervention and the follow-up evaluation point.
There may also be an effect of having a multi-
professional team delivering the educational
programme. 
Studies of focused educational interventions did
not yield consistent results. Some effects were
shown on measures of diabetic control in studies
that focused on diet or exercise alone. Although
the effects shown were generally small, those that
were present did appear to be relatively long-
lasting. This update review does not substantially
alter the conclusions of the previous systematic
review; for each outcome, the proportion of
studies that demonstrated significant effects of
education was similar.
Discussion
Overall, the results of educational interventions
aimed at patients with Type 2 diabetes are difficult
to interpret due to differences in the interventions,
the populations, the study designs and the
outcomes reported. There is little evidence to
suggest whether and how educational programmes
might currently be directed to achieve maximal
benefit for patients with Type 2 diabetes. Multi-
component educational interventions appear to
have better effects on outcomes than those focused
on particular aspects of diabetes self-care alone,
and this is currently reflected in national guidance
for diabetes education. 
There are a number of issues around the
complexity of the intervention, the possibility of
confounding, and methodological issues around
study designs which need to be taken into account
in any interpretation of the results of this review. 
The review has a number of strengths which
should minimise bias: a research protocol defined
the research question and the inclusion criteria;
consistent methods of critical appraisal were
applied; and the work was informed by an
advisory group. Limitations of the review are that,
owing to time and resource restrictions, authors of
trials were not contacted for further information.
Also, perhaps due to publishing word length limits
in the primary literature, details of some trials
were not reported. It is unlikely, however, that
these limitations would have made a difference to
the overall results of the review. 
Conclusions
Implications for service provision 
Based on the evidence reviewed in this report, it
would seem that education delivered by a team of
educators, with some degree of reinforcement of
that education made at additional points of
contact, may provide the best opportunity for
improvements in patient outcomes. Educators need
to have time and resources to fulfil the needs of
any structured educational programme. There is
also a need for education to have a clear
programme at the outset. From the evidence
reported it is unclear what resources would need to
be directed at the educators themselves to ensure
that they can deliver programmes successfully. 
Recommendations for further research 
Any future research should consider patient
education within the context of overall diabetes
care and as such follow guidelines for the
development and evaluation of complex
interventions. Good-quality, longer-term studies
would be desirable but these would require careful
consideration around the nature of any control
group. Information is needed to clarify the
sensitivity of diabetes education programmes to
the performance of the diabetes educators, in
order to ensure success and cost-effectiveness of
education programmes. 
Executive summaryT
his research updates a previous systematic
review of structured education for diabetes. It
was commissioned to inform the National Institute
for Health and Clinical Excellence (NICE) Type 2
diabetes guideline update. 
The aim of the study is to provide a review of the
clinical effectiveness of current models of diabetes
self-management education.
The potential clinical benefit of an effective
programme of education would be better self-
management. This may be measured in the long
term by a reduced level of diabetes-related
complications and in the short term by
maintenance of recommended levels of blood
glucose (BG) control, as reflected by glycated
haemoglobin (GHb) levels. Other potential
benefits would be greater flexibility of lifestyle and
hence better quality of life (QoL).
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Chapter 1
Aim of the reviewDescription of underlying health
problem
Diabetes mellitus (diabetes) is a state of chronic
hyperglycaemia (raised blood sugar), due to an
absolute or relative deficiency of insulin, a
hormone for metabolism.
There are two main types of diabetes that are
distinguished by their pathological mechanisms:
● Type 1: Type 1 diabetes is a condition in which
most or all of the insulin-producing cells in the
pancreas have been destroyed, usually due to an
auto-immune process. Patients with Type 1
diabetes are ‘insulin dependent’ and need
insulin for survival; it was formerly called
insulin-dependent diabetes (IDDM).1 Type 1
diabetes will not be addressed in this report.
● Type 2: Type 2 diabetes is caused by a defect in
the way the body responds to insulin – insulin
resistance – or by a relative reduction in insulin
production, or a combination of both. The
pancreas may initially produce more insulin
than normal in order to overcome the insulin
resistance, but over time the production may
fail. This type of diabetes was formerly called
‘non-insulin-dependent’ diabetes (NIDDM).1
Other types of diabetes, including gestational
diabetes and less common types such as maturity
onset diabetes of the young, will not be addressed
in this report. Diabetes can also be secondary to
other diseases such as pancreatitis or other
endocrine disorders.
The symptoms of diabetes can include increased
thirst, increased urination, extreme tiredness,
weight loss, genital itching and blurred vision.
However, Type 2 diabetes may also be symptomless.
Complications
The adverse effects of diabetes have traditionally
been known as ‘complications’, although this term
usually refers to effects that appear over the
longer term. The effects fall into three main
groups – acute metabolic upsets such as
ketoacidosis or hypoglycaemia; microvascular
disorders specific to diabetes; and an increased
risk of large vessel disease such as heart disease.
Ketoacidosis
Without adequate supplies of insulin the body
cannot use glucose effectively, and may break
down fat and muscle for energy in an inefficient
way, leading to acidosis, a disturbance of the
acid–base balance. Ketoacidosis requires prompt
hospital treatment, and can result in coma and
occasionally death; however, this is relatively
uncommon in Type 2 diabetes.2
Hypoglycaemia
Hypoglycaemia means that the BG has fallen too
low. This is chiefly caused by the inadequacy of
current methods of insulin delivery, but can also
be due to too high a dose of oral hypoglycaemic
agents (OHAs), inadequate food intake or sudden
or sustained exercise, or it can occur without any
apparent cause. It is not seen in patients
controlled by diet alone and rates in Type 2
diabetes are substantially lower than in Type 1
diabetes.3 Falling glucose concentrations cause an
array of symptoms, which include shakiness,
sweating and irritability. If not corrected by food
or sugary drinks, these can progress to confusion,
faintness, headache and disturbances of vision.
Hypoglycaemia can cause loss of consciousness
and convulsions if corrective steps are not taken.3
More long-term or ‘late’ complications from
persistently raised BG levels include damage to
large and small blood vessels and nerves.
Microvascular
Damage to small blood vessels (microangiopathy)
can affect the eyes (diabetic retinopathy), kidneys
(nephropathy) and nerves (neuropathy).4 Diabetes
is the single most common cause of blindness
among adults aged 16–64 years.5 Nephropathy
may develop in 20–25% of people with diabetes
and may progress to kidney failure.5 The principal
forms of neuropathy are sensorimotor peripheral
neuropathy and autonomic neuropathy. 
Macrovascular
Damage to large blood vessels (macroangiopathy)
can lead to ischaemic heart disease,
cerebrovascular disease, intermittent claudication,
or gangrene of the feet. Patients with diabetes
have a two- to three-fold higher risk of coronary
heart disease in men and a four- to five-fold
Health Technology Assessment 2008; Vol. 12: No. 9
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Chapter 2
Backgroundincreased risk in premenopausal women.5 Stroke
risk is increased two- to three-fold.5
People with diabetes are prone to foot ulceration
and gangrene of the lower limb (which can result
in amputation).6 Other complications can affect
the skin, joints and tendons, gastrointestinal tract,
and sexual function.
Mortality is higher in people with diabetes than in
people of similar age and sex, although diabetes is
not usually recorded as the cause of death.
Therefore, the contribution of diabetes to
mortality is likely to be four to five times greater
than reported in routine mortality statistics.7
The main cause of death in diabetes is heart
disease.8–10
Management
The three main goals in the treatment of diabetes
are the normalisation of BG levels, blood pressure
control, and lipid management. There is good
evidence to show that tight control of BG and
blood pressure (BP) can prevent or delay diabetic
complications [as reported in the United Kingdom
Prospective Diabetes Study (UKPDS)11 and the
Diabetes Control and Complications Trial
(DCCT)12]. Blood glucose levels can be controlled
by diet, oral hypoglycaemic drugs and/or insulin
injections.
One of the features of diabetes care is that it aims
to empower the patient to take charge of the
disease. This is because of the chronic nature of
diabetes and the relation between BG and factors
such as diet and exercise (i.e. lifestyle). People with
diabetes must monitor BG levels, either directly or
via urine testing, take appropriate medication
and/or insulin, eat a healthy diet aimed at both
minimising BG levels and reducing future heart
disease risk, engage in activity or exercise to
maintain a healthy weight and to improve insulin
sensitivity, and avoid smoking.
Diet plays a major role in the management of
diabetes. Patients are advised to have a high-
carbohydrate, high-‘viscous’-fibre, low-fat and, if
overweight, low-calorie diet. This kind of diet is
difficult for patients to maintain. Attention to
factors such as how rapidly different foods are
metabolised (as reflected in the ‘glycaemic index’
of how rapidly BG levels rise after eating) can also
help, but adds another complexity to the diet. 
Exercise also plays an important part in diabetes
management. Exercise helps overweight patients
with Type 2 diabetes to bring their weight under
control. Regular exercise can improve glycaemic
(and BP) control. 
OHAs are often prescribed in Type 2 diabetes.
Sulfonylureas sensitise the insulin-secreting cells
and may upregulate insulin receptors and increase
their number.1 Metformin reduces BG
predominantly by improved regulation of hepatic
glucose production, which shows little dependence
on the residual effectiveness of insulin-secreting
cells.1 Metformin is commonly prescribed as the
first-line treatment of choice.13,14 Other oral
agents, such as the glitazone drugs, are available
and are used as an adjunct to sulfonylureas and
metformin. Sometimes, insulin and metformin are
used in combination (e.g. for obese patients).
Insulin therapies and regimens vary. Depending
on the goals of therapy, the frequency of insulin
dosing can vary. Recent evidence that tight control
of blood glucose levels can prevent or delay
serious complications has led to regimens that
involve more complex patterns of daily insulin
treatment. 
Incidence and prevalence
Diabetes is one of the most common chronic
disorders, but estimates of incidence and
prevalence vary. It has been estimated that over
two million people in the UK today have
diagnosed diabetes and a further 750,000 have
diabetes without knowing it.15 More than one-fifth
of older white British citizens have either
undiagnosed Type 2 diabetes or impaired fasting
glucose.16 Cases of Type 2 diabetes are much more
common than those of Type 1 and estimates
suggest that 85–95% of people with diabetes have
Type 2.15 The number of patients with diagnosed
diabetes has been increasing significantly in recent
years in the UK and worldwide. Between 1994 and
2001, the prevalence of Type 2 diabetes in the UK
increased, on average, by 0.11% per annum in the
male population and by 0.09% per annum in the
female population, with signs that the rate of
increase is rising (Figure 1).17
Based on these data17 and assuming a constant
rate of increase since 1994, approximately 3.5% of
the male population and 3% of the female
population would be expected to have Type 2
diabetes in the UK by 2008. This would equate
(using a population projection from the Office of
National Statistics) to over 1.63 million people
with Type 2 diabetes in England in 2008.17 It has
been estimated that the number of people in the
UK with diabetes will reach 3 million by 2010.19
Rising levels of obesity and an ageing population
Background
4are thought to be largely responsible, although
changes in the definition of diabetes may have
had some effect.17
Table 1 demonstrates the prevalence of insulin- and
non-insulin-treated diabetes per 1000 patients in
1998. It is important to note that insulin-treated
patients are likely to be a mix of patients with 
Type 1 diabetes and patients with Type 2 diabetes.
Table 2 presents data on the prevalence of Type 2
diabetes reported by family practices in the UK in
2001 by age and gender from the study by 
de Lusignan and colleagues.17 Type 2 diabetes
primarily affects people over age 40 years as seen
in Table 2, although increasingly it is appearing in
young people and young adults.20–22 Type 2
diabetes tends to have a more gradual onset than
Type 1 diabetes and may be found incidentally, for
example at routine health checks.5
Risk factors for Type 2 diabetes include being
overweight, having a close relative with diabetes,
or having gestational diabetes during pregnancy.
It is more common in some ethnic groups,
particularly Asians. 
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FIGURE 1 Prevalence of Type 2 diabetes in the UK, 1962–2001, based on records from general practices. Data from Harvey and
colleagues18 and de Lusignan and colleagues.17 Note that in the study by de Lusignan and colleagues,17 the age-standardised prevalence
rates were almost identical with the crude overall prevalence rates.
TABLE 1 Prevalence of insulin- and non-insulin-treated diabetes per 1000 patients
Age (years)
0–4 5–15 16–24 25–34 35–44 45–54 55–64 65–74 75–84 85+
Prevalence of insulin-treated diabetes per 1000 patients, by age and gender in 1998
Males
Rate/1000 0.2 1.7 3.5 4.6 6.2 7.2 10.0 13.3 10.9 6.8
Females
Rate/1000 0.3 1.9 3.2 4.3 5.2 5.7 9.4 12.1 9.4 5.9
Prevalence of non-insulin-treated diabetes per 1000 patients, by age and gender in 1998 
Males
Rate/1000 0 0 0.2 0.6 3.6 11.8 30.5 47.5 47.4 43.1
Females
Rate/1000 0 0 0.2 0.6 2.8 7.9 20.3 35.7 37.1 33.8
Source: Office for National Statistics.Type 2 diabetes is more common in men than
women (Figure 1, Table 2). Diabetes seems to
remove women’s natural protection against heart
disease and stroke before the menopause.20 In a
population-based study in Finland (1986–8) in
women aged 65–74 years, the age-adjusted
prevalence of ischaemic heart disease was 65.9% in
those with Type 2 diabetes compared with 39.7%
in the non-diabetic population.23
Diabetes is three to five times more common
among people of African-Caribbean and Asian
origin living in the UK.24 Diabetes in these groups
tends to develop at a younger age and may be
related to different underlying mechanisms.25
Type 2 diabetes is more prevalent among less
affluent populations. Those in the most deprived
one-fifth of the population are 1.5 times more
likely than average to have diabetes at any given
age.20 Prevalence of diabetes overall (Type 1 and
2) in England varies both with household income
(higher prevalence with lower household income)
and geographical location (lower prevalence in
northern England).26
Education
The goals of management for patients with
diabetes include optimisation of BG control,
prevention of immediate complications, and
prevention of long-term complications (by good
BP management and lipid control).27 All of the
treatment factors, diet, medication, and exercise,
must be carefully managed on a daily basis by
patients themselves. Patients must also be able to
recognise when they need professional help. Good
self-management depends on initial education
about the interaction of all the treatment factors
and ongoing support and reinforcement. 
Education of patients with diabetes is considered a
fundamental aspect of diabetes care.28 Because
patients are responsible for the day-to-day control
of their diabetes, it is critical that patients
understand the condition and how to treat it.29 All
members of the diabetes care team play a role in
education. Education can be on a one-to-one basis
or in groups, or both. All contacts between
patients and practitioners can be an opportunity
for education.
For patients treated with insulin, monitoring BG
levels is necessary to try to maintain levels as
consistently near normal as possible.11,12 BG can
be checked by means of a simple blood test or, less
sensitively, by testing the urine. Learning when
and how to monitor and how to interpret BG is an
important aspect of self-management, particularly
for insulin-treated patients, who are at risk from
hypoglycaemia and ketoacidosis. 
Current service provision
The National Service Framework (NSF) for
diabetes, published in 2001, identified the
importance of patient-centred care in the
management of diabetes and the need to
empower people to take responsibility for
managing their condition on a daily basis.20 This
was outlined in standard 3, which states that “all
children, young people and adults with diabetes
will receive a service which encourages partnership
and decision-making, supports them in managing
their diabetes and helps them adopt and maintain
a healthy lifestyle”.30 The complexities of self-care
and the vital role of education in providing people
with the knowledge and skills necessary to manage
their diabetes were recognised in the NSF for
diabetes delivery strategy.31 The delivery strategy
stated that treatment in line with the NSF
standards for diabetes should include referral to
structured education. Other national policy
initiatives linked to the NSF for diabetes have
echoed the valuable role of education programmes
in improving health and the need for establishing
standards.32–36
Since the publication of the NSF standards and
delivery strategy, several initiatives have been
Background
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TABLE 2 Prevalence (per 1000) of Type 2 diabetes reported by family practices in the UK in 2001 (adapted from de Lusignan and
colleagues17)
Age (years)
0–34 35–44 45–54 55–64 65–74 75–84 85+
Male 1 9 27 57 101 109 89
Female 2 9 19 40 73 76 68developed to provide guidance and
recommendations to the NHS and to patients.
NICE undertook an appraisal of the use of
patient-education models for diabetes, publishing
guidance in April 2003.28 NICE recommended
that “structured patient education is made
available to all people with diabetes at the time of
initial diagnosis and then as required on an
ongoing basis, based on a formal, regular
assessment of need”.28 Although initially this
guidance was not mandatory, from January 2006 it
became a legal obligation for Primary Care Trusts
(PCTs) to make funds available for this guidance
to be followed. This is important as it was
recognised that patient-education programmes
were not delivered in a formal, comprehensive and
standardised way in England and Wales.28,37
Differences were evident in the length, content
and style of education programmes available, with
many being unstructured, unevaluated and
delivered by health professionals with no specific
training.19
The Patient Education Working Group (PEWG) for
diabetes, established in May 2004 by the
Department of Health and Diabetes UK, has
reported recommendations for establishing 
high-quality patient-education programmes.32 The
framework has been developed from current best
practice and provides a basis for local services to
meet the recommendations made in the NSF for
diabetes and NICE guidance. It presents advice on
quality standards, health professional training and
quality assurance in addition to reporting on
current education programmes. The key priority
for PEWG was to establish quality standards for
patient-education programmes. It recognised that
programmes should be evidence based, dynamic
and flexible to individual needs, and involve users
in their development. The report recommended
that programmes should support self-management
attitudes, beliefs, knowledge and skills for the
learner, their family and their carers, and also that
programmes should have specific aims and
learning objectives which are shared with the
patient, carers and family. Importantly, patient-
education programmes should have a structured,
written curriculum, be delivered by trained
educators, undergo quality assurance and be
audited. Specific guidance on course content has
been recommended by Diabetes UK,38 including
information on the nature of diabetes, day-to-day
management, specific issues, living with diabetes,
and sick-day rules. Monitoring of progress against
PEWG’s quality standards was considered
important and it was felt this could be achieved
through use of the Diabetes Continuing Care
Reference Dataset, which brings together relevant
data from the National Diabetes Audit, General
Medical Services (GMS) Quality and Outcomes
Framework, DiabetesE performance management
tool, and the Better Metrics Performance Indicator
Project.
Underlying patient-education programmes is the
need to ensure appropriate training for health
professionals which aims at encouraging
promotion of behaviour change among patients.
Education programmes for educators have been
developed internationally by the International
Diabetes Federation and, in England and Wales,
within the Dose Adjustment For Normal Eating
(DAFNE) (for Type 1 diabetes), Diabetes
Education and Self-Management for Ongoing 
and Newly Diagnosed (DESMOND), and Diabetes
X-PERT programmes and other local initiatives 
(e.g. in Bournemouth and Warwick). These
programmes address the theoretical basis and
underlying philosophy of structured education,
and include observation of an education
programme and quality assurance. PEWG
identifies the importance of quality assurance in
ensuring the quality and validity of any education
programme, maintaining standards and allowing
further development. The PEWG report provides
recommendations for internal and external quality
assurance and accreditation of programmes.
Further guidance has emerged from the
Department of Health, National Diabetes Support
Team, and Diabetes UK initiative in the form of
toolkits to assist commissioners and local diabetes
groups in developing structured diabetes
education programmes and commissioning
services.39,40
Patient-education programmes 
in the UK
When NICE undertook their appraisal of patient-
education models for Type 2 diabetes, they
identified a lack of evaluated UK-based
programmes, something already recognised by the
Audit Commission.19 Some local programmes had
developed in Bournemouth, Leicester,
Northumbria, Portsmouth, and St Helens and
Knowsley. Details of the Bournemouth and St
Helens and Knowsley programmes are discussed
elsewhere.37 However, limited formal evaluation of
these programmes meant an inadequate evidence
base from which to adopt a model of good
practice nationwide. As a consequence, the
DESMOND collaboration was established in
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evaluating a programme of patient education
targeted at newly diagnosed patients through a
pilot phase involving 15 PCTs in England. A full
evaluation through a randomised controlled trial
(RCT) of 1000 patients from 12 PCTs in England
and two Community Health Partnerships in
Scotland was due to report in 2007. DESMOND
has a theoretical and philosophical base,
supporting people in identifying their own health
risks and setting their own behavioural goals. Also,
it will examine development of an education
programme for ethnic or cultural minorities.
Despite the fact that evaluation of the DESMOND
programme is ongoing and preliminary results
have not been released, it is at the time of writing
undergoing phase one of a national roll-out. By
the end of April 2006, 50 PCTs had DESMOND-
trained educators and a further 20 PCTs were
planned to be included by the end of 2006.31 It
will be essential to ensure that results from the
RCT evaluation of DESMOND inform future
development of local programmes, whether based
on DESMOND or other initiatives.
Another programme, the Diabetes X-PERT
Programme, has been developed by Burnley,
Pendle and Rossendale PCT. It is an award-
winning initiative based on theories of
empowerment and discovery learning.41 The
programme was developed systematically over
5 years and has been evaluated through an RCT,
showing positive impacts on clinical, lifestyle and
psychosocial outcomes. Other RCT evaluations of
structured education programmes for Type 2
diabetes are under way in the UK, although these
are limited in number. In Warwick, an RCT of a
structured education programme is under way
using a diabetes manual given to patients in
general practice, backed up by one-to-one
consultations between patients and health
professionals. Another structured education
programme for black and minority groups is being
undertaken by the Royal London Hospital,
focusing on Bangladeshi communities
[Bangladeshi Initiative for Prevention of Diabetes
(BIPOD)]. BIPOD focuses on determining
knowledge of risk, and developing understanding
of the relationship between eating, activity and
prevention of diabetes. Established local education
programmes have had to undergo quality
assurance to ensure the programmes meet the
requirements established as part of the NSF for
diabetes (e.g. in Poole, Bournemouth and Torbay)
(Carter L, Somerset PCT; personal
communication, 2007). Despite these initiatives,
more research is required into education
programmes to assess the importance of one-to-
one education and ongoing support in children
and adolescents, black and minority ethnic groups,
carers, pregnant women and other groups who
have special needs.32
Despite the lack of an evaluated nationally led
diabetes education programme in the UK, PCTs
were legally obligated from January 2006 under
NICE guidance to fund and provide a patient-
education programme for people with diabetes.
For those who do not already operate a quality-
assured local education programme, DESMOND
and X-PERT programmes provide a framework. It
is thought that many PCTs and local diabetes
communities have adopted these programmes, in
some instances replacing existing local initiatives.
Concerns have been raised that DESMOND and
X-PERT may not meet the needs of different
communities, which may be better served by
programmes tailored to their specific
requirements. Further research may be necessary
to assess the comparative performance of
DESMOND and X-PERT against other locally
developed patient-education programmes,
although this is unlikely to be through controlled
trials. It is important that structured education
programmes are flexible and responsive to the
needs of individuals and their communities,
irrespective of whether they are a nationally
recommended or a locally developed programme.
Evaluation of the different methods of delivery of
structured education programmes may be
justified, comparing aspects such as the staff and
setting for delivering the programme. Despite this
legal obligation, funding of NICE guidance is a
common concern. Provision of the structured
diabetes education programmes has led to
concerns that developing and implementing such
programmes will be at the cost of other aspects of
the diabetes service.
Description of the interventions
considered in this review
Education for people with diabetes aims to
improve their knowledge and skills, enabling them
to take control of their own condition and to
integrate self-management into their daily lives.
Self-management also occurs within the context of
overall health management. Education is a
foundation for understanding how (and whether)
to regulate one’s own diabetic medication and
often cannot be evaluated outside the context of
treatment modifications. For these reasons, it is
somewhat artificial to consider the effects of
Background
8education alone, as the aim of education is to
enable patients to use the various therapies better. 
The educational interventions considered in this
review are all aimed at educating adults with 
Type 2 diabetes. A number of differences can be
observed between the included interventions, such
as the duration of the intervention, and the
specific topics covered. However, all can be
described as structured educational interventions
for diabetes self-management, and have met a
number of criteria assessing their reproducibility
(see the section ‘Methods for reviewing
effectiveness’, p. 11).
Interventions for Type 2 diabetes fall into two
basic categories: those in which the aim of the
intervention was to educate patients on a range of
topics related to diabetes self-management, and
those in which the intervention was focused on
one or two aspects of self-management alone (e.g.
diet and/or exercise).
Due to the differences in the interventions 
within each of these groups, a summary only 
has been provided here; more detailed
descriptions of interventions are given with 
the assessment of clinical effectiveness (see
Chapter 3).
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effectiveness
The a priori methods for systematically reviewing
the evidence of clinical effectiveness are described
in the research protocol (Appendix 1), which was
sent to experts for comment. Although helpful
comments were received relating to the general
content of the research protocol, there were none
that identified specific problems with the methods
of the review. The methods outlined in the
protocol are briefly summarised below.
Search strategy
Sources of information, search terms and a flow
chart outlining the identification of studies are
presented in Appendix 2.
Inclusion and data extraction process
Titles and abstracts of studies identified by the
search strategy were assessed for potential
eligibility by two reviewers. The full text of
relevant papers was then obtained and inclusion
criteria were applied by one reviewer and checked
by a second reviewer. Data were extracted by one
reviewer using a standard data extraction form
and checked by a second reviewer. 
The quality of included RCTs and controlled
clinical trials (CCTs) was assessed using criteria
recommended by NHS Centre for Reviews and
Dissemination (CRD)42 (Appendix 4). Quality
criteria were applied by one reviewer and checked
by a second reviewer.
At each stage, any differences in opinion were
resolved through discussion or consultation with a
third reviewer.
Inclusion criteria
Design
RCTs and CCTs that compared a specific
educational programme with usual care or with
another educational programme were included.
Because diabetes care is constantly evolving, CCTs
were required to have a concurrent control group.
RCTs or CCTs that compared models of group
education with individual education were
included.
Interventions
The review was limited to educational
interventions, that is, the dissemination of
knowledge and skills brought about using a
number of approaches, which can be carried out
with the normal range of personnel available in
diabetes care. Trials that only evaluated specific,
specialised psychological interventions aimed at
changing an individual’s perceptions, such as
cognitive/behavioural or psychoanalytic therapy, or
counselling, were excluded. Educational
interventions that included a psychological
component were included. Studies of education
solely about specific complications (e.g. foot care)
were not included. 
Reporting
In order potentially to inform practice, included
studies were required to have been reported 
with sufficient detail to be reproducible. They 
were required to have described the main
components of the educational programme, 
such as:
● what the intervention is, with some description
of the topics covered
● who provides instruction (e.g. post and
qualification)
● how is education delivered (e.g. in person, or by
computer)
● group or individual
● length of intervention and number of sessions
● target audience (e.g. Type 2; newly diagnosed)
● didactic or interactive instruction
● training for the educators.
Educational interventions that were not described
in sufficient detail to allow them to be reproduced
were not included.
Participants
Participants should have been diagnosed with
Type 2 diabetes using the standard diagnostic
criteria in effect at the inception of the study. Both
newly diagnosed and patients with established
diabetes were included. Participant populations
should have been described as ‘adults’ or
comprised a minimum of 80% at 18 years of age
or older. 
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Chapter 3
Assessment of clinical effectivenessOutcomes
A range of outcomes was assessed for the included
trials as stated a priori in the research protocol. As
diabetes is a chronic condition and complications
may not appear for years after diagnosis, it is
important that an intervention has a lasting effect.
The effects on lifestyle interventions in chronic
conditions are often difficult to maintain over a
long period.43
Included studies were required to report results
from a minimum of 1 year after the beginning of
the intervention. For ease of understanding, these
will be discussed within each subsection of the
clinical effectiveness sections, in three categories:
diabetic control, diabetic end-points, and QoL and
cognitive measures. 
Diabetic control outcomes
These outcomes are physiological measures that
are indicative of metabolic control, lifestyle
modifications or cardiovascular risk. They are
important indicators of self-management success
and serve as surrogate indicators of the risk of
long-term complications: 
● GHb (e.g. HbA1c) is a measure that reflects
glucose levels in the blood over a relatively long
interval (6–8 weeks), and therefore provides a
much better guide to diabetes control than
simple BG measurements.
● BP and blood lipids (cholesterol and
triglycerides) are risk factors for cardiovascular
disease (CVD).
● Body mass index (BMI) and weight are related
to the development of problems in glycaemic
control initially and are also risk factors for 
the development of cardiovascular disease
(CVD).
● In Type 2 diabetes, patients may be able to
control their BG (at least early in the disease) by
modifying lifestyle factors such as diet and
exercise. Therefore, an important treatment
goal and indicator of intervention success may
be reductions (or lack of increases) or other
changes in the level of oral hypoglycaemic
agents used by patients.
Diabetic end-points
Certain variables are indicators of the progression
of diabetes into the associated complications
discussed previously, or the general deterioration
of health or diabetic status: 
● Episodes of hypoglycaemia or ketoacidosis:
patients may have too little glucose in the
system or too much. In Type 2 diabetes these
are relatively rare occurrences; however, where a
study reported these outcomes they have been
discussed. 
● Retinopathy and nephropathy are long-term
complications associated with long-term poor
regulation of BG. Neuropathy can be an acute
or long-term complication. Many studies will be
too short in duration to measure these long-
term complications. 
● Rates of hospital admission are an indication of
the general health of patients and whether BG
is under control. 
Quality of life and cognitive measures
Interventions can affect how patients feel about
themselves, how they are functioning in society,
and their perceived control of their health status.
QoL has been measured with a number of
validated instruments. Some instruments are
disease-specific to assess QoL in relation to
diabetes whereas others are generic measures. 
Some of the studies used assessment instruments
that were not validated and this may mean that
the instruments may not be measuring what they
claim to. Results of non-validated instruments
were not data extracted and will not be discussed. 
Cognitive outcome measures include attitudes
toward diabetes, and diabetes knowledge.
Increased knowledge of diabetes may contribute as
much or more to patients’ perceived control of
diabetes as to metabolic control. Patients who are
more knowledgeable may feel better about their
diabetes and their ability to self-manage. 
Validated measures of QoL, knowledge and 
other cognitive measures that were used in the
included studies are described in more detail in
Appendix 7.
Quality considerations
As for most interventions, it is important to
consider the effects of diabetes education relative
to a control group. Ideally, to minimise bias,
patients should be randomly assigned to
intervention and control groups (RCTs). In 
this review, CCTs are also considered provided
that a control group was evaluated concurrently
with the intervention group(s). Although many
studies of diabetes interventions have used 
designs that have not used a control group and
relied upon before-and-after measures, this 
is not a satisfactory approach. Other factors 
could be confounded with the intervention such
that after measures would differ from before
measures. These differences cannot be attributed
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uncontrolled designs. 
It is important that statistical comparisons are
made between the intervention and control groups
rather than considering only within-group changes
from baseline. If within-group changes are
reported, they may reflect not only the effect of an
intervention, but also effects of the study
conditions or other factors that co-vary with the
intervention. In newly diagnosed patients with
diabetes, it might be expected that various
measures will change simply as patients adjust to
the diagnosis and attempt to make recommended
adjustments to lifestyle and/or medication. The
natural evolution of Type 2 diabetes is for diabetic
control to worsen over time, and methods to
compare results appropriately between
intervention and control groups are crucial. For
example, maintaining diabetic control in an
intervention group relative to deteriorating
control in a control group may be a valuable
outcome. 
Data synthesis
Data were synthesised through a narrative review
with tabulation of results of all included studies.
Full data extraction forms are presented in
Appendix 5. It was not considered appropriate to
combine the included studies in a meta-analysis
due to heterogeneity of the patient groups and
comparator treatments.
Results
Quantity and quality of research
available
Included studies of educational effects in Type 2
diabetes have generally focused on evaluations of
metabolic control, diabetic end-points such as late
complications, and QoL. There are some
circumstances in which some of the basic
treatment goals are not sought. For instance, in
older patients the goal of normoglycaemia may
not be as prominent. In most patients with Type 2
diabetes, a treatment goal is to minimise or avoid
the use of OHAs for as long as possible and
therefore some studies measured the use of OHAs
as an end-point (for full details see the next
section and the section ‘Trials of focused self-
management interventions’, p. 29).
Twenty-one published trials [academic in
confidence (AIC) data removed] that included
only participants with Type 2 diabetes met the
inclusion criteria. These trials fell into two
categories: those in which the intervention was a
more or less complete self-management approach
(13 published trials, [AIC data removed] see 
Table 3) and those in which the intervention was
focused on one or two aspects of self-management
(e.g. diet and/or exercise) (eight trials; see Table 12,
p. 30). The clinical effectiveness of the two
categories of trials will be discussed separately
followed by a summary of findings from
interventions directed at Type 2 diabetes generally.
The nature of interventions aimed at Type 2
diabetes is variable. There are variations in the
characteristics of patients recruited, the focus of
the intervention, the intensity and duration of the
intervention, the theoretical foundation (if any) for
the intervention, the providers and the setting.
There is very little consistency among studies, which
makes it difficult to fully summarise the results.
Trials of self-management
interventions
Of the 13 studies that compared self-management
education for patients with Type 2 diabetes and
met the inclusion criteria for the review, 11 were
RCTs and two were CCTs (Table 3; Appendix 5).
The number of participants recruited varied from
51 to 437 in the published RCTs and from 124 to
127 in the CCTs. [AIC data removed].
Interventions were very similar in two of the
published RCTs49,52 and for the two CCTs (Table 3).
One of the published RCTs compared education in
more than two groups of patients.51 Another
published RCT compared ‘extended’ and
‘compressed’ versions of an intervention.52 All the
remaining published trials compared an
intervention group with a usual-care control group.
In three of these studies (altogether six
publications) the usual care group was randomised
to a waiting list.49,50,56–58,60 [AIC data removed]. Six
of the published trials were carried out in primary
care,46,49,52,61,63,64 two in secondary care,59,62 one in
a university clinic (three publications),53–55 one in
pharmacies,60 one across both primary and
secondary care (three publications)56–58 and one
which started in secondary care but continued
reinforcement interventions after hospital
discharge.45 One trial did not report the setting for
the study.51 [AIC data removed].
In two published studies the duration of diabetes
was within 1 year of diagnosis51,59 [AIC data
removed]. The duration of diabetes in the
remaining trials ranged from 2.6 years60 to
9.8 years.53–55 In 12 of the published studies 
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TABLE 3 Included studies of self-management education interventions for Type 2 diabetes [ordered by type (RCT, CCT) and size
(largest first)]
Reference and  Intervention No. of  Duration of  Timing of 
design participants intervention evaluationa
44[AIC data removed]
Ko et al., 200745 Two groups: 437 5 days inpatient  2 months then at 
1. Self-management education delivered to  followed by  3-monthly intervals 
RCT inpatient groups by 8 professional diabetes  annual 3-hour  after discharge 
health providers; 30 hours over 5 days in  outpatient  (data reported for 
hospital followed by one 3-hour outpatient sessions 6 months and 
education reinforcement session per year annually up to 
2. Same as intervention but given only the first  4 years)
4 hours of inpatient education and with no 
education reinforcement during annual 3-hour 
follow-up sessions
Deakin et al., Two  groups: 314  6 weeks 14 months
2003, 200646–48 1. Self-management education in groups 
delivered by a diabetes research 
RCT dietician in six, weekly, 2-hour sessions
2. Usual care plus diabetes education and 
individual review with (separately) a 
dietician (30 minutes), practice nurse 
(15 minutes) and GP (10 minutes)
Brown et al.,  Two groups: 256 9 months +  1 year
200249,50 1. Self-management education. Team provided  3 months of 
group education for 52 contact hours support group 
RCT 2. Usual care by physicians and waiting list sessions = 1 year
Campbell et al., Four  groups: 238 Differed  1 year
199651 1. Minimal instruction. Team-delivered with  between and 
2 contact hours  within groups. 
RCT 2. Individual education. Team-delivered with  Up to 1 year
8 contact hours
3. Group education. Team-delivered with 
~4 days total contact time
4. Behavioural programme. One nurse 
provided at least 6 contact hours
Brown et al., Two  groups: 216 1 year 3 years  (but 
200552 1. Self-management, didactic and interactive,  extractable data 
group education delivered by a team  not given for 
RCT (nurses, dieticians and community workers)  >1 year)
with 52 hours of contact over 12 months
2. Similar intervention components to 
(1) but compressed to 22 hours of contact 
over 12 months based on information 
from focus groups
Trento et al., Two  groups:
2001;53 2002;54 1. Self-management education in groups by  112 Varied amongst  5 years
200455 a team (1 or 2 physicians and an  patients; up to 
educationalist). Up to 32 contact hours  5 years
RCT over first 2 years; contact continued over 
the following three years (details unclear)
2. Usual care (seen by physicians every 
3 months). Also kept weekly weight and 
nutrition diaries, and received individual 
education sessions from a nutritionist 
(details not given)
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TABLE 3 Included studies of self-management education interventions for Type 2 diabetes [ordered by type (RCT, CCT) and size
(largest first)] (cont’d)
Reference and  Intervention No. of  Duration of  Timing of 
design participants intervention evaluationa
Cooper et al., Two  groups: 89 8 weeks 1 year
2002;56 200357,58 1. Self-management, mainly interactive, 
group education delivered by DSNs with 
16 hours of contact
RCTb 2. Usual care and randomised to a waiting 
list for 12 months
Heller et al., Two  groups: 87 6 months 1 year
198859 1. Self-management group education (weight 
loss focus). Delivered by dietician and 
RCT DSN with 7.5 contact hours
2. Usual care with physician and also saw 
dietician every 3 months
Sarkadi and  Two groups: 77 1 year 2 years
Rosenqvist,  1. Self-management, didactic and interactive, 
200460 group education delivered by specially 
trained pharmacists, initially with a DSN 
RCT (contact time not reported)
2. Patients randomised to a waiting list for 
two years (no other details)
Goudswaard Two  groups: 58 6 months 18 months
et al., 200461 1. Self-management (assume mainly didactic) 
individual education, delivered by 
RCT one-to-one contact with DSNs. 
Approximately 2.5 hours of total contact 
over 6 months
2. Usual care according to the Dutch 
Guideline on Type 2 diabetes, with 
education given during normal medical 
appointments
Raz et al., 198862 Two groups: 51 1 year 1 year
1. Self-management group education. Team-
RCT delivered. Minimum of 12 contact hours
2. Usual care. Follow-up every 2 months
Kronsbein et al., Two  groups: 127 1 month 1 year
198863 1. Self-management education. Group 
education by physician assistants. 
CCT (groups  ~7 contact hours 
from medical  2. Usual care with GP . No details
practices, 
waiting-list 
controls)
Domenech et al., Two groups: 124  1 month 1 year
199564 1. Self-management education. Group 
education by physicians. ~7 hours 
CCT (groups  contact time 
from similar  2. Usual care. No details
medical practices)
DSN, diabetes specialist nurse.
a Based on the start of the intervention.
b Cooper et al.65 also refer to this trial but duplicate existing information.[AIC data removed] diabetes duration was similar
in the intervention and control groups (difference
<0.6 year). In the remaining published trial,60 the
difference was larger (5.9 years in the intervention
group compared with 2.6 years in the control
group), but it is unclear whether this was
statistically significant. The mean age of the
participants in all published studies was in the
range 49.6–66.5 years; [AIC data removed]. In the
majority (eight) of the published studies, the
maximum period of follow-up from inception was
1 year (i.e. the minimum period eligible for
inclusion in this review), [AIC data removed]. The
longest periods of follow up were 5 years,53–55
4 years,45 2 years,46,47 18 months61 and
14 months.60
The quality of reporting and methodology of the
included studies was generally poor (Tables 4 and
5), perhaps reflecting publication word limits. The
method of randomisation was unknown for all but
five of the published RCTs, by Trento and
colleagues,53–55 Goudswaard and colleagues,61
Heller and colleagues,59 Ko and colleagues,45 and
Cooper and colleagues56 [AIC data removed].
Concealment of allocation was adequately
reported in only four of the published
trials,46,56,59,61 [AIC data removed], and only three
published trials reported whether outcome
assessors were blinded to treatment identity.46,62,45
The similarity of groups at baseline was reported
in all included published trials [AIC data
removed], but only one of the published studies
reported an analysis by intention-to-treat (ITT)
that was assessed as adequate.49
Description of the interventions
Although most of the trials developed their
interventions independently, the interventions
were broadly similar in educating patients about a
wide range of components of self-management in
diabetes. Unfortunately, the descriptions of
interventions were often limited and vague. This is
despite an attempt to include only trials that
provided some detail as to the nature of the
intervention. An overview of the different
interventions is provided here but for further
detail see Appendix 5.
Topics that were covered in the intervention
arm(s) of all of these studies included nutrition,
diet and self-monitoring (blood and/or urine).
Only two studies did not specifically include the
importance of body weight in their education
intervention,52,60 and only two studies did not
include exercise or physical activity.53–55,59 The
majority of studies (apart from four51,61,62,64) also
discussed diabetes complications and/or
management of complications. Seven studies
described education for foot care
specifically,45,49,51,52,56,63,64 and five included
consideration of how to handle sick
days.45,49,56,63,64 Two studies63,64 trained patients to
reduce or stop oral agents in the case of
hypoglycaemia (Mühlhauser I, University of
Dusseldorf: personal communication, 2002).
Several other topics were incorporated into only
one study each. Coverage of these topics might
have been underestimated in this review, however,
as the brief methodological summaries in many of
the studies might not have described all the
relevant intervention components (for example,
provision of basic information to patients on the
causes and treatment of diabetes was mentioned in
only five of the 13 published studies of self-
management interventions45,51,61–63) [AIC data
removed].
In eight published studies [AIC data removed] the
training was provided by a team. The most frequent
health professionals who delivered education in
teams were nurses (eight studies)49,51,52,56–62 and
dieticians (five studies).49,51,52,59,62 All teams that
had dieticians also included nurses. Other members
of the education teams were physicians (three
studies),53–55,62,45 community workers (two
studies),49,52 pharmacists (two studies),60,45 and 
an educationalist and medical students (one
study).53–55 [AIC data removed]. In four studies, the
training (description of which was often vague)
appears to have been provided by one person. The
individual trainers were a diabetes research
technician,46 diabetes nurse,61 physician,64 or
physician assistant.63 In the remaining study 
it is unclear how many people provided the
training.60
Only three published studies [AIC data removed]
mentioned that they trained educators. In two
studies by Brown and colleagues,49,52 nurses and
dieticians attended seminars on diabetes
education and participated in a supervised clinical
practicum with outpatients, and community
workers with Type 2 diabetes participated in an 
8-week programme on diabetes self-management.
In the study by Cooper and colleagues,56 nurse
trainers trained together, were provided with a
training manual, and each ran a supervised pilot
course to ensure standardisation of content and
reduce potential treatment heterogeneity. [AIC
data removed].
There was considerable variation in the number of
hours of contact between the patient(s) and
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T
ABLE 4
Quality assessment of RCT
s of education for T
ype 2 diabetes (CRD criteria) [ordered by type (RCT
, CCT) and size (largest first)
]
Study
R
andomisation
Concealment 
Baseline 
Eligibility 
Blinding of 
P
rimary 
ITT analysis 
Missing values
of allocation
characteristics
criteria
assessors
outcome 
results
[AIC data removed]
Ko
et al., 2007
45
Adequate
Inadequate
R
eported
Y
es
Adequate
Adequate
Inadequate
P
artial
Deakin 
et al., 2003, 2006
46–48
P
artial
Adequate
R
eported
No
Adequate
Adequate
Inadequate
Adequate
Brown 
et al., 2002
49,50
Unknown
Unknown
R
eported
Y
es
Unknown
Adequate
Adequate
P
artial
Campbell, 
et al., 1996
51
Unknown
Unknown
R
eported
Y
e
s
Unknown
P
artial
Unknown
P
artial
Brown 
et al., 2005
52
Unknown
Unknown
R
eported
Y
es
Unknown
Adequate
Inadequate
Inadequate
T
rento 
et al., 2001–4
53–55
Adequate
Unknown
R
eported
Y
es
Inadequate
Adequate
Inadequate
Adequate
Cooper 
et al., 2002–3
56–58
Adequate
Adequate
R
eported
Y
es
Unknown
Adequate
Inadequate
P
artial
Heller 
et al., 1988
59
Adequate
Adequate
R
eported
Y
es
P
artial
Adequate
Unknown
Adequate
Sarkadi and R
osenqvist, 2004
60
P
artial
Unknown
R
eported
Y
es Unknown 
P
artial
Inadequate
P
artial
Goudswaard 
et al., 2004
61
Adequate
Adequate
R
eported
Y
es
Unknown
Adequate
Inadequate
Adequate
R
az 
et al., 1988
62
Unknown
Unknown
R
eported
Y
es
Adequate
Inadequate
Unknown
Adequate 
T
ABLE 5
Quality assessment of CCT
s of education for T
ype 2 diabetes (CRD criteria)
Study
Baseline 
Eligibility 
Blinding of 
P
rimary 
ITT analysis
Missing values
R
epresentativeness
characteristics
criteria
assessors
outcome results
Domenech 
et al., 1995
64
R
eported
Y
es
Unknown
P
artial
Unknown
Adequate
Y
es
Kronsbein 
et al., 1988
63
R
eported
Y
es
Unknown
Adequate
Unknown
P
artial
Noprovider(s) for each intervention. This ranged from
approximately 2.5 hours (in a 6-month
intervention)61 to 52 hours [in a 1-year intervention
(in two studies)].49,52 Some interventions began with
2–4 intensive sessions of 90–120 minutes followed
up with additional sessions at, for instance, 3 and
6 months.51,59,62 One study included four
interventions (three included in this review) that
varied in duration and other characteristics, with
the shortest intervention being 2 hours and the
longest approximately 30 hours of contact.51 The
interventions also varied considerably in whether
sessions were provided over a short interval or were
spaced out over time. In one of the longest
studies,53–55 the interventions were spread
throughout a 4-year period but the timing varied
among patients (details are clearly reported only
for the first 2 years). The briefest interventions in
the published studies lasted for 1 month.63,64 [AIC
data removed]. In two studies the total contact
time is unclear51,53–55 and in two studies it was not
reported.60,62
Interventions were provided to groups of
participants in all but two of the studies.51,61 Of
three interventions compared by Campbell and
colleagues51 that are eligible for inclusion in this
review, two involved individual instruction and one
was a group intervention.
Six of the studies did not mention that they were
based on any particular theory of health
psychology or behaviour change. Of the
remaining seven published studies, [AIC data
removed] two were based on patient
empowerment,46,56–58 two developed a culturally
specific intervention aimed at Mexican-Americans
based on four meta-analytic reviews of previous
diabetes education interventions,49,50,52 two used
cognitive-behavioural strategies in a behaviour
change intervention,45,51 and one used an
experience-based learning intervention with a
pedagogical principle that problems would be
solved by the group rather than by the leader.60
[AIC data removed]. Limited detail of the theory
underpinning the educational intervention was
provided in the majority of these studies but any
additional information can be seen in the relevant
section of Appendix 5. Details are as described by
the trial authors and the reviewers have not
attempted to comment on the validity or the
nature of these theories. 
All of these studies attempted to address multiple
components of diabetes self-management, but
there were no specific manipulations of medical
treatment associated with the educational
interventions. Individual patients were followed by
their physicians or trialists and may have had their
medical treatment varied as deemed necessary, 
but patients were not being trained to self-regulate
their own medication, for instance. There were
also variations in how many patients were
receiving medications. 
Outcomes reflecting diabetic control
Table 6 shows the results for GHb for the included
studies of self-management education in Type 2
diabetes.
Six published studies reported statistically
significant differences between intervention and
control groups in GHb.45–47,49,53,60,62 [AIC data
removed]. All six of these were RCTs (Table 6). 
Ko and colleagues45 reported a lower (better)
percentage of GHb in the intervention than the
control group on all occasions after the
intervention. This difference was statistically
significant after 6 months (data not shown here)
and after the third and fourth years, but not at the
end of the first and second years. On observation
of the data, it is apparent that these participants
started with a high HbA1c, which is likely to be a
reflection of the fact that they were inpatients,
hospitalised due to poor glycaemic control. 
In this study, there was a reduction in HbA1c in
both the intervention and control groups over 
the duration of the RCT. Fourteen months after
the intervention in the Deakin and colleagues
trial,46–48 the change from baseline in HbA1c
differed significantly between the intervention 
arm and the control arm: the change was 
negative in direction (improvement) in the
intervention arm, compared with a slight 
increase in the control arm. In this study there 
was a higher level of participant drop-out in the
control group, which may bias the result shown. 
At the 12-month evaluation, the intervention
group in the Brown and colleagues study49 had
HbA1c approximately 0.75% lower than the
control group. In this study, the baseline HbA1c of
participants in both groups was high. The
intervention group in the Trento and colleagues
study53 had HbA1c 0.8% lower than the control
group at 2 years and 1.8% lower at 5 years. The
intervention in the Trento and colleagues study
seems to have prevented the deterioration of BG
levels rather than improving BG. The intervention
group’s BG remained approximately the same
whereas the control group had lower BG at the
end of the trial. The intervention group in the Raz
and colleagues study62 had HbA1c approximately
1.35% lower than the control group at 12 months.
In the Sarkadi and Rosenqvist60 trial, HbA1c was
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TABLE 6 Glycated haemoglobin in studies of self-management education in adults with Type 2 diabetes. Data may represent HbA1 or
HbA1c (details in Appendix 5). The studies are ordered by type (RCT, CCT) and size (largest first)
Study and  Time-point Mean (SD) (unless stated) HbA1 or HbA1c (%) Difference between
design
Intervention Control
groups
[AIC data removed]
Ko et al., 200745 Baseline 9.4 (2.0) (n = 219) 9.2 (1.9) (n = 211) NS
1 year 7.9 (1.7) (n = 174) 8.1 (1.5) (n = 187) NS
RCT 2 years 7.9 (1.5) (n = 168) 8.2 (1.5) (n = 169) NS
3 years 7.8 (1.5) (n = 167) 8.4 (1.6) (n = 148) p = 0.004
4 years 7.9 (1.2) (n = 161) 8.7 (1.6) (n = 147) p = 0.0001
Deakin et al.,  Baseline 7.7 (1.6) (n = 157) 7.7 (1.6) (n = 157) NSa
2003;47,48 200646 14 months 7.1 (1.1) (n = 150) 7.8 (1.6) (n = 141) p < 0.05a
RCT Change –0.6 0.1 p < 0.001
Brown et al., Baseline 11.81  (3.0) (n = 128) 11.8 (3.02)  (n = 128) –
200249,50 1 year 10.89 (2.56) (n = 112) 11.64 (2.85) (n = 112) p < 0.05
RCT adjusted 10.87 adjusted 11.66
Campbell et al.,  Mean (SEM)  Individual education group  NS
199651 change from  n = 57 at baseline, n = 25 at end-point (all pairwise contrasts)
RCT baseline –3.3 (0.9)
Group education group
n = 66 at baseline, n = 19 at end-point
–3.0 (1.1)
Behavioural education group
n = 56 at baseline, n = 39 at end-point
–4.8 (0.7)
Brown et al., Extended  intervention Compressed  intervention
200552 Baseline 11.5 (3.5) (n = 102) 11.8 (3.4) (n = 114) –
RCT 1 year 10.5 (3.0) (n = 89) 11.1 (3.2) (n =9 6 ) –
Change –1.0 –0.7 NS
Trento et al.,  Baseline 7.4 (1.4) (n = 56) 7.4 (1.4) (n = 56) –
2001;53 2002;54 2 years 7.5 (1.4) (n = 43) 8.3 (1.8) (n = 47) p < 0.01
200455 5 years 7.3 (1.0) (n = 42) 9.0 (1.6) (n = 42) –
RCT
Change –0.1 (95% CI –0.5 to 0.4) 1.7 (95% CI 1.1 to 2.2) p < 0.001
0–5 years
Cooper et al.,  Baseline 7.9 (range 4.5–11) (n = 53) 7.0 (range 4.6–10.6) (n = 36) –
2002;56 200357,58 1 year 7.9 (2.1) (n = 48) 7.2 (1.6) (n = 30) NS
RCT
Heller et al.,  Baseline 12.3 (95% CI 11.4 to 13.2)  12.7 (95% CI 11.9 to 13.5) –
198859 (n = 40) (n = 47)
1 year 9.0 (95% CI 8.2 to 9.8)  9.9 (95% CI 8.9 to 10.9) NS
RCT (n = 36) (n = 39)
continuednot statistically significantly different between the
intervention group and control group at
12 months but was statistically significant at
24 months.
The other published studies of this kind reported
no statistically significant differences between
intervention and control groups on measures of
GHb, despite what would seem to be relatively
large differences in mean levels of GHb between
the intervention and control groups in some of the
studies. [AIC data removed]. In the trial by Brown
and colleagues,52 the aim of the study was to
compare two different versions of the intervention
(one ‘compressed’) rather than to compare the
intervention with a control group of usual care. In
this study, no statistically significant differences
were demonstrated between the two interventions
although both interventions did reduce HbA1c at
12 months. 
It should be noted that although the Campbell
and colleagues study51 did not report significant
differences in GHb between the three intervention
groups that were evaluated, it would appear that
these interventions did improve BG. These
findings should, however, be interpreted with
caution because no control group (who might also
have shown improvement) was available for
comparison. Furthermore, there was a very high
attrition rate in this study. Improvements in
outcomes through time may be attributable to the
most motivated patients remaining in the study.
Of the studies that demonstrated statistically
significant results, five were interventions
delivered by a team of different professions, which
might suggest a broader range of presented
information and provider expertise, but two
studies using such teams did not produce
significant differences in GHb and one study with
significant results had a single provider only.46–48
In the studies demonstrating a statistically
significant effect of education on HbA1c, the
difference between the intervention and control
groups was on or around 1%, which may represent
Assessment of clinical effectiveness
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TABLE 6 Glycated haemoglobin in studies of self-management education in adults with Type 2 diabetes. Data may represent HbA1 or
HbA1c (details in Appendix 5). The studies are ordered by type (RCT, CCT) and size (largest first) (cont’d)
Study and  Time-point Mean (SD) (unless stated) HbA1 or HbA1c (%) Difference between
design
Intervention Control
groups
Sarkadi and  Baseline ~6.5 (n = 39) ~6.5 (n = 38) NS
Rosenqvist,  1 year 6.2 (95% CI 5.7 to 6.7)  6.4 (95% CI 5.8 to 7.0) NS
200460 (n = 33) (n = 31)
2 years 6.1 (95% CI 5.5 to 6.7) 6.6 (95% CI 6.0 to 7.2) p < 0.01
RCT (n = 33) (n = 31)
Baseline means and all CI 
estimated from graph
Goudswaard  Baseline 8.2 (1.1) (n = 28) 8.8 (1.5) (n = 30) –
et al., 200461 18 months 7.8 (0.9) (n = 25) 8.2 (1.4) (n = 29) –
RCT Change –0.4 (adjusted) –0.6 (adjusted) NS
Raz et al.,  Baseline 10.0 (2.7) (n = 25) 9.6 (2.6) (n = 26) –
198862 1 year 8.25 (n = 23) 9.6 (n = 26) –
RCT (estimated from graph) (estimated from graph)
Change –1.75 0 p < 0.05
(estimated from graph) (estimated from graph)
Kronsbein et al., Baseline 7.1(1.6) (n = 65) 6.5 (1.6) (n = 62) –
198863 1 year 7.1 (1.6) (n = 50) 6.7 (1.5) (n = 49) NS
CCT
Domenech Change  from  –0.2%  (0.4) 0.8%  (0.4) NS
et al., 199564 baseline (n at baseline 53,  (n at baseline 71, 
CCT n at end-point 40) n at end-point 39)
NS, not statistically significant; SD, standard deviation; SEM, standard error of the mean.
a Based on 95% confidence interval (CI) (p > 0.05 if CI for a difference includes zero).a clinically significant difference. Four of the
studies with statistically significant results
continued some contact with the intervention
groups over the period of follow-up and,
speculatively, this may have had a role in
maintaining the benefits shown. 
Blood pressure
BP was reported in three studies.46,47,51,53 The
results are shown in Table 7.
The behavioural intervention in the Campbell and
colleagues study51 resulted in greater decreases in
diastolic BP than in standard group or individual
self-management interventions. As to whether this
is a meaningful difference, or whether this effect
would be maintained in the long term, is unclear
and care is required in interpretation as there were
large drop-out rates in this study. In the Deakin
and colleagues trial,46,47 no statistically significant
differences in systolic or diastolic BP were
observed at the end of the 14-month study
between the intervention group and the control
group. In the Trento and colleagues study,53 more
patients in the intervention group were no longer
considered hypertensive at the end of the study
than in the control group. This difference was not
statistically significant; however, there may have
been a lack of power to detect differences in this
outcome. [AIC data removed].
BMI or weight
Outcomes relating to weight or BMI were reported
in nine included trials and are given in Table 8.
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TABLE 7 Blood pressure characteristics in studies of self-management education in adults with Type 2 diabetes
Study and  Time-point Mean (SD) BP (mmHg) (unless stated)  Difference between
design
Intervention Control
groups
[AIC data removed]
Deakin et al., Systolic  BP:
2003;47,48 200646 Baseline 147.5 (19.8) (n = 157) 147.8 (23.7) (n = 157) NSa
14 months 141.3 (16.8) (n = 150) 144.4 (23.5) (n = 141) NS
RCT
Diastolic BP:
Baseline 82.6 (11.0) (n = 157) 82.2 (12.2) (n = 157) NSa
14 months 78.4 (9.6)  (n = 150) 80.2 (10.9) (n = 141) NS
Campbell et al., Systolic  BP: Individual  education NS
199651 Mean (SEM)  (n at baseline 57, n at end-point 16) (all pairwise 
RCT change from  –6.8 (5.8) contrasts)
baseline Group education
(n at baseline 66, n at end-point 11)
–12.4 (6.8)
Behavioural education
(n at baseline 56, n at end-point 37)
–16.9 (3.8)
Diastolic BP: Individual education Individual and
Mean (SEM)  (n at baseline 57, n at end-point 16) group vs behavioural:
change from  –5.3 (3.0) both p < 0.05;
baseline Group education Individual vs group: NS
(n at baseline 66, n at end-point 11)
–5.0 (4.0)
Behavioural education
(n at baseline 56, n at end-point 37)
–7.9 (2.6)
Trento et al., No.  hypertensive:
200153 Baseline 34 (n = 56) 25 (n = 56) –
RCT 2 years 26 (n = 43) 22 (n = 47) NS
NS, not statistically significant. 
a Based on 95% CI (p > 0.05 if CI for a difference includes zero).Assessment of clinical effectiveness
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TABLE 8 Body mass characteristics (BMI and weight) in studies of self-management education in adults with Type 2 diabetes [ordered
by type (RCT, CCT) and size (largest first)]
Outcome Study and  Time-point Mean (SD) (unless stated) Difference between
design
Intervention Control
groups
BMI (kg/m2) [AIC data removed]
Deakin et al.,  Baseline 30.8 (5.3) (n = 157) 30.6 (5.7) (n = 157) NSb
2003;47,48 200646 14 months 30.6 (5.5) (n = 150) 31.0 (6.4) (n = 141) NSb
RCT Change –0.2 0.4 p < 0.001
Brown et al.,  Baseline 32.33 (5.97) (n = 128) 32.12 (6.35) (n = 128) NS
200249,50 1 year 32.17 (6.45) (n = 113) 32.28 (6.52) (n = 114)
RCT
Campbell et al.,  Mean (SEM)  Individual education NS
199651 change from  (baseline n = 57, end-point n = 30) (all pairwise 
RCT baseline –2.0 (0.4) contrasts)
Group education
(baseline n = 66, end-point n = 25)
–1.4 (0.5)
Behavioural education
(baseline n = 56, end-point n = 41)
–2.6 (0.5)
Trento et al.,  Baseline 29.7 (4.5) (n = 56) 27.8 (4.1) (n = 56) –
2001;53 2002;54 2 years 29.0 (4.4) (n = 43) 27.6 (4.2) (n = 47) p = 0.06
200455 5 years 28.6 (4.1) (n = 42) 27.6 (4.4) (n = 42) –
RCT
Change –1.4 –0.1 NS
0–5 yearsc
Cooper et al.,  Baseline 32.5 (6.7) (n = 53) 32.1 (6.1) (n = 36) –
2002;56 200357,58 1 year 31.3 (5.7) (n = 48) 30.5 (3.9) (n = 30) NS
RCT
Weight (kg) [AIC data removed]
Deakin et al.,  Baseline 83.2 (14.5) (n = 157) 82.8 (17.6) (n = 157) NSb
2003;47,48 200646 14 months 82.7 (14.8) (n = 150) 83.9 (18.8) (n = 141) NSb
Change -0.5 1.1 p < 0.001 RCT
Trento et al.,  Baseline 77.4 (13.1) (n = 56) 78.2 (14.6) (n = 56) –
2001;53 2002;54 2 years 76.0 (13.4) (n = 43) 77.1 (14.7) (n = 47) NS
200455 5 years 76.1 (12.9) (n = 42) 77.3 (16.0) (n = 42) –
RCT Change –3.50 –0.24 p = 0.015
0–5 yearsc
continuedOne trial46,47 showed a statistically significant
difference in BMI between the intervention group
and the control group after 14 months where BMI
was shown to have increased in the control group
compared with a decrease in the intervention
group. This study had differential drop-out rates
between the two arms of the trial with more
participants dropping-out in the control group. In
one study,53 the intervention group had a higher
BMI than the control group at baseline and at the
2- and 5-year evaluation but this was not
statistically significantly different. [AIC data
removed]. Six published studies46,47,53,59,62–64
reported statistically significant differences in
weight (or changes in weight) between the
intervention and control groups. In five studies
weight loss was greater in the intervention group
than the control group. In one study,46,47 weight
increased in the control group compared with a
decrease in the intervention group. [AIC data
removed]. Most of the weight losses were not of
great magnitude with the exception of those in the
Heller study.59 This study, although educating on
multiple aspects of self-management, was
primarily directed at weight loss. The programme,
starting with individualised weight targets, did
produce significant weight loss in the intervention
group (mean 5.5 kg); however, the control group
in the study also lost a mean of 3 kg. In one study
with a positive effect on weight the analysis was
based on a change from baseline value, although
this was only calculated from values of those who
were followed up to end-point.53
Cholesterol and triglycerides
Five published studies [AIC data removed]
reported other physiological
outcomes46,47,49,51,53,62 shown in Table 9.
Only two published trials reported any significant
differences in cholesterol or triglycerides between
intervention and control groups. Trento and
colleagues53 reported in the text that high-density
lipoprotein (HDL) cholesterol was lower in
intervention patients at 24 months, but this was
inconsistent with values reported in a results table
in which an increase in HDL cholesterol was
reported for intervention patients between
baseline and follow-up whereas it remained the
same in control participants. The same study
reported that triglycerides were marginally 
lower in the intervention patients than in 
control patients. Values reported in the results
table suggest that triglycerides were reduced 
in the intervention group whereas they 
remained the same in the control group. However,
triglycerides were higher at baseline and at 
follow-up for the intervention group than 
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TABLE 8 Body mass characteristics (BMI and weight) in studies of self-management education in adults with Type 2 diabetes [ordered
by type (RCT, CCT) and size (largest first)] (cont’d)
Outcome Study and  Time-point Mean (SD) (unless stated) Difference between
design
Intervention Control
groups
Heller et al.,  Mean (95% CI)  –5.5 (4 to 6.5) –3 (2 to 4) p < 0.05
198859 change from  (n = 40 at baseline,  (n = 47 at baseline, 
RCT baseline n = 36 at end-point) n = 39 at end-point)
Raz et al.,  Baseline 75.4 (11.7) (n = 25) 73.4 (11.5) (n = 26) –
198862 1 year 73 (n = 23) 73 (n = 26) –
(estimated from graph) (estimated from graph)
RCT Change –2.4 –0.4  p < 0.05
(estimated from graph) (estimated from graph)
Kronsbein  Baseline 76.5 (12.6) (n = 65) 75.1 (12.9) (n = 62) Difference in change
et al., 198863 1 year 73.8 (12.6) (n = 50) 74.8 (13.2) (n = 49) from baseline: 
CCT p < 0.01
Domenech  Change from  –2.4 (0.5) –0.4 (0.5) p < 0.01
et al., 199564 baseline (n = 53 at baseline,  (n = 71 at baseline,
CCT n = 40 at end-point) n = 39 at end-point)
NS, not statistically significant. 
a Based on calculation adjusted for cluster effects, not statistically significant on unadjusted calculation.
b Based on 95% CI (p > 0.05 if CI for a difference includes zero).
c Based on baseline values for those participants followed up to end-point.Assessment of clinical effectiveness
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TABLE 9 Lipid characteristics (cholesterol and triglyceride) in studies of self-management education in adults with Type 2 diabetes. 
In studies where concentrations were reported in mg/dl, these were converted to mmol/l (1 mg/dl = 0.0555 mmol/l). The studies are
ordered by type (RCT, CCT) and size (largest first)
Outcome Study and  Time-point Mean (SD) (unless stated) Difference between
design
Intervention Control
groups
Total  [AIC data removed]
cholesterol
(mmol/l) Deakin et al.,  Baseline 5.1 (1.1) (n = 157) 4.9 (1.0) (n = 157) NSa
2003;47,48 200646 14 months 4.8 (1.1) (n = 150) 4.7 (1.0) (n = 141) NSa
RCT
Change –0.3 –0.2 p = 0.01
Brown et al.,  Baseline 21.7 (2.5) (n = 128) 11.3 (2.7) (n = 128) –
200249,50 1 year 10.5 (2.0) (n = 112) 10.4 (2.4) (n = 113) NS
RCT
Campbell et al.,  Mean (SEM)  Individual education NS
199651 change from  (baseline n = 57, end-point n = 23) (all pairwise 
RCT baseline 0.12 (0.20) contrasts)
Group education
(baseline n = 66, end-point n = 19)
0.16 (0.16)
Behavioural education
(baseline n = 56, end-point n = 34)
–0.33 (0.15)
Trento et al.,  Baseline 5.8 (1.1) (n = 56) 5.5 (0.9) (n = 56) –
2001;53 2002;54 2 years 5.7 (1.2) (n = 43) 5.6 (1.2) (n = 47) NS
200455 5 years 5.50 (1.06) (n = 42) 5.27 (1.13) (n = 42) –
RCT Change –0.32 –0.43 NS
0–5 yearsb
Raz et al.,  Baseline 12.5 (2.4) (n = 25) 12.2 (3.1) (n = 26) –
198862 1 year 11.8 (2.1) (n = 23) 12.5 (3.4) (n = 26) NS
RCT
HDL  [AIC data removed]
cholesterol
(mmol/l) Deakin et al.,  Baseline 1.3 (0.3) (n = 157) 1.3 (0.4) (n = 157) NSa
2003;47,48 200646 14 months 1.1 (0.4) (n = 150) 1.1 (0.4) (n = 141) p = 0.3
RCT
Campbell et al., Mean (SEM)  Individual education NS
199651 change from  (baseline n = 57, end-point n = 21) (all pairwise 
RCT baseline 0.02 (0.04) contrasts)
Group education
(baseline n = 66, end-point n = 16)
0.18 (0.10)
Behavioural education
(baseline n = 56, end-point n = 27)
0.06 (0.08)
continuedfor the control group. Analysis of the 5-year 
data in a secondary publication55 showed no
statistically significant differences between groups
on either HDL cholesterol or triglycerides. In the
trial by Deakin and colleagues,46,47 the change in
total cholesterol was reported to be statistically
significantly different (p = 0.01) after 14 months
in favour of the intervention group. However,
neither HDL nor low-density lipoprotein (LDL)
cholesterol at end-point were statistically
significantly different between the intervention
group and the control group. [AIC data removed].
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TABLE 9 Lipid characteristics (cholesterol and triglyceride) in studies of self-management education in adults with Type 2 diabetes. 
In studies where concentrations were reported in mg/dl, these were converted to mmol/l (1 mg/dl = 0.0555 mmol/l). The studies are
ordered by type (RCT, CCT) and size (largest first) (cont’d)
Outcome Study and  Time-point Mean (SD) (unless stated) Difference between
design
Intervention Control
groups
Trento et al. Baseline 1.2 (0.3) (n =  56) 1.3 (0.3) (n = 56) –
2001;53 2002;54 2  years 1.4 (0.4) (n =  43) 1.3 (0.3) (n = 47) p < 0.05
200455 5 years 1.39 (0.33) (n = 42) 1.42 (0.31) (n = 42) –
RCT Change 0.14 0.10 NS
0–5 yearsb
Raz et al.,  Baseline 2.6 (0.2) (n = 25) 2.5 (0.2) (n = 26) –
198862 1 year 2.7 (0.2) (n = 23) 2.5 (0.2) (n = 26) NS
RCT
LDL  [AIC data removed]
cholesterol
(mmol/l) Deakin et al.,  Baseline 2.7 (0.9) (n = 157) 2.7 (0.8) (n = 157) NSa
2003;47,48 200646 14 months 2.7 (0.9) (n = 150) 2.7 (0.8) (n = 141) p = 0.1
RCT
Triglyceride  [AIC data removed]
(mmol/l)
Brown et al., Baseline 11.9 (7.2)  (n = 128) 10.8 (6.6) (n = 128) –
200249,50 1 year 11.9 (10.8) (n = 113) 11.0 (8.2) (n = 113) NS
RCT
Deakin et al.,  Geometric mean (95% CI) Ratio of means: 
2003;47,48 200646 Baseline 2.2 (2.0 to 2.4)  2.0 (1.9 to 2.2)  NSa
RCT (n = 157) (n = 157)
14 months 1.8 (1.6 to 2.0)  1.8 (1.6 to 1.9) NSa
(n = 141) (n = 141)
Trento et al., Baseline 2.6 (95% CI 0.7 to 11.5)  1.7 (0.5 to 5.2)  –
2001;53 2002;54 (n = 56) (n = 56)
200455 2 years 2.1 (95% CI 0.7 to 6.9)  1.7 (0.6 to 3.9)  p = 0.053
RCT (n = 43) (n = 47)
5 years 2.17 (SD 2.30) 1.52 (0.75)  –
(n = 42) (n = 42)
Change –0.48 –0.28  NS
0–5 yearsb (95% CI –1.15 to 0.20) (–0.60 to 0.03)
Raz et al.,  Baseline 12.8 (1.8) (n = 25) 11.7 (1.9) (n = 26) –
198862 1 year 11.8 (1.3) (n = 23) 11.3 (1.7) (n = 26) NS
RCT
NS, not statistically significant. 
a Based on 95% CI (p > 0.05 if CI for a difference includes zero, or if CI for a ratio includes 1).
b Based on baseline values for those participants followed up to end-point.Oral hypoglycaemic treatment 
Stopping OHA therapy was an explicit objective of
the programme in two studies.63,64 Both reported
significant differences in the use of medication
between the intervention and control groups. In
the Kronsbein and colleagues study,63 the
proportion of patients not using glucose-lowering
medications in the intervention group rose 
from 32% to 62% between baseline and 
evaluation whereas it remained at 39% in the
control group. In the Domenech and colleagues
study,64 intervention patients had reduced their
average daily intake of OHAs (–1.4 tablets)
whereas the control group had increased intake
(+0.9 tablets), but units of the variance 
(±0.2 in each case) were not stated. This 
outcome would need to be interpreted along with
the outcome on measures of glycaemic control,
which in this study showed a difference between
groups but this difference was not statistically
significant.
Interestingly, these studies were both CCTs rather
than RCTs. In the Kronsbein and colleagues
study,63 the intervention patients came from
practices in which their physician chose to
participate immediately in the programme.
Although the physicians of both intervention and
control patients had attended a training session, 
it is possible that those physicians who chose to
start the programme immediately were more
motivated to change the treatment of their
patients. In the Domenech and colleagues study,64
the intervention and control patients were treated
by the same physicians; however, there was no
blinding as to which patients were in which group.
These two interventions were also the most brief,
consisting of only 6–8 hours of education over
4 weeks.
In the Trento and colleagues trial,53–55 data were
presented on the numbers of participants being
treated on diet alone, OHAs and insulin. No
statistically significant differences were observed
between the intervention group or the comparator
group after 2 years of follow-up. The data were not
presented as changes from baseline values, and no
data were presented at the 5-year follow-up. In the
Cooper and colleagues trial,56–58 changes in drug
treatment were assessed as either moving from
diet treatment to oral drug treatment, or from oral
drug treatment to insulin treatment. Data showed
that more patients in the intervention group had
treatment increased or decreased relative to
baseline but this was not statistically significantly
different from changes in the control group. [AIC
data removed].
Outcomes reflecting diabetic end-points
Very few of the studies included complications as
outcomes, usually because the follow-up in these
studies was too short. It is acknowledged that for
the most part it is not feasible for studies to be of
long enough duration to assess these longer-term
end-points. However, those that were reported are
shown in Table 10.
There were no statistically significant differences
between the intervention and control groups for
any of these outcomes. In the study by Ko and
colleagues,45 the median frequency of hospital
admissions due to any diabetic complications over
4 years was reported to differ significantly between
the treatments (p = 0.005). However, to which
treatment group the data presented by Ko and
colleagues refers, for this outcome, is unclear as
the tabulated and narrative descriptions of the
findings do not concur.
Outcomes reflecting quality of life and
cognitive measures
It is possible that interventions may affect the QoL
of patients either in conjunction with or instead of
effects on physiological or behavioural measures.
However, few studies included measures of QoL or
knowledge using validated instruments. Reported
effects on QoL and diabetes knowledge that were
assessed using validated instruments are given in
Table 11; details of the instruments are given in
Appendix 7.
Two published trials46,47,53 reported on QoL using
a validated scale. In the Trento and colleagues
study,53 the Diabetes Quality of Life (DQOL) scale
was used. This scale used questions that were to be
answered on a Likert scale such that lower overall
scores reflect higher satisfaction. This study
reported results from 2 years follow-up from
inception; however, educational sessions were
conducted every 3 months throughout the 2-year
period. At 2 years the intervention did statistically
significantly improve patients’ QoL compared with
that in the control group, which had deteriorated.
In a follow-up study at 5 years, this trend
continued, where the mean change in DQOL was
–23.7 in the intervention group compared with
19.2 in the control group. When interpreting this
analysis, it is important to note the level of drop-
outs in the samples, although this was at a similar
rate in each comparison arm of the trial. In the
trial by Deakin and colleagues,46,47 no statistically
significant difference in QoL as measured by the
Audit of Diabetes-Dependent Quality of life
(ADDQoL) was observed between the treatment
group and control group after 14 months,
Assessment of clinical effectiveness
26although it would appear that the change in mean
scores was greater in the treatment group than the
control group. In this study, the
intervention–evaluation interval was much larger
as participants had a 6-week intervention and then
were followed up at 14 months. Speculatively, this
may account for the difference in findings between
the two studies. [AIC data removed].
Three of four studies46,47,53,63 reporting results for
knowledge measures demonstrated that
intervention patients had a statistically
significantly higher knowledge of diabetes than
the control patients and this continued for up to
5 years in the Trento and colleagues study.53
Patients who are more knowledgeable are better
able to communicate with their physicians and
likely to feel in better control of their own health.
However, it is unclear whether knowledge of
diabetes alone has any effect on metabolic control
(see, e.g., Glasgow and Osteen66).
Cooper and colleagues56 reported significantly
better attitudes to diabetes and its treatment in the
intervention group at 12 months on the Diabetes
Integration Questionnaire {baseline 72.8
[standard deviation (SD) 13.2], 12 months 75.1
(SD 11.0)} than the control group [baseline 76.7
(SD 14.2), 12 months 70.5 (SD 11.0), p < 0.01].
The test measured the integration of diabetes and
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TABLE 10 Diabetic end-points from studies of self-management education in adults with Type 2 diabetes
Outcome Study and design Time-point Intervention Control Differences 
between 
groups
Diabetic Trento  et al., 2001;53 Baseline 42/8/6 (n = 56) 38/13/5 (n = 56) –
retinopathy 2002;54 200455 2 years 35/5/3 (n = 43) 33/7/7  (n = 47) NS
(none/mild/ RCT
more severe)
Foot ulcers Trento et al., 2001;53 Baseline 54/0/2 (n = 56) 53/2/1 (n = 56) –
(never/past/active) 2002;54 200455 2 years 42/1/0 (n = 43) 45/1/1 (n = 47) NS
RCT
Mean (SD)  Trento et al., 2001;53 Baseline 91.94 (14.14) (n = 56) 91.05 (14.14) (n = 56) –
creatinine 2002;54 200455 2  years 88.8 (16.5) (n =  43) 87.8 (17.2) (n = 47) NS
(mol/l) RCT 5 years 75.14 (25.63) (n = 42) 78.67 (47.73) (n = 42) –
Change –16.79 –12.37 NS
0–5 years (95% CI  (–26.52 to 2.65)
–25.63 to –10.60)
Proportion Campbell  et al.,  (No baseline  Individual education NS
consulting 199651 data) (baseline n = 57, end-point n = 38) (all pairwise 
ophthalmology RCT 1 year 97 contrasts)
(%) Group education
(baseline n = 66, end-point n = 37)
95
Behavioural education
(baseline n = 56, end-point n = 47)
89
Proportion Campbell  et al.,  (No baseline  Individual education NS
consulting 199651 data) (baseline n = 57, end-point n = 31) (all pairwise 
podiatry
RCT
1 year 55 contrasts)
(%) Group education
(baseline n = 66, end-point n = 30)
73
Behavioural education
(baseline n = 56, end-point n = 42)
74
NS, not statistically significant. its treatment into the lifestyle and personality of
the patient. Higher scores indicate better
psychological adjustment to diabetes.
The QoL and knowledge results suggest that some
of these programmes may affect the psychological
well-being of patients with diabetes, although
these effects are by no means universal.
Interim summary
Of the studies designed to instruct patients about
multiple components of self-management for
Type 2 diabetes, the majority compared a single
intervention with a usual care control group over
12 months. One study followed up patients for 
5 years and another for 4 years.
Some effects of education on diabetic control, as
measured by HbA1c, were demonstrated in some
studies. These were mostly attributable to longer-
term interventions that had a shorter interval
between the intervention’s conclusion and the
follow-up. There may also be an effect of 
having a multi-professional team delivering the
Assessment of clinical effectiveness
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TABLE 11 QoL and knowledge from studies of self-management education in adults with Type 2 diabetes
Outcome Study and design Time-point Mean (SD) (unless stated) of outcome Differences
(scale) between
Intervention Control groups
[AIC data removed]
[AIC data removed]
QoL Deakin et al.,  Baseline –2.2 (2.2) (n = 157) –1.9 (2.2) (n = 157) NSa
(ADDQoL: 2003;47,48 200646 14 months –1.4 (1.7) (n = 100) –1.7 (2.1) (n = 91) NS
–9 to +9) RCT
QoL Trento et al., Baseline 67.6  (19)  (n = 56) 66.7 (25)  (n = 56) –
(Modified 2001;53 2002;54 2 years 55.6 (15.9) (n = 43) 80.8 (31.5) (n = 47) p < 0.01
DQOL: 39  200455 5 years 43.7 (7.2)  (n = 42) 89.2 (30.1) (n = 42) –
questions:  RCT Change –23.7 19.2 p < 0.001
each 1 to 5) 0–5 years (95% CI –30.0 to –17.3) (95% CI 8.4 to 29.9) –
Knowledge Deakin et al.,  Baseline 7.5 (3.5) (n = 157) 7.0 (3.1) (n = 157) NSa
(0–14) 2003;47,48 200646 14 months 9.3 (3.1) (n = 100) 7.8 (2.7) (n = 91) p < 0.001
RCT
Knowledge Campbell et al.,  Mean (SEM)  Individual education NS
(DKNA) 199651 change from  (baseline n = 57, end-point n = 29) (all pairwise 
baseline 4.4 (0.6) contrasts)
RCT Group education
(baseline n = 66, end-point n = 26)
4.2 (0.5)
Behavioural education
(baseline n = 56, end-point n = 35)
5.6 (0.6)
Knowledge Trento et al.,  Baseline 14.9 (7.9) (n = 56) 20.2 (7.4) (n = 56) –
(GISED: 2001;53 2002;54 2 years 24  (6.6) (n = 43) 17.4 (8.6) (n = 47) p < 0.01
0 to 38) 200455 5 years 27.9 (5.7) (n = 42) 18.0 (8.5) (n = 42) –
RCT Change 12.4 –3.4 p < 0.001
0–5 years (95% CI 9.7 to 15.2) 95% (CI: –1.1 to –5.7)
Knowledge Kronsbein et al.,  Baseline 9 (3) (n = 65) 9 (3) (n = 62) –
(based on  198863 1 year 13 (4) (n = 50) 10 (4) (n = 49) p < 0.01
NIDDM  CCT
questionnaire)
ADDQoL, Audit of Diabetes-Dependent Quality of Life; DKNA, Diabetes Knowledge scale – form A; DQOL, Diabetes
Quality of Life measure; GISED, Group of the Italian Society for Diabetes.
a Based on 95% CI (p > 0.05 if CI for a difference includes zero).educational programme. There was little effect on
weight loss or BMI shown. Two studies reported
reduced usage of OHAs in the intervention
groups. 
Very few studies were of long enough duration to
report outcomes relating to diabetic end-points.
Where these were reported, no significant effects
were demonstrated.
Patients’ QoL was assessed with a validated
measure in only two published trials [AIC data
removed]. QoL was better in the intervention
group than the control group in one published
trial but no difference was demonstrated between
groups in the second published study. [AIC data
removed]. Diabetes knowledge scores were found
to be significantly higher amongst participants in
the intervention groups in three studies.
Trials of focused self-management
interventions
Rather than educating patients on all aspects of
diabetes self-care as in the studies just discussed,
the following studies attempted to address specific,
limited topics in diabetes self-management.
Quantity and quality of evidence
Eight studies (seven RCTs, one CCT) comparing
focused self-management education for patients
with Type 2 diabetes met the inclusion criteria for
the review and are reported in Table 12 and
Appendix 5. These interventions focused on diet
and exercise (four studies67–69,74), diet,70 exercise,72
weight versus self-regulation73 or weight versus
self-monitoring of blood glucose (SMBG).71 Study
sample sizes were generally small, varying from
2073 to 104.74 Three of the included studies
compared education in more than two groups of
patients.67,70,74 All trials that reported the study
setting carried out the trial in primary care. Two
trials did not report the setting.67,73 Duration of
diabetes was not widely reported. In the four trials
that reported duration it ranged from newly
diagnosed68 to 13 years.69 The majority of trials
followed up their participants for 12 months from
inception; the follow-up was 18 and 24 months in
the trials by Kaplan and colleagues67 and
Uusitupa and colleagues,68 respectively. 
The quality of reporting and methodology of the
included studies was poor by today’s standards
(Tables 13 and 14). No details of an adequate
method of randomisation, or concealment of
allocation were reported in any of the included
trials. The similarity of groups at baseline and the
eligibility criteria were reported in all seven
included RCTs. No trial reported analysis 
by ITT.
Description of interventions
These interventions, due to their focused nature,
are more self-explanatory than those that included
a range of diabetes-related topics. However, as in
the previous group of interventions, it is often
difficult to describe the exact nature of the
interventions as published reports were vague or
incomplete. Some assumptions as to the
interventions have been made by the reviewers
based on the reported outcomes used or vague
descriptions (see below). An overview of the
different interventions is provided here; further
details can be found in the relevant sections in
Appendix 5.
Interventions for diet and exercise
Four studies focused on diet and exercise.67–69,74
Detailed dietary education was provided in each of
these studies and two of the four68,69 used
individualised dietary programmes. Another67
used the American Diabetes Association (ADA)
exchange diet. Little detail of the nature of the
dietary education was reported in the fourth
study.74
Exercise programmes were individualised in two of
the studies67,69 and in one other study68 exercise
was recommended at a particular intensity and
frequency for all. Little detail of the nature of the
exercise programme was reported in the fourth
study.74 Three of these interventions used
behaviour modification principles to greater or
lesser extents. One study67 required a monetary
deposit that was returned with the meeting of
goals and meeting attendance. One used
contracts69 and the other68 used food records. 
All of these studies involved at least some 
group work. 
Providers of the interventions varied but generally
involved teams of specialists such as dieticians,
nutritionists, DSNs and physicians. In the
Gilliland and colleagues study,74 a trained
community mentor provided the intervention.
Only two studies mentioned that they 
trained educators, but no further detail was
given.69,74
The duration and intensity of the interventions
varied. Two interventions involved approximately
9 hours of contact.68,69 One of these involved six
monthly sessions, the other was six sessions
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TABLE 12 Included studies of focused self-management education for Type 2 diabetes [ordered by type (RCT, CCT) and size (largest
first)]
Reference and  Intervention No. of  Duration of  Timing of 
design participants intervention evaluationa
Kaplan et al.,  Four groups 87 10 weeks 18 months
198767 1. Group diet education. Dietician delivered. 
RCT 20 contact hours
2. Group exercise education. Contact hours 
not given
3. Group diet and exercise education over 5 weeks, 
no details contact time
4. Control education in group with team – each 
gave a lecture. ~14 contact hours
Uusitupa et al., Two  groups
1992–668 1. Diet and exercise education. Provided by a team.  86 12 months 24 months
RCT Contact = 6 clinic visits (duration not given)
2. Usual care control. Local health centre visits 
every 2–3 months + outpatient clinics
Both groups given basic diabetes education
Ridgeway et al., Two  groups:
199969 1. Group diet and exercise education. Nurse and  56 6 months 12 months
RCT dietician delivered. 9 contact hours
2. Usual care control. No details
Wing et al.,  Three groups: 53 16 weeks 16 months
198570 1. Diet – behaviour modification
RCT 2. Nutrition education
3. Usual care (with nutrition education)
Groups 1 and 2 = group education provided by 
psychologist and nutritionist. Contact = 
16 weekly sessions
Group 3 = content identical with group 2 but only 
4 monthly meetings
Wing et al.,  Two groups: 50 12 months 62 weeks
198671 1. Diet – weight control. Contact time not given
RCT 2. Diet – SMBG. Contact time ~ 20 meetings
Samaras et al., Two  groups:
199772 1. Exercise education. Group sessions provided by  26 6 months 12 months
RCT a team. Contact time ~6 hours
2. Usual care. routine clinic visits + 3 assessment 
visits (no details of duration)
Wing et al., Two  groups:
198873 1. SMBG with education on meaning of SMBG  20 10 months 68 weeks
RCT (‘self-regulation’), 13 sessions
2. SMBG (‘self-monitoring’). Contact time not given
Gilliland et al.,  Three groups: 104  10 months 12 months
200274 1. Friends and family. Group culturally appropriate  (Mexican-
CCT diet and exercise education with support. 5 sessions,  American)
one every 6 weeks, for ~2 hours
2. One-on-one. Individual culturally appropriate diet 
and exercise education. 5 sessions, once every 
6 weeks for ~45 minutes
3. Usual care control (some education but not 
culturally appropriate and no details given)
a Based on the start of the intervention.Health Technology Assessment 2008; Vol. 12: No. 9
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T
ABLE 13
Quality assessment of RCT
s of focused education for T
ype 2 diabetes [ordered by type (RCT
, CCT) and size (largest first)]
Study
R
andomisation
Concealment 
Baseline 
Eligibility 
Blinding of 
P
rimary 
ITT analysis 
Missing values
of allocation
characteristics
criteria
assessors
outcome 
results
K
aplan 
et al., 1987
67
Unknown
Unknown
R
eported
Y
es
Unknown
Inadequate
Unknown
R
eported
Uusitipa 
et al., 1992–6
68
Unknown
Unknown
R
eported
Y
es
Unknown
Adequate
Inadequate
Unknown
Ridgeway 
et al., 1999
69
Unknown
Unknown
R
eported
Y
es
Unknown
Inadequate
Inadequate
Adequate
Wing 
et al., 1985
70
Unknown
Unknown
R
eported
Y
e
s
Unknown
P
artial
Unknown
P
artial
Wing 
et al., 1986
71
Unknown
Unknown
R
eported
Y
es
Adequate
P
artial
Unknown
R
eported
Samaras 
et al., 1997
72
Unknown
Unknown
R
eported
Y
e
s
Unknown
P
artial
Unknown
Unknown
Wing 
et al., 1988
73
Unknown
Unknown
R
eported
Y
es
Not applicable
P
artial
Inadequate
P
artial
T
ABLE 14
Quality assessment of CCT of focused education for T
ype 2 diabetes
Study
Baseline 
Eligibility 
Blinding of 
P
rimary 
ITT analysis
Missing values
R
epresentativeness
characteristics
criteria
assessors
outcome results
Gilliland 
et al., 2002
74
R
eported Y
es
Unknown
Adequate
Inadequate
P
artial
Nobimonthly. Another67 involved 20 hours of contact
in 10 2-hour meetings over 10 weeks. The group
intervention in the Gilliland and colleagues
study74 involved approximately 12 contact hours
over 10 months, and the individual intervention
approximately 4 hours over the same period.
In studies with a control group, participants
underwent usual care, most often provided by
their physicians or local clinics, and received clinic
appointments as necessary.
Other focused interventions
Four other studies involved focused interventions
that were each unique.
One study72 used an exercise intervention. This
intervention was theoretically motivated using the
‘proceed–precede’ health promotion model which
is built on the notion that health and health risks
are determined by multiple factors.75 The
intervention involved group sessions focusing on
barriers to exercise, diabetes and exercise, self-
esteem, goal-setting, etc. Education sessions were
followed by group aerobic exercise sessions. The
intervention formally involved 6 months of
sessions, but exercise sessions were also available
after 6 months.
One study70 compared a diet intervention with a
weight loss-focused intervention. This study only
reported within-group differences and is not
discussed further.
One study71 compared a group who focused on
the relation between weight loss and BG control
with a group who focused on weight control. This
study used behaviour modification for weight
control with self-monitoring of calories by diaries.
Patients gave a deposit which was returned on the
basis of meeting goals and attendance. There were
12 weeks of weekly meetings followed by monthly
meetings for the next 6 months and follow-up
sessions at 9 and 12 months.
Another study73 was similar to the previous one
using a behavioural weight control programme
and use of participants’ monetary deposits. The
two groups in this study differed in what they were
taught about SMBG. One group (self-regulation)
was taught how to use SMBG information to
regulate behaviour using behaviour modification
principles. The other group (self-monitoring) was
taught how to do SMBG but not how to use the
information. The intervention involved 13 sessions
in 16 weeks with follow-up education sessions
lasting until 10 months.
Assessment of effectiveness
Outcomes reflecting diabetic control
Table 15 shows the results for GHb for the
included studies that considered focused
interventions.
The Kaplan and colleagues intervention involving
combined diet and exercise67 produced
significantly lower HbA1c than in a control group
who received only didactic education. The diet
plus exercise intervention produced a sizeable
reduction in HbA1c (–1.48%), whereas the drop
was small in the diet group (–0.46%) and HbA1c
increased from baseline in the exercise group
(+1.3%) and education group (+0.36%). The diet
plus exercise intervention was the most intensive
intervention involving 20 hours of contact, but it
lasted only 10 weeks. Therefore, this effect was
reasonably long-lasting as the outcome was
measured at 18 months.
In the Uusitupa and colleagues study,68 mean
levels of HbA1c did not differ between the
intervention and control groups (although there
was a marginal difference at 12 months), but the
proportion of patients with HbA1c 7.0% was
greater in the intervention group. This was true at
both the 12- and 24-month evaluations. Again,
this was a long-lasting effect as the intervention
ceased at 12 months. In the Gilliland and
colleagues CCT,74 all groups saw an increase in
HbA1c but the two intervention groups combined
showed a significantly smaller rise than the control
group.
The Samaras and colleagues exercise study72
reported no overall significant differences in
HbA1c between intervention and control patients.
However, HbA1c levels among patients who were
treated with metformin or diet alone rose less in
intervention patients (change +0.4) than in
control patients (+1.5%), p < 0.05. 
The remaining four studies did not report any
differences in measures of GHb between
intervention and control groups (Ridgeway and
colleagues’ study69) or between different
interventions (Wing and colleagues’ studies70,71,73). 
Blood pressure
Only two studies68,74 reported BP results. There
were no significant differences between the
intervention and control groups in the Uusitupa
and colleagues study.68 There was a significant
difference in diastolic BP between the two
intervention groups combined [Friends and family
–6.5 (±2.0), One-to-one –0.4 (±1.7)] and the
Assessment of clinical effectiveness
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TABLE 15 Glycated haemoglobin (%) findings from studies of focused education in adults with Type 2 diabetes [ordered by type (RCT,
CCT) and size (largest first)]
Study and  Outcome Time-point (Mean ± SD) (unless stated) Differences
design between
Intervention Control groups
Diet and exercise interventions
Kaplan et al., HbA1 (%) Diet Overall 
198767 Baseline 8.97 (2.82) (group n values not reported) difference 
RCT 18 months 8.51 (group n values not reported) between 
Exercise groups, 
Baseline 8.16 (3.44) (group n values not reported) p < 0.10; diet 
18 months 9.46 (group n values not reported) + exercise 
Diet + exercise differs from 
Baseline 9.18 (2.46) (group n values not reported) education, 
18 months 7.70 (group n values not reported) p < 0.05
Education
Baseline 8.21 (1.54) (group n values not reported)
18 months 8.57 (group n values not reported)
Uusitupa et al., HbA1c (%) Baseline 7.1 (1.8) (n = 40) 7.8 (2.0) (n = 46) p = 0.06
1992–668 12 months 6.6 (1.6) (n not reported) 7.5 (1.7) (n not reported) NS
RCT 24 months 7.2 (1.9) (n = 38) 8.0 (1.6) (n = 44)
Uusitupa et al., HbA1c Baseline 7.4 (n = 40) 7.8 (n = 46) NS
1992–668 (% adjusted) 12 months 6.7 (n not reported) 7.3 (n not reported) NS
RCT 24 months 7.4 (n = 38) 7.9 (n = 44)
Uusitupa et al., HbA1c Baseline Not reported (NR) (n = 40) NR (n = 46)
1992–668 (% patients  12 months 74.4% (n not reported) 47.8% (n not reported) p < 0.01
RCT with 7.0%) 24 months 55.3% (n = 38) 31.8% (n = 44) p < 0.05
Ridgeway et al.,  GHb Baseline 12.3 (2.2) (n = 28) 12.3 (SD3.0) (n = 28) NS
199969 12 months 11.52 (n = 18) 11.64 (n = 20)
RCT
Gilliland et al., HbA1c Reported  Friends and  One-to-one
200274 (% values  are  family
CCT adjusted) changes from  +0.5 (0.3) +0.2 (0.3) +1.2 (0.4) Between 3 
baseline (baseline (baseline  (baseline  n = 33,  groups, 
n = 32,  n = 39,  end-point n = 33) p < 0.05
end-point end-point  Between 
n = 32) n = 39) Friends family 
and 
One-to-one 
combined and 
control, 
p < 0.05
Other focused interventions
Wing et al., HbA1 Weight control
198671 Baseline 10.86 (2.0) (n = 25)
12 months 10.44 (2.16) (n = 22)
RCT Glucose monitoring
Weight vs  Baseline 10.19 (2.51) (n = 25)
SMBG 12 months 10.19 (2.29) (n = 23)
continuedcontrol group [–0.3 (±2.1)] in the Gilliland and
colleagues CCT.74
BMI or weight
Five studies reported either BMI or
weight.68,69,72–74 In none of these studies was there
a significant difference between the intervention
and control groups. In one study74 there was a
significant difference in weight between the two
intervention groups combined [Friends and family
–2.0 (±1.5), One-to-one –1.8 (±1.5)] compared
with the control group [+1.7 (±1.8)]. Any effect
on BMI or weight may be attributed to more
motivated participants remaining in the
intervention arms of this study. 
Cholesterol and triglycerides
Four studies reported cholesterol and triglyceride
levels.68,69,72,74 There were no reported differences
between the intervention and control groups for
total cholesterol, HDL cholesterol, LDL
cholesterol or triglycerides in these studies.
Treatment intensity
Uusitupa and colleagues68 reported the
percentage of patients taking glucose-lowering
drugs. At 24 months, 12.5% of intervention
patients and 34.8% of control patients were taking
drugs (p < 0.01). Wing and colleagues71 reported
no significant differences in medication decreases
between patients trained in weight control and
those trained in glucose self-monitoring.
Outcomes reflecting quality of life and cognitive
measures 
One study67 considered QoL effects using a
validated measure (see Appendix 7). In this study,
QoL was significantly better in the diet (+0.03)
and diet plus exercise groups (+0.06) than in a
didactic education control group (–0.04). The
differences are small, but placed on an overall scale
of 0 to 1.0 they may be meaningful to patients.
Summary of clinical effectiveness
A wide variety of interventions have been designed
to impact on self-management of diabetes in
patients with Type 2 diabetes. Many have
attempted to instruct patients about the multiple
facets of self-care required whereas others have
focused on changing major lifestyle characteristics
that have a negative impact on BG control (e.g.
diet and/or exercise). There have also been limited
attempts to tailor interventions to particular
cultural subgroups of the population (e.g.
Mexican-Americans).
In general, the impact on outcomes that are
relevant to patients (e.g. HbA1c, QoL, or long-
term complications) has been limited in these
programmes. 
On measures of diabetic control (mostly using
measures of glycaemic control), it appears from
the evidence that in general the educational
programmes that affected diabetic control were
those delivered over longer intervals and/or those
that provided more frequent contact between the
participants and the educators. However, there
were some interventions that did result in long-
lasting effects on GHb despite longer intervals
between the last point of contact with the
educators and the point of outcome measurement. 
Assessment of clinical effectiveness
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TABLE 15 Glycated haemoglobin (%) findings from studies of focused education in adults with Type 2 diabetes [ordered by type (RCT,
CCT) and size (largest first)] (cont’d)
Study and  Outcome Time-point (Mean ± SD) (unless stated) Differences
design between
Intervention Control groups
Samaras et al., HbA1c 12 months + 0.86 (SEM 0.29) + 0.86 (SEM 0.27) NS
199772 (reported (baseline  n = 13,  (baseline n = 13, 
values are  end-point n = 13) end-point n = 13)
RCT changes from 
Exercise baseline)
Wing et al., HbA1 Self-regulation NS
198873 Baseline 10.57 (SEM 0.44) (n = 10)
12 months 10.8 (SEM 0.8) (n = 9)
RCT Self-monitoring
self-regulation vs Baseline 10.54 (SEM 0.55) (n = 10)
self-monitoring 12 months 9.71 (SEM 0.78) (n = 8)Reductions in the need for OHAs may also be an
important measure of the success of an
intervention. This may be particularly true if
glycaemic control levels are already relatively low
in patients. Two multifaceted interventions
demonstrated reduced use of OHAs,63,64 as did
one focused intervention.68 From the results of
these studies, it is difficult to say what
characteristics of an educationally based
intervention may be crucial to successful metabolic
control in Type 2 diabetes. The two multifaceted
interventions that reduced the use of OHAs were
based on the same basic programme. Surprisingly,
these interventions were limited in contact
(6–8 hours).
Most studies were far too short to allow for the
measurement of diabetic complications. None of
the studies of short-term complications reported
any significant effects. 
Few studies measured QoL using a validated
measurement scale. One published study of a
multifaceted intervention reported a significant
improvement in QoL, whereas another did not.
[AIC data removed]. The published study which
demonstrated an improvement in QoL between
the two groups was an intervention that involved
multiple sessions spaced over most of the entire
evaluation period and may therefore reflect the
effects of continual contact. 
Three studies reported significant improvements
in patients’ knowledge of diabetes. It is not
surprising that educational programmes should
affect knowledge. If anything, it is perhaps
surprising that more studies did not report such
effects. Some studies did not test for knowledge
changes or did not use a validated measure to do
so. Improved knowledge is desirable, but its
relation to metabolic control is unclear.66
Most of the interventions aimed at Type 2 diabetes
were group interventions. The study designs
included in this review do not allow for any strong
conclusions about the merits of group versus
individual interventions. However, generally those
studies that reported significant results used group
interventions. Groups have the advantages that
patients can serve as support for one another and
may form a sort of behaviour modification milieu
even if the intervention itself is not formally
oriented towards behaviour modification. In
addition, group interventions are generally less
costly and allow staff to use the time they devote
to patient education more efficiently.
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eviews of educational interventions in diabetes
were identified and checked for
methodological rigour. Those that did not use
systematic methods are excluded from further
discussion. 
The systematic reviews did not use the same
inclusion criteria as those set out for the current
review. In particular, most did not impose any
requirement for a long-term follow-up. In
addition, many allowed a wider range of study
designs including single-group, pre-test, post-test,
designs. Due to these differences, the reviews have
not been data extracted and will not be discussed
in detail. Instead, the bibliographies of these
reviews have been used as sources of studies that
meet our inclusion criteria. Five systematic reviews
of educational interventions in Type 2 diabetes
were located76–80 and brief summaries are
provided below.
In a review by Norris and colleagues,76 72 studies
of self-management training were included. They
reported short-term positive effects (<6 months)
for knowledge, frequency and accuracy of SMBG,
self-reported dietary habits and glycaemic control.
“With longer follow-up, interventions that used
regular reinforcement throughout follow-up were
sometimes effective in improving glycaemic
control” (p. 561). This review concluded that self-
management training in Type 2 diabetes is
effective in the short term, but that further
research is needed.
A second review by Norris and colleagues77 was
based on the search strategy of the previous review
and discussed a subset of the same trials included
in the above review. Studies with follow-up periods
shorter than 1 year were included. Thirty-one
studies were assessed to evaluate the effects of self-
management education on glycaemic control. The
findings were similar to those reported above.
“Self-management education improved GHb levels
at immediate follow-up, and increased contact
time increases the effect. The benefit declines
1–3 months after the intervention ceases, however,
suggesting that learned behaviours change over
time.” (p. 1159). Improvements in GHb averaged
only 0.26% in studies with follow-up of
4 months, suggesting that it is difficult to
maintain improvements in glycaemic control
without maintenance of educational or other
supportive contact. 
Norris and colleagues78 also reviewed the
effectiveness and economic efficiency of self-
management interventions for people with Type 2
diabetes in community settings. Thirty trials met
the inclusion criteria and evaluated a variety of
outcomes, over a range of follow-up periods. 
Self-management education was demonstrated 
to be effective in community gathering places 
(e.g. community centres, libraries) in terms of
glycaemic control at 6 months. Evidence was
insufficient for outcomes such as dietary intake,
physical activity and blood pressure and was also
inadequate to assess the effects of interventions in
the workplace or at home.
A systematic review was also conducted by the
Alberta Heritage Foundation for Medical
Research.79 This review stated that reliable
conclusions could not be made as to which types
of programmes or components are most effective
in improving self-management in Type 2 diabetes
or which category of patients might benefit most.
“There is no consistent pattern of effect across
outcomes based on type of intervention, length of
educational intervention, core team composition
or type of educational setting; and there is no
standard method to describe formal patient
diabetes education programmes and interventions,
thus making it difficult to replicate studies.” (p. ii).
Deakin and colleagues80 conducted a systematic
review to investigate group-based training for self-
management of Type 2 diabetes. They included
RCTs and CCTs in which group-based education
was compared with routine treatment, a waiting
list control or no intervention. They excluded
studies for which follow-up was less than 6 months
and/or group size was less than six patients.
Eleven studies (eight RCTs and three CCTs)
comprising 1532 patients met these inclusion
criteria (of which six studies are included above in
the current review). Overall, at 12–14 months
follow-up, the intervention group had a
significantly lower weighted mean HbA1c (%)
(seven trials), and a significantly higher weighted
mean diabetes knowledge score (three trials). 
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Chapter 4
Evidence from systematic reviewsA significantly larger number of patients in the
intervention group reduced their use of diabetes
medication over 12–14 months (five trials). The
significant treatment effect on HbA1c was also
supported at 24 months’ follow-up (two trials).
The overall conclusion from these findings was
that group-based education in self-management
strategies improves clinical and lifestyle outcomes
in patients with Type 2 diabetes.
These systematic reviews had some differences in
their aims and therefore some differences in their
inclusion criteria. In addition, the systematic
reviews were undertaken at different points in
time. Overall, the reviews seem to concur with
many of the findings of the present review.
Evidence from systematic reviews
38P
orta and Trento81 reported preliminary results
of an Italian 4-year multi-centre study
(ROMEO: Rethink Organization to iMprove
Education and Outcomes) that is comparing
group care versus individual care in 812 patients
with Type 2 diabetes. At the time of censoring
searches for the present review, results of this
study were restricted to a description of the
baseline characteristics of the patient 
populations. 
Samuel-Hodge and colleagues82 reported
preliminary findings from a 1-year church-based
intervention for diabetes self-management in
North Carolina, USA (DAWN: Diabetes AWareness
Network). The study was aimed at African-
Americans with Type 2 diabetes and involved 24
churches and a total of 201 participants. Although
the study was completed in 2003, only outcome
data for baseline (pre-intervention) populations
are available at the time of writing (January 2007).
The DESMOND study, an RCT of a structured
group education programme for people with
newly diagnosed Type 2 diabetes is ongoing at the
time of writing. This multi-centre practice based
trial aims to recruit 1000 participants and will
compare structured education with control groups
receiving structured care. The intervention arm
will have a structured group education programme
providing 6 hours of contact time between patients
and healthcare professionals. Outcomes will
include HbA1c, lipid profiles, QoL and
psychosocial outcomes and will be assessed at
12 months.
The effectiveness of patient self-managed
structured education for Type 2 diabetes (The
Diabetes Manual), a multi-centre cluster RCT, is
ongoing at the time of writing. This is a 24-month
study which aims to examine the effectiveness of a
patient self-managed structured education
programme, called the Diabetes Manual, 
for Type 2 diabetes in primary care. Outcomes
include measures of glycaemic control,
psychological distress, QoL and self-efficacy 
at 6 months and maintenance of effect at
12 months. The study aims to recruit 424 
eligible patients and GP practices will be
randomised into intervention or 6-month 
waiting list control groups.
A multi-centre RCT, ‘Does the chronic disease self-
management programme (Xpert Patient
Programme) improve metabolic control of
diabetes?’ is in progress and is expected to
complete in 2008. The study aims to recruit 255
participants. The nature of the educational
intervention is not described on the National
Research Register.
A Phase II trial of an Internet-based group
diabetes self-management education programme
is ongoing in the USA. Participants with Type 2
diabetes are randomised to participate in the
Internet programme or serve as controls
continuing with usual care. Participants will
participate in a structured 6-week interactive web-
based online class with 20–24 other participants
and two trained peer moderators. This study is
funded by the Robert Wood Johnson Foundation
and expects to complete in June 2008
(ClinicalTrials.gov [NCT00372463]).
Cochrane Review protocols are available for two
systematic reviews that will investigate the
effectiveness of educational or education-related
interventions for patients with Type 2 diabetes
(The Cochrane Library, 2006, Issue 4). Colagiuri
and colleagues83 aim to evaluate interventions for
individual patient education, whereas Armour and
colleagues84 intend to evaluate interventions for
maintaining physical activity in diabetic patients,
which could include educational strategies.
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Chapter 5
Research in progressStatement of principal findings
Across the studies whose interventions aimed to
teach multiple aspects of diabetes self-
management, the effects on measures of diabetic
control, such as HbA1c, BMI or cholesterol, were
variable. Whereas some studies showed a
statistically significant effect of education on
HbA1c, others did not. In the case of reduction in
HbA1c, statistically significant effects were in the
region of a 1% change in many of the studies,
which may reflect a clinically significant effect. A
number of studies showed significant effects of
education on weight loss but less showed
significant effects on BMI. Very few studies showed
significant effects of education on lipid
concentrations. On measures of diabetic
complications (e.g. retinopathy) or outcomes
which may be considered as possible indicators of
diabetic complications (e.g. consultations with
ophthalmologists), very few studies had a long
enough follow-up duration to measure these but,
where they did, no significant effects were seen.
QoL (using a validated scale) was only measured
by two published studies [AIC data removed] and
the results were conflicting, but knowledge was
shown to have been influenced by education.
Some effects of education on measures of diabetic
control were demonstrated in studies focusing on
diet or exercise alone. Although the effects were
not large, those that were present did appear to be
relatively long-lasting. Overall, inconsistent effects
of educational interventions aimed at patients with
Type 2 diabetes make the results difficult to
interpret; there were positive effects of
interventions in each of the types of outcomes
considered, but also studies reporting few or no
significant effects of the educational interventions. 
Interventions which were more frequent and
extended over a longer period did appear to
improve outcomes more than less frequent,
shorter duration interventions, but this
observation has not been tested in a scientific way.
As education for people with Type 2 diabetes is
already provided, and because there is likely to be
little negative effect of education on participants,
it should continue. However, there is little
evidence to suggest whether and how educational
programmes might currently be directed to
achieve maximal benefit for patients with Type 2
diabetes.
In the PEWG structured education report,32 four
key criteria were noted for education programmes:
they should have a structured, written curriculum;
have trained educators; be quality assured; and be
audited. The present review includes only studies
with a reasonable amount of information about
the intervention, the topics covered, the provider
and the sessions. Although not expressed as such
in the publications, it is our view that in the most
part these included studies would have had a
structured, written curriculum to some extent or
other. However, only five of the 21 published
studies [AIC data removed] reported that they
provided training for the diabetes educators and
only three of these gave any details. Data on
quality assurance or audit was not extracted from
the studies in the present review.
Other considerations
Complexity of the interventions
Patient education is an example of a complex
intervention as it is a package of care that has
several interconnecting components. This presents
a number of problems for evaluation and also for
the interpretation of any demonstrated effects. It
is difficult to establish with any precision what the
‘active ingredient’ causing any such effect is. It
may be, for example, that knowledge of one key
topic is responsible for the effect; on the other
hand, it may be that it is a subtle combination of
factors that may thereafter be difficult to
reproduce, beyond the setting in which the
education was undertaken, or with the providers of
the education. 
Not only are educational interventions complex in
themselves, but they exist in a complex
environment of management of a chronic disease.
Educational interventions will interact with factors
such as the medical management of diabetes, the
overall healthcare setting in which patients are
routinely seen and patient lifestyles. These factors
may affect the effectiveness of an intervention or
may have indirect impacts through other factors,
such as compliance. Ideally, these complexities
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Chapter 6
Discussionwould be considered in modelling exercises and
pilot studies prior to conducting an RCT as
recommended by the Medical Research Council
(MRC) framework for the development and
evaluation of RCTs for complex interventions.85
Few of the interventions seem to have been
developed in a way such that the crucial
components of interventions can be teased apart
from those aspects that may be less important.
The MRC framework describes the need to
establish the theoretical basis of why the
intervention should have the anticipated effect.
This is seen as the first phase of any study design.
Given the poor quality of reporting, it is unclear
whether certain characteristics of studies have
simply not been reported or whether they were
not incorporated into the studies. Primary among
these is a theoretical foundation to the
intervention under study. Although health
psychology is well established and a great number
of findings suggest that there are particular
methods of health promotion that are more
effective than others, very little of this research
seems to have been incorporated into studies of
diabetes education. This is a disappointing finding
as an integrated, theoretically motivated, approach
may improve the effects of the intervention.
Confounding
There is likely to be confounding in some studies
of this nature, for instance, personal factors such
as the personality types of participants who
volunteer for a research trial and who are able to
remain throughout the duration of the trial. In
some studies, the participants were to a greater or
lesser extent self-selected. When people volunteer
to participate in programmes it is always a concern
that they may be more motivated or otherwise
differ from those who have not volunteered and
this may affect the generalisability of results.
Similarly, results of self-report measures may be
compromised as some participants may try to
anticipate the desired effect or to give socially
desirable answers; these are reasons for ensuring
that self-report measures are validated instruments
which may reduce some confounding and/or bias
in patients’ outcomes. 
Quality of study design
The designs of several studies were flawed. A few
that claimed to be randomised were only
randomised in the broadest sense, for instance
randomly choosing the order in which
interventions would be implemented in
consecutive groups of patients. These studies have
been classed as CCTs in this report. 
Several studies also had fairly small sample sizes
and therefore are likely to have been
underpowered, particularly when multiple
interventions were tested. Very few studies
mentioned performing prior power calculations in
order to determine an appropriate size for the
study.
Quality of reporting
The quality of reporting of important design
issues was mostly poor. The method of
randomisation was usually not described and most
studies made no mention of any efforts to conceal
the allocation of patients to treatment groups.
This is a major shortcoming that can produce
significant bias. 
Although a prerequisite for including trials in this
review was a good level of detail about the
interventions, in terms of the topics covered, the
providers and the number and nature of the
sessions, many of the included studies still did not
include enough detail about interventions to allow
them to be replicated. This shortcoming is
important, not only scientifically, but practically. If
studies have shown that an intervention has been
effective, then sufficient detail should have been
provided to allow that intervention to be
implemented, and tested, in other settings. 
Another problem that relates to the poor quality
of reporting is uncertainty about the nature of the
control group in many of the studies. Several
studies stated that the control group was receiving
‘usual care’. However, in many cases what this
consists of is unclear. As a result, the extent to
which the interventions actually differed from the
controls is sometimes unclear. The lack of a clear
boundary between interventions and controls can
obscure the determination of what component of
the intervention may be effective and it may
influence the size of effect that is shown for an
intervention (either an over- or underestimate).
Generality of studies is difficult to determine if it
is not clear to what extent a study resembles the
practice setting where the intervention might be
implemented. 
These issues might in part reflect word length
limits in peer-reviewed publications; however,
some studies were able to provide more detail
than others. Ideally, complex studies or those
necessitating lengthy descriptions should be
supported in the literature by online material or
by cross-referencing between publications to
ensure that all the important methodological
details can be presented.
Discussion
42Length of follow-up
Because diabetes is a chronic disease with a
natural history of worsening metabolic control and
the development of very serious long-term
complications, it is critical to demonstrate that
interventions can have lasting effects. Ideally, trials
should report on interventions evaluated after a
reasonably long follow-up in which no further
intervention was conducted. However, there are
very few such studies in the diabetes education
literature.
Clearly, studies that report results immediately
following an intervention or those with very brief
follow-up are not useful in this context. Such
studies were excluded, unless outcomes were
evaluated at least 12 months following the
introduction of an intervention. A few of these
studies involved relatively short interventions with
long follow-ups, but many used relatively lengthy
interventions with additional educational sessions
at intervals throughout almost all of the study
follow-up period. With such a mix of designs, it is
difficult to draw any conclusions about whether
there are time-limited interventions in diabetes
education that are effective. It is therefore difficult
to draw any conclusions as to the optimum length
of an intervention. Of the included studies, 14
reported results at interim time-points and,
although these are not reported in the present
review, it is worth pointing out that nine of these
showed a significant effect of diabetes education
on HbA1c at earlier analyses (12 months) than
the end-point analysis. Only three of these also
demonstrated significant effects of the intervention
on HbA1c at end-point analysis (12 months).
Although long-term studies are desirable, care is
needed to ensure that bias is not caused by the
introduction of other interventions, or by
changing the initial interventions, in response to
changes in the participants’ circumstances.
Attrition
Many included studies had fairly high levels of
drop-out between initial recruitment and
reporting of results. This is problematic for a
number of reasons. Only one study reported that
an ITT analysis was carried out; the other studies
tested for differences between intervention and
control groups on the basis of patients who
remained in each group at the time of evaluation.
When there is considerable attrition this can
produce misleading results, particularly if there is
differential attrition between groups. If, for
instance, the most motivated patients remain in an
intervention while those who are less motivated
drop out, then the estimate of effectiveness for an
unselected group of patients would be
overestimated. Even testing for (or statistically
adjusting for) differences in baseline characteristics
will not adjust for effects such as motivational
differences that are not captured in baseline
evaluations. If attrition is greater in the control
group than the intervention group, this could
reduce the estimate of the effectiveness of the
intervention (for example, if the patients who are
least motivated toward self-management and who
are most ill are those most likely to leave the study).
High attrition rates affect the validity of study
results, but they are also of practical concern. If an
intervention results in very high attrition rates,
then it is questionable as to whether large numbers
of patients would attend such an intervention once
it is implemented in a healthcare setting. 
Transferability
Of the 21 studies, only three were carried out in
the UK,46,56,59 all of which addressed complete
self-management interventions. The remaining
trials were carried out in the USA (eight studies),
Australia (two studies), and Argentina, Finland,
Germany, Israel, Italy, Korea, Sweden and The
Netherlands (one study each). It is unclear to what
extent educational interventions delivered in other
countries are transferable to the UK and it is
important to consider this within the context of
these interventions. Cultural issues, not only of
ethnicity, but also of traditions and customs, may
have an impact upon outcomes. Patient health
beliefs and attitudes are likely to differ from one
country to another, and the healthcare context
(private/state provision) may also affect outcomes.
Generality of results may be reduced if
participants are not adequately representative of
the population groups likely to suffer from the
condition. For example, diabetes is more prevalent
in socially isolated individuals and within groups
known to have health inequalities, but trials have
tended either not to include participants with
these backgrounds or, when such groups have
been included, they have not been analysed
separately from other groups.
Strengths and limitations of the
assessment
The systematic review has the following strengths:
● It is independent of vested interest.
● The systematic review brings together the
evidence on the effectiveness of diabetes
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consistent methods of critical appraisal and
presentation.
● A broad and thorough systematic search of the
literature has identified English-language RCTs
and has highlighted gaps in the literature and
areas for further research.
● The work was guided by the best practice
principles for undertaking a systematic 
review. 
● Before undertaking the review, the methods
were set out in a research protocol (Appendix
1), which was commented on by an advisory
group. The protocol defined the research
question, inclusion criteria, quality criteria, 
data extraction process and methods employed
to undertake the different stages of the 
review.
● An advisory group has informed the review
from its initiation, through the development of
the research protocol and completion of the
report.
In contrast, there were certain limitations:
● Owing to time constraints, there was a lack of
follow-up with authors of the primary studies to
clarify methodological details and results.
However, it is unlikely that further details from
the authors would have changed our overall
conclusions. 
● Inclusion was limited to English language due
to time constraints. 
● Synthesis of the included studies was through
narrative analysis with no quantitative meta-
analysis because of the many differences in the
interventions, the designs, and the outcome
measures described in the included studies.
This update review does not substantially alter the
conclusions of the previous systematic review; for
each outcome (HbA1C, weight, BMI, cholesterol and
lipids, complications, QoL and diabetes knowledge)
the proportion of studies that demonstrated
significant effects of education was similar.
Discussion
44Implications for service provision
National policy initiatives support the role of self-
management education programmes in improving
health in Type 2 diabetes and recommendations
and guidance have been issued for establishing
high-quality patient-education programmes. Based
on the evidence reviewed in this report, it would
seem that education delivered by a team of
educators, with some degree of reinforcement of
that education made at additional points of
contact, may provide the best opportunity for
improvements in patient outcomes. This remains
in line with the conclusions of the previous
systematic review. The implications of this for
service provision would be the need for educators
to have time and resources to fulfil the needs of
any structured educational programme, and for
there to be a clear programme for the education.
These issues are currently set out in national
strategy (see current service provision) and it is
expected that there should not be barriers to their
implementation if resources are made available as
part of these policy recommendations. The
evidence reviewed provided little information on
the training of trainers and as such a key question
remains as to whether the level of training of
educators could affect the success of the education.
From the evidence reported, it is unclear how
much resource would need to be directed at the
educators themselves to ensure that they can
deliver programmes successfully. 
There is no evidence at present to suggest that
locally implemented interventions that meet the
recommendations and guidance for practice issued
by national policy would be better, or worse,
placed to achieve the goals of self-management
education compared with nationally implemented
interventions. 
Suggested research priorities
Despite being based upon the best available
empirical evidence, this review has only been able
to give limited guidance about the effectiveness of
educational interventions for Type 2 diabetes. This
reflects the complex and heterogeneous multi-
component nature of the interventions, which has
not been helped by poor reporting in some cases.
Several areas would benefit from further
clarification (see below). When thinking about
these, it is important for researchers to consider
patient education as a complex intervention.
Research methodologies are required that allow an
understanding of the processes involved so that
outcomes can be interpreted correctly. Education
should be considered in the context of overall
diabetes management and future evaluations
should be considered in the broader context of
understanding theory, testing intervention
interactions and longer-term surveillance after
testing effectiveness. The MRC framework
provides useful recommendations for developing
evaluations of complex interventions. 
● Long-term studies of the effectiveness of
diabetes education are desirable because the
natural progression of diabetes is to worsen over
time, and because diabetes self-management
behaviour may decline through time if not
reinforced. Future long-term RCTs of diabetes
education interventions face challenges because
a non-intervention control arm may be difficult
to justify as practitioners are set targets to
achieve optimal glycaemic and BP control. The
design of any future study looking at diabetes
education would therefore require creativity
around the nature of the control group and to
minimise attrition bias, which was a particular
problem in the studies reviewed. Currently, there
is insufficient evidence to determine whether
newly diagnosed and previously diagnosed
patients should receive similar educational
interventions and researchers may wish to
consider these subgroups in any future research.
● Realistically, long-term monitoring of clinical
effects and complications of diabetes is unlikely
to happen in all but a minority of trials.
Therefore, the pace at which diabetes education
programmes are implemented is likely to
exceed the rate of generation of supporting
evidence. Accordingly, procedures should be
available, or developed, to monitor closely the
performance of education programmes once
implemented. This will require careful
consideration about methodology, in order to
provide meaningful information in the absence
of randomisation and control populations.
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Chapter 7
Conclusions● Information is needed to clarify the sensitivity
of diabetes education programmes to the
performance of the diabetes educators, in order
to ensure success and cost-effectiveness of
education programmes. 
● The generality of diabetes education
programmes is very difficult to establish from
the available literature, partly because trials
have been carried out in specific clinical or
cultural settings, and partly because reporting
has been of a poor standard. Future studies
could benefit by more explicitly evaluating the
generality of their findings, in order to
maximise possible uptake and wider relevance
of the work.
● Research should also address the issues around
the methodologies of systematic reviews of
complex interventions and particularly issues
around quantitative meta-analysis of data from
such studies.
Conclusions
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52Full title of research question 
Clinical effectiveness of models for educating
people with Type 2 diabetes mellitus in diabetes
self-management.
Clarification of research question
and scope
● This research updates a previous systematic
review on self-management interventions for
diabetes. It was commissioned to inform the
NICE Type 2 diabetes guideline update. 
● The primary question for this review is whether
current models of diabetes self-management
education are clinically effective. 
● Self-management in diabetes refers to achieving
and maintaining BG control through diet,
exercise, oral medications and insulins.
● The potential clinical benefit of an effective
programme of education would be better self-
management. This may be measured in the
long term by a reduced level of diabetes-related
complications and in the short term by
maintenance of recommended levels of BG
control, as reflected by GHb levels and
hypoglycaemic episodes. Other potential
benefits would be greater flexibility of lifestyle,
and hence better QoL.
● The main comparator for this review will be
usual care in clinics or primary care. This will
vary amongst clinics and general practices, but
will include informal education and
unevaluated, locally developed education
packages. 
● Self-management interventions are generally
complex, often including education in addition
to changes in the intensity of medical
treatment. This type of data may provide
limited information about the educational
interventions per se (without confounding with
intensity of treatment). 
Report methods
● The review will be undertaken as systematically
as time allows following the general principles
outlined in NHS CRD Report 4.
Search strategy 
● We will search the following databases:
Cochrane Systematic Reviews Database,
Cochrane Central Register of Controlled Trials,
NHS CRD (University of York) databases
(including DARE, NHS EED and HTA
database), MEDLINE (Ovid), MEDLINE In
Process (Ovid), EMBASE (Ovid), PsycINFO
(Ovid), CINAHL (Ovid), ERIC, Science Citation
Index, Biosis Previews, ISI Proceedings (Web of
Knowledge), National Research Register,
Clinical Trials.gov and Current Controlled
Trials.
● Searches will include RCTs, CCTs, systematic
reviews and meta-analyses for evidence of
efficacy. Searches will include terms relating to
learning mechanisms, so as to exclude trials
that appraise the effectiveness of self-
management alone, since the focus of the
review is on how to facilitate self-management,
rather than whether self-management in itself is
valuable. 
● Searches will be limited to the years from 2002
to the present and will also be limited to English
language. Reports published only as meeting
abstracts will be excluded. Unpublished Masters
dissertations and theses will be excluded. 
● All studies will be collated and filtered on
retrieval of the abstracts and full papers.
Bibliographies of included studies and other
relevant papers will be assessed for relevant
studies.
● Expert advisers will be asked to comment on
the comprehensiveness of our searches.
Inclusion and exclusion criteria
● Systematic reviews and meta-analyses of RCTs
and CCTs and also individual RCTs and CCTs
will be included.
Design
● RCTs and CCTs that compare a specific
educational programme with usual care or with
another educational programme will be
included. Because diabetes care is constantly
evolving, CCTs must have a concurrent control
group.
● RCTs or CCTs that compare models of group
education with individual education will be
included.
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Appendix 1
Protocol methodsIntervention
● The review will be limited to educational
interventions, that is, the dissemination of
knowledge and skills brought about using a
number of approaches, which can be carried
out with the normal range of personnel
available in diabetes care. Trials that 
evaluate specific, specialised psychological
interventions such as cognitive/behavioural or
psychoanalytic therapy or counselling alone will
be excluded. Educational interventions that
include a psychological component will be
included. 
● Studies of education solely about specific
complications (e.g. foot care) will not be
included.
● Studies of case management interventions will
not be included.
Reporting
1. In order potentially to inform practice,
included studies must be reported with
sufficient detail to be reproducible. They 
must describe the main components 
of the educational programme, 
such as: 
(a) what the intervention is with some
description of the topics covered
(b) who provides instruction (e.g. post and
qualification)
(c) how education is delivered (e.g. in person,
by computer)
(d) group or individual
(e) length of intervention (length and number
of sessions)
(f) target audience (e.g. Type 2; newly
diagnosed)
(g) didactic or interactive instruction
(h) training for the educators.
Educational interventions that are not described 
in sufficient detail to replicate will not be
included.
Participants
● Participants should be diagnosed with Type 2
diabetes using the standard diagnostic criteria
in effect at the inception of the study. Both
newly diagnosed and participants with
established diabetes will be included. Studies
which include a mixed group of Type 1 and
Type 2 participants, or that do not clearly
define the type of diabetes as being Type 2, 
will be excluded.
● Participants should be described as ‘adults’ or a
minimum of 80% of participants should be
18 years of age or older.
Outcomes
● Diabetes is a chronic condition and
complications may not appear for years after
diagnosis. Many ‘lifestyle’ interventions do 
not have lasting effects. Therefore, included
studies must report results from a minimum 
of 1 year after the beginning of the
intervention. 
● To be included, studies must report at least one
of the primary outcomes: long-term blood
glucose levels (HbA1c), severe hypoglycaemic
episodes, diabetes-related complications or QoL
[as assessed by validated measures, e.g. Short
Form with 36 Items (SF-36)].
● Additional outcomes that will be reported if
available within trials that meet the other
inclusion criteria will include: BP, hospital
admissions, relief of distress or anxiety, uptake
of screening (e.g. eye screening or BP checks),
patient knowledge, patient satisfaction,
achievement of individual treatment goals and
resource use/costs. Any psychological measures
must be evaluated with validated psychometric
instruments.
● Results that address individual preferred
learning styles or meeting the needs of ethnic
minorities or others with specific needs will be
included if they are reported in studies that
meet the inclusion criteria set out above.
● Inclusion and exclusion criteria will be 
applied by one reviewer and checked by a
second. Any disagreement will be resolved by
discussion.
Data extraction strategy
● Data concerning details of the study population,
the intervention and outcomes will be extracted
by one person and checked by a second. Any
disagreements will be resolved through
discussion. A draft data extraction sheet is
attached, but is subject to change.
Quality assessment strategy
● The quality of included systematic reviews will
be assessed using the NHS CRD (University of
York) six criteria.
● Quality assessment for RCTs will be done in
accordance with Chapter II.5 of CRD Report 4
(2nd Edition). The criteria for blinding patients
and care providers are not achievable for this
intervention and will not be included. 
● Quality assessment for CCTs will focus on
comparability of groups and the assessment of
outcomes.
● Criteria will be applied by one reviewer and
checked by a second with any disagreements
resolved through discussion. 
Appendix 1
54● If sufficient numbers allow, the reporting of
results may be subject to a sensitivity analysis
based on the quality of included studies. Where
the quality of any included studies is assessed to
be particularly poor, the reporting of these
studies within the review may be restricted.
Methods of analysis/synthesis
● Clinical effectiveness will be synthesised through
a narrative review with tabulation of results of
included studies. 
● Data will be combined statistically if of sufficient
quantity and quality and if sufficiently similar 
by meta-analysis using Review Manager
software. 
Research in progress 
● Research in progress will be sought by searching
protocols on the Cochrane Database of
Systematic Reviews, the National Research
Register, Current Controlled Trials and the
MRC Trials database, plus personal
communication with the review advisors.
External advisory group
The review will be informed by an external
advisory group made up of a number of experts
drawn from relevant disciplines. These experts will
be chosen according to academic seniority and
content expertise. The advisory group will also
include a methodological advisor. External
advisors will see a complete and near final draft of
the review and will understand that their role is
part of external quality assurance. Advisors will be
required to sign a copy of the NCCHTA
Confidentiality Acknowledgement and
Undertaking form and be asked to alert us of any
potential conflicts of interest.
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he databases described in Appendix 1 were
searched for published studies, and recently
completed and ongoing research. All searches
were limited to English language only. Update
searches were undertaken in January 2007.
Search strategies for the main databases are
described below.
Cochrane Library Issue 3 (2006)
#1 MeSH descriptor Diabetes Mellitus, Type 2
explode all trees
#2 ((typ* 2 or type ii or type two) NEAR/5
diabet*)
#3 NIDDM:ti
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Patient Education explode
all trees
#6 MeSH descriptor Models, Educational
explode all trees
#7 MeSH descriptor Self Care explode all 
trees
#8 ((educat* or train* or learn* or teach*)
NEAR/3 (patient* or self* or program* or
model* or system*))
#9 MeSH descriptor Self Efficacy explode all
trees
#10 (#5 OR #6 OR #7 OR #8 OR #9)
#11 (#4 AND #10)
#12 (#11), from 2002 to 2006
#13 (random* or control* near (study or group
or trial or usual care))
#14 (#12 AND #13)
Ovid MEDLINE 1966 to September
Week 4 2006
1 ((typ$ 2 or type ii or type two) adj5 diabet$).ti.
(832)
2 ((adult-onset or "adult onset" or matur$ or late
or slow or stable) adj4 diabet$).ti. (13)
3  (NIDDM or (("non insulin" or non-insulin or
noninsulin) adj5 diabet$)).ti. (29)
4 1 or 2 or 3 (868)
5 ((educat$ or train$ or learn$ or teach$) adj3
(patient$ or self$ or program$ or model$ or
system$)).ti,ab. (2160)
6 (self$ adj3 (care$ or monitor$ or regulat$ or
manage$)).ti,ab. (547)
7 (self regulat$ or self manage$ or self care or
self monitor$).ti,ab. (457)
8 (blood glucose adj4 (monitor$ or regulat$ or
manage$ or control$)).ti,ab. (158)
9 (patient$ adj3 (empower$ or control$ or
manage$ or regulat$)).ti,ab. (4092)
10 5 or 6 or 7 or 8 or 9 (6577)
11 10 and 4 (108)
12 limit 29 to english language (83)
13 randomized controlled trial.pt. (286)
14 controlled clinical trial.pt. (20)
15 clinical trial.pt. (312)
16 (clin$ adj5 trial$).mp. [mp=title, original title,
abstract, name of substance word] (3982)
17 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
or 39 or 40 (4269)
18 ((singl$ or doubl$ or tripl$ or trebl$) adj5
(blind$ or mask$)).tw. (1665)
19 placebo$.tw. (2287)
20 random$.tw. (16773)
21 or/13-20 (20459)
22 21 and 12 (26)
23 (review or review-tutorial or review-
academic).pt. (499)
24 meta-analysis.pt. (2)
25 (meta-analys$ or meta analys$ or
metaanalys$).mp. [mp=title, original title,
abstract, name of substance word] (910)
26 (systematic$ adj9 review$).mp. [mp=title,
original title, abstract, name of substance
word] (992)
27 (systematic$ adj9 overview$).mp. [mp=title,
original title, abstract, name of substance
word] (18)
28 (quantitativ$ adj9 review$).mp. (77)
29 (quantitativ$ adj9 overview$).mp. [mp=title,
original title, abstract, name of substance
word] (6)
30 (quantitativ$ adj9 synthesis$).mp. (41)
31 (methodologic$ adj9 review$).mp. (112)
32 (methodologic$ adj9 overview$).mp. (9)
33 (integrative research review$ or research
integration).mp. (1)
34 or/23-33 (1898)
35 34 and 12 (3)
36 35 not 22 (1)
PsycINFO (Ovid) including Psyc
ARTICLES 2000–present
1 exp Diabetes Mellitus, Type 2/ (0)
2 ((typ$ 2 or type ii or type two) adj5 diabet$).ti.
(287)
Health Technology Assessment 2008; Vol. 12: No. 9
57
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Appendix 2
Literature search strategies3 ((adult-onset or "adult onset" or matur$ or late
or slow or stable) adj4 diabet$).ti. (1)
4 (NIDDM or (("non insulin" or non-insulin or
noninsulin) adj5 diabet$)).ti. (12)
5 1 or 2 or 3 or 4 (299)
6 exp Patient Education/ (622)
7 exp models, educational/ (0)
8 exp Learning/ (28168)
9 ((educat$ or train$ or learn$ or teach$) adj3
(patient$ or self$ or program$ or model$ or
system$)).ti. (3143)
10 (self$ adj3 (care$ or monitor$ or regulat$ or
manage$)).ti,ab. (6453)
11 exp Self Care/ (529)
12 self administration/ or self medication/ (378)
13 self efficacy/ (3427)
14 (self regulat$ or self manage$ or self care or
self monitor$).ti,ab. (5206)
15 (patient$ adj3 (empower$ or control$ or
manage$ or regulat$)).ti,ab. (5737)
16 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
or 15 (45548)
17 letter.pt. (0)
18 editorial.pt. (0)
19 17 or 18 (0)
20 (5 and 16) not 19 (88)
21 limit 20 to (human and english language and
yr="2002 – 2006") (64)
22 controlled study/ (0)
23 single blind procedure/ (0)
24 double blind procedure/ (0)
25 clinical trial/ (878)
26 crossover procedure/ (0)
27 randomized controlled trial/ (0)
28 (trial or random$).ti,ab. (33665)
29 22 or 23 or 24 or 25 or 26 or 27 or 28 (33945)
30 21 and 29 (9)
31 (meta analy$ or metaanaly$ or systematic
review or systematic overview$).mp. [mp=title,
abstract, heading word, table of contents, key
concepts] (4749)
32 21 and 31 (1)
National Research Register – Searched
31 October 2006
#1. (diabet* and (model* or (self next care) or
(self next manage*))) 421 
#2. (diabet* and (patient and education)) 208 
#3. (#1 or #2) 568
#3 Limited to 2002–2006 317
In addition, handsearching of the bibliographies
of included studies was undertaken.
A flow chart of identification of studies is
presented in Figure 2.
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Identified on searching
n = 1696 
[AIC data removed]a
Abstracts inspected 
n = 1696
Excluded
n = 1643
Excluded
n = 42
Full papers inspected
n = 53
Papers for appraisal 
and data extraction
n = 11
(11 papers reported 
7 studies, 2 of which 
were updates of studies 
included in the 
2002 TAR )
[AIC data removed]
Included studies from the 2002 diabetes education 
review which were of type 2 diabetes: 16
aAIC data obtained from contacting experts
FIGURE 2 Flow chart of identification of studies (RCTs, CCTs
and systematic reviews) for clinical effectiveness systematic
review (update review searches only presented)Health Technology Assessment 2008; Vol. 12: No. 9
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Appendix 3
Inclusion criteria worksheet
Trial name or number: Comments
Patients with Type 2 diabetes?
NB exclude gestational diabetes Yes Unclear No
↓↓ →
next question next question EXCLUDE
Patients described as ‘adults’ or <20% under  Yes Unclear No
18 years old? ↓↓ →
next question next question EXCLUDE
RCT or CCT or Sys review/MA
NB CCT must have concurrent control Yes Unclear No
↓↓ ↓
next question next question EXCLUDE
Education programme?
NB exclude purely psychological/counselling  Yes Unclear No
interventions ↓↓ →
next question next question EXCLUDE
Education for self-management of diabetes? Yes Unclear No
NB exclude education for prevention/treatment  ↓↓ →
of specific complications (e.g. foot ulcer) next question next question EXCLUDE
Comparator: Educational programme vs usual  Yes Unclear No
care OR another ed. programme? OR Group  ↓↓ →
programme vs individual programme? next question next question EXCLUDE
Is description of intervention sufficient to  Yes Unclear No
reproduce? ↓↓ →
NB must include topics (or content obtainable). next question next question EXCLUDE
Other characteristics: provider, length & no. of sessions, 
target audience, mode of delivery (in person or 
distance), group or individual, didactic/interactive, 
changes in treatment
Follow-up from inception 1 year? Yes Unclear No Length of 
↓↓ → follow-up?
next question next question EXCLUDE
Report one or more of primary outcomes: HbA1c Yes Unclear No Costs reported?
OR severe hypos OR diabetic complications OR QoL? ↓↓ →
NB other outcomes will also be included if primary  next question next question EXCLUDE
outcomes reported.
Final Decision INCLUDE UNCLEAR EXCLUDE Results of 
(Discuss) Discussion:
1. Individual aspects of self-management, such as diet, exercise education alone to be included if there is a taught
component (and meet other criteria). Where only a diet is prescribed or where fitness training occurs with no taught
component, exclude.
2. Self-monitoring of diabetes – include any education programme directed at training in self-monitoring.
3. Exclude case management systems which are prompts for clinics, self-care behaviours, etc., which may or may not
include some aspects of education.
4. Include education about intensifying treatment even though the effect may be due to the intensification – this can be
discussed in the narrative.Health Technology Assessment 2008; Vol. 12: No. 9
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Appendix 4
Quality assessment criteria
1. Was the assignment to the treatment groups really random?
2. Was the treatment allocation concealed?
3. Were the groups similar at baseline in terms of prognostic factors?
4. Were the eligibility criteria specified?
5. Were outcome assessors blinded to the treatment allocation?
6. Was the care provider blinded? Not applicable
7. Was the patient blinded? Not applicable
8. Were the point estimates and measure of variability presented for the primary outcome measure?
9. Did the analyses include an ITT analysis?
10. Were withdrawals and drop-outs completely described?
Quality criteria for assessment of experimental studies
Some instructions for using a checklist for RCTs
Quality item  Coding Explanation
1. Was the assignment to the treatment groups really random?
Random sequence generation Adequate
Partial
Inadequate
Unknown
Adequate: random numbers table or computer and
central office or coded packages
Partial: (sealed) envelopes without further description
or serially numbered opaque, sealed envelopes 
Inadequate: alternation, case record number, birth
date or similar procedures
Unknown: just the term ‘randomised’ or ‘randomly
allocated’, etc.
2. Was the treatment allocation concealed?
Concealment of randomisation 
The person(s) who decide on eligibility should not
be able to know or be able to predict with
reasonable accuracy to which treatment group a
patient will be allocated. In trials that use good
placebos this should normally be the case; however,
different modes or timing of drug administration in
combination with the use of small block sizes of
known size may present opportunities for clinicians
who are also involved in the inclusion procedure to
make accurate guesses and selectively exclude
eligible patients in the light of their most likely
treatment allocation; in centres with very low
inclusion frequencies combined with very brief
follow-up times this may also present a potential
problem because the outcome of the previous
patient may serve as a predictor of the next likely
allocation
Adequate
Inadequate
Unknown
Adequate: when a paper convinces you that
allocation cannot be predicted (separate persons,
placebo really indistinguishable, clever use of block
sizes (large or variable). Adequate approaches might
include centralised or pharmacy-controlled
randomisation, serially numbered identical containers,
on-site computer-based system with a randomisation
sequence that is not readable until allocation, and
other approaches with robust methods to prevent
foreknowledge of the allocation sequence to
clinicians and patients
Inadequate: this option is often difficult. You have to
visualise the procedure and think how people might
be able to circumvent it. Inadequate approaches
might include use of alternation, case record
numbers, birth dates or week days, open random
numbers lists, serially numbered envelopes (even
sealed opaque envelopes can be subject to
manipulation) and any other measures that cannot
prevent foreknowledge of group allocation
Unknown: no details in text. Disagreements or lack
of clarity should be discussed in the review team
continuedAppendix 4
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Quality item  Coding Explanation
3. Were the groups similar at baseline regarding the prognostic factors?
Baseline characteristics
Main aim is to enable the reviewer to see which
patients were actually recruited. It enables one to
get a rough idea on prognostic comparability. A real
check on comparability requires multi-variable
stratification (seldom shown)
Reported
Unknown
Consult the list of prognostic factors or baseline
characteristics (not included in this appendix)
Reviewer decides
4. Were the eligibility criteria specified?
Prestratification
Consult the list of prognostic factors or baseline
characteristics (not included in this Appendix)
Adequate
Partial
Inadequate
Unknown
Single-centre study
Adequate: prestratification on at least one factor
from the list or no prestratification if the number of
patients exceeds a prespecified number.
Partial: leave judgement to reviewer 
Inadequate: stratification on a factor(s) not on our list
or no stratification whereas the number of patients is
less than the prespecified number
Unknown: no details in text and no way to deduce
the procedure from the tables.
Multi-centre study
Adequate: must prestratify on centre. Within each
centre the criteria for single-centre studies also apply
Partial: impossible option 
Inadequate: no prestratification on centre or violating
the criteria for single-centre studies (see above)
Unknown: no details in text and no way to deduce
the procedure from the tables
5. Were outcome assessors blinded to the treatment allocation?
Blinding of assessors
The assessor may be the patient (self-report), the
clinician (clinical scale, BP…) or, ideally, a third
person or a panel. Very important in judgement of
cause of death but unimportant in judgement of
death
Adequate
Inadequate
Unknown
Adequate: independent person or panel or (self)
assessments in watertight double-blind conditions
Inadequate: clinician is assessor in trial on drugs with
clear side-effects or a different influence on
laboratory results, ECGs, etc.
Unknown: no statements on procedures and not
deducible
6. Was the care provider blinded?
Blinding of care givers
Look out for good placebos (see, hear, taste, feel,
smell), tricky unmasking side-effects accounting for
the subjectivity of the outcome measurements and
the accessibility of co-interventions by the care
givers
Adequate
Partial
Inadequate
Unknown
Adequate: placebo described as ‘indistinguishable’
and procedures watertight (use your imagination with
the ‘cheat’ in mind; e.g. statement that
sensitive/unmasking laboratory results were kept
separate from ward personnel)
Partial: just ‘double blind’ in text and no further
description of procedures or nature of the placebo
Inadequate: wrong placebo (e.g. fructose in trial on
ascorbic acid)
Unknown: no details in text
Co-interventions
Register when they may have an impact on any of
the outcome phenomena. Consult the list of
cointerventions (not included in this Appendix)
Adequate
Partial
Inadequate
Unknown
Adequate: percentages of all relevant interventions in
all groups
Partial: one or more interventions omitted or
omission of percentages in each group
Inadequate: not deducible
Unknown: no statements
continuedHealth Technology Assessment 2008; Vol. 12: No. 9
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Quality item  Coding Explanation
7. Was the patient blinded?
Blinding of patients
This item is hard to define. Just the statement
‘double blind’ in the paper is really insufficient if the
procedure to accomplish this is not described or
reasonably deducible by the reviewer. Good
placebos (see, hear, taste, feel, smell), tricky
unmasking side-effects accounting for the
subjectivity of the outcome measurements and the
accessibility of co-interventions by the patient are
required
Adequate
Partial
Inadequate
Unknown
Adequate: placebo described as ‘indistinguishable’
and procedures watertight
Partial: just ‘double blind’ in text and no further
description of procedures or nature of the placebo
Inadequate: wrong placebo
Unknown: no details in text
8. Were the point estimates and measure of variability presented for the primary outcome measure?
Results for the primary outcome measure Adequate
Partial
Inadequate
Unknown
Adequate: mean outcome in each group together
with mean difference and its standard error (SE) or
standard deviation (SD) or any CI around it or the
possibility to calculate those from the paper. Survival
curve with log-rank test and patient numbers at later
time-points
Partial: partially reported
Inadequate: no SE or SD or SD without N
(SE = SD/N)
Unknown: very unlikely
9. Did the analysis include an ITT analysis?
ITT analysis 
Early drop-out can make this very difficult. Strictest
requirement is sensitivity analysis including early
drop-outs
Adequate
Inadequate
Reviewers should not just look for the term ITT but
assure themselves that the calculations were
according to the ITT principle
Compliance 
Dosing errors and timing errors
Adequate
Partial
Inadequate
Unknown
Adequate: Medication Event Monitoring System
(MEMS or eDEM)
Partial: blood samples, urine samples (use of indicator
substances)
Inadequate: pill count or self-report
Unknown: not mentioned
Check on blinding
Questionnaire for patients, care givers, assessors
and analysis of the results; the (early) timing is
critical because the treatment effect may be the
cause of unblinding, in which case it may be used as
an outcome measure
Reported
Unknown
Reviewer decides
continued
Dealing with missing values
The percentage missing values on potential
confounders and outcome measurements (seldom
given) is a rough estimate of a trial’s quality. One
can carry them forward, perform sensitivity analysis
assuming the worst and best case scenarios, use
statistical imputation techniques, etc. Note that the
default option (deletion) assumes that the value is
randomly missing, which seems seldom justified
Adequate
Partial
Inadequate
Unknown
Adequate: percentage of missing values and
distribution over the groups and procedure of
handling this stated
Partial: some statement on numbers or percentages
Inadequate: wrong procedure (a matter of great
debate)
Unknown: no mention at all of missing and not
deducible from tablesQuality criteria for assessment of CCTs – CRD Report 4
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Quality item  Coding Explanation
Loss to follow-up
This item examines both numbers and reasons;
typically an item that needs checking in the
methods section and the marginal totals in the
tables. Note that it may differ for different outcome
phenomena or time-points. Some reasons may be
reasons given by the patient when asked and may
not be the true reason. There is no satisfactory
solution for this
Adequate
Partial
Inadequate
Unknown
Adequate: number randomised must be stated.
Number(s) lost to follow-up (dropped out) stated or
deducible (from tables) for each group and reasons
summarised for each group
Partial: numbers, but not the reasons (or vice versa) 
Inadequate: numbers randomised not stated or not
specified for each group
Unknown: no details in text
Were the groups similar at baseline in terms of prognostic factors?
Were the eligibility criteria specified?
Were outcome assessors blinded to the treatment allocation?
Were the point estimates and measure of variability presented for the primary outcome measure?
Did the analyses include an ITT analysis?
Were withdrawals and drop-outs completely described? 
Were participants likely to be representative of the intended population?Health Technology Assessment 2008; Vol. 12: No. 9
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Appendix 5
Data extraction forms
Interventions of multifaceted self-management education (RCTs in
alphabetical order, followed by CCTs)
Reference and  Intervention Participants Outcome 
design measures
Study: Brown
et al., 200249,50
Source: Journal
article
Country: USA
Setting:
Community
Language: English
Trial design: RCT
Treatment intervention:
Culturally referenced diabetes self-
management group education
intervention using didactic and
interactive approach, delivered in
person. 4 cohorts over 1 year
Topics: nutrition, self-monitoring,
exercise, hygiene, illness days, foot
care, complications (short and long
term). Promotion behaviour changes
through problem-solving, food
preparation demonstrations and
social support
Provider: Mexican-American nurses,
dieticians and community workers
Sessions: 52 contact hours (3 months
of weekly 2-h sessions, 6 months of
biweekly + 3 months of monthly 2-h
support group sessions)
Theory: based on results of four
meta-analytic reviews and 6 years of
development and piloting of
intervention
Delivery: groups with each participant
bringing a ‘support’ person
Treatment changes:
Training trainers: 4 nurses and 4
dieticians attended seminars on
diabetes education and participated
in supervised clinical practicum with
outpatients. 8 community workers
with Type 2 diabetes participated in
an 8-week programme on diabetes
self-management
Mode: written materials limited due
to low literacy rates. Language
predominantly Spanish with a blend
of English and each participant
nominated a family member as a
support person. Ref. 16 in trial gives
more details of intervention plus
Table 1, p. 261
Control intervention:
Usual care by physicians or local
clinics (wait-list controls)
Duration of intervention:
12 months
Eligibility/exclusion criteria: 
Inclusion: Type 2 diabetes (defined p. 260)
diagnosed after 35 years of age, aged
between 35 and 70 years, willing to
participate
Exclusion: if pregnant or if had medical
conditions for which diet and exercise
changes would be contraindicated
How selected: randomly selected from
rosters of previous research studies (none
intervention studies, all blood sampling).
Grouped by area of county in which they
lived
Numbers involved: 256 [128 intervention
(int.), 128 control (con.)]
Numbers on insulin: int. 25; con. 26
Tablets: int. 83; con. 86
Diet alone: int. 10; con. 7
Oral and insulin: int. 8; con. 7
Type of diabetes?: Type 2
Mean duration of diabetes: int. 7.6
(SD 5.8) years; con. 8.1 (SD 6.9) years
Baseline measurements of outcome
parameter (mean ± SD):
HbA1c int. 11.81% ± 3; con. 11.8% ±
3.02
BMI: int. 32.33 ± 5.97; con. 32.12 ± 6.35
Cholesterol: int. 211.83 ± 45.34; 
con. 203.57 ± 48.82
Triglycerides: int. 215.35 ± 130.07; 
con. 195.58 ± 118.95
Gender (M/F): int. 51/75; con. 40/86 
Mean age: int. 54.7 (SD 8.2) years; 
con. 53.3 (SD 8.3) years
Ethnic groups: all Mexican-Americans
Losses to follow-up: not reported.
Baseline data on 126 int. and 126 con.
patients, 12 months data based on 112 int.
and 112 con. patients
Compliance: attendance at first session
was 79%. At end of 12 months it was 50%.
Dropped to 40% at 13 weeks when focus
changed from education to support group
sessions
Primary
outcomes used:
HbA1c
Secondary
outcomes used:
diabetes-related
knowledge, fasting
BG, BP , total
cholesterol, HDL
and LDL
cholesterol,
triglycerides,
health beliefs,
home glucose
monitoring, BMI,
costs
Individual
preferred
learning style
addressed?: no
Any subgroups:
age and gender
Normal range(s)
for outcomes:
none reported
How outcomes
assessed?: no
details reported
Validated?:
physiological
measures yes,
knowledge and
health beliefs
unclear
Timing of
outcomes same
for both groups:
yes
Length of
follow-up:
12 months from
inception
continuedAppendix 5
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Outcome (mean ± SD) Intervention Control Difference between
groups
HbA1c (n = 112) 10.89% (2.56),  11.64% (2.85),  *p < 0.05
adjusted 10.87%* adjusted 11.66%
FBG (n = int. 114; con. 113) 194.95 (63.27)* 210.51 (66.55) *p < 0.05
Cholesterol (n = int. 112; con. 113) 189.88 (36.35) 187.64 (42.66)
Triglycerides (n = 113) 214.43 (194.93) 198.65 (148.38)
BMI (n = int. 113; con. 114) 32.17 (6.45) 32.28 (6.52)
Knowledge/beliefs not reported as not a validated measure. 3 and 6 months data reported
Costs: total for eight subjects/group = US$3070. Total per person US$384
Methodological comments
Allocation to treatment groups: reports that individuals allocated to groups and then later that groups were randomly assigned
to experimental or control conditions. In ‘data analysis’ section also states random assignment but no method described
Blinding of outcome assessors?: not reported
Allocation concealment?: not reported
Analysis by ITT?: see Method of data analysis
Comparability of treatment groups: reported to be no significant differences only any baseline variables
Method of data analysis: multi-level modelling (within subjects and between subjects analysis) which estimates for a given
subject from available data and thus doesn’t eliminate those with missing data. SD reported, no CIs
Sample size/power calculation: not reported
Attrition/drop-outs: not reported except numbers in results tables
General comments
Generalisability: high HbA1c at baseline, culturally referenced to Mexican-Americans, different cohorts over time
Conflict of interests: funded by National Institute for Diabetes and Digestive and Kidney Diseases and the Office of Research
on Minority Health
Other:
FBG, fasting blood glucose.
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
7. Did the analyses include an ITT analysis? Adequate
8. Were withdrawals and drop-outs completely described? Partial
Quality criteria for RCTs (CRD Report 4)Health Technology Assessment 2008; Vol. 12: No. 9
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Reference and  Intervention Participants Outcome 
design measures
Study: Brown 
et al., 200552
Source: Journal
article
Country: USA
Setting:
Community
(schools, churches,
day care centres,
health clinics)
Language: English
Trial design: RCT
Treatment intervention:
Some data (in italics) here taken
from previous publication.49
Topics: nutrition, home glucose
monitoring, physical activity, other
self-management topics [Hygiene,
illness days, foot care, complications
(short and long term)]. Promotion of
behaviour changes through problem
solving and goal setting
Provider: bilingual Mexican-American
nurses, dietitians and community
workers
Sessions: 52 contact hours over
12 months: 12 weekly 2-h sessions,
followed by 14 2-h support group
sessions
Audience: group based with family
member support
Delivery: didactic and interactive
approach
Treatment changes: Not reported
Training trainers: 4 nurses and 4
dieticians attended seminars on
diabetes education and participated
in supervised clinical practicum with
outpatients. 8 community workers
with Type 2 diabetes participated in
an 8-week programme on diabetes
self-management
Theory: based on results of four
meta-analytic reviews and 6 years of
development and piloting of
intervention
Mode: written materials limited due
to low literacy rates. Language
predominantly Spanish with a blend
of English
Control intervention: 
Culturally referenced compressed
(shorter) educational intervention
which was informed by focus groups
from a previous publication. NB:
some data (in italics) here taken from
previous publication49
Topics: nutrition, home glucose
monitoring, physical activity, other
self-management topics. 
Hygiene, illness days, foot care,
complications (short and long term).
Promotion of behaviour changes
through problem-solving and goal
setting
Provider: bilingual Mexican-American
nurses, dietitians, community
workers
Sessions: 22 contact hours over
12 months: 8 weekly 2-h sessions
Eligibility/exclusion criteria:
Inclusion: age 35–70 years, diagnosed with
Type 2 diabetes (two verifiable FBG results
140 mg/dl or taking or having taken insulin
or hypoglycaemic agents for 1 year).
Exclusion: pregnant or had medical
conditions for which changes in diet and
walking were contraindicated (e.g renal
failure or previous amputation)
How selected: selected from rosters of
ongoing genetic studies. Six cohorts were
recruited and individuals assigned to groups
organised within a specific area of the
county and then randomly assigned to
either condition. Four groups of eight
participants (and support people)
constituted each cohort, two groups were
randomly assigned to each intervention.
The same process occurred every 3 months
until 23 groups were enrolled
Numbers involved: 216 participants
selected. 114 to ‘compressed’ groups and
102 to ‘extended’ groups
Losses to follow-up: attendance at data
collection sessions averaged 82%, only
10 participants were considered by the
authors as true drop-outs as they did not
return to any data collection sessions
Numbers on insulin: 6.3% extended,
5.3% compressed
Tablets: 81.1% extended, 78.0%
compressed
No medication (diet alone): 10.5%
extended, 10.6% compressed
Duration of diabetes: not reported
Gender (F/M): extended 61/41,
compressed 69/45
Age (mean ± SD): extended 49.6 ±
8.2 years, compressed 49.6 ± 7.6 years 
Ethnic groups: Mexican-Americans
Compliance: attendance at data collection
sessions averaged 82%; however, this does
not measure compliance with the
intervention
Baseline measurements of outcome
parameters (mean ± SD): 
Age at diagnosis: extended 44.6 ± 9.2 years,
compressed 44.4 ± 8.3 years
BMI (kg/m2): extended 32.9 ± 8.3,
compressed 32.2 ± 5.8
HbA1c: extended 11.5 ± 3.5, compressed
11.8 ± 3.4
FBG: extended 190.5 ± 68.3, compressed
192.1 ± 64.4
Primary
outcomes 
used: HbA1c; 
FBG
Secondary
outcomes used:
diabetes
knowledge (data
not extracted as
the outcome was
not validated).
Also BP , BMI,
cholesterol,
triglycerides (data
not presented in
publication).
Others not
reported here as
do not fit the
protocol for this
review
Individual
preferred
learning style
addressed?: no
Subgroups: high
and low
attendance,
gender (not data
extracted)
Normal range(s)
for outcomes:
not reported
How outcomes
were assessed:
HbA1c by Glyc-
Affin GHb)
Validation of
outcomes: not
reported;
knowledge
instrument was
from an
unpublished thesis
– not validated
Timing of
outcomes the
same for both
groups?:
intervention
groups began
immediately after
baseline data
collection and data
were collected as
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Reference and  Intervention Participants Outcome 
design measures
Results
Outcome  Extended group,  Compressed group,  Comparisons between groups
n = 114 n = 102
Mean HbA1c change  n = 89 n = 96 Not significant (p-values of differences 
from baseline at  –1.0% –0.7% between groups not given).
12 months
HbA1c end-point value  n = 89 n = 96 Not reported
(12 months),  10.5 ± 3.0 11.1 ± 3.2
mean ± SD
FBG change from baseline  n = 89 n = 97 Not reported
at 12 months –16.7 –12.4
FBG end-point value  n = 89 n = 97 Not reported
(12 months), mean ± SD 173.8 ± 63.6 179.7 ± 61.6
Methodological comments
Allocation to treatment groups: no details reported
Blinding of outcome assessors: not reported
Allocation concealment: not reported
Analysis by ITT: method of data analysis suggests that all participants with missing data were incorporated into the analysis;
however, the numbers presented in the table of results suggest that missing data were not used
Comparability of treatment groups: reports no statistically significant differences between groups for any baseline measure
Method of data analysis: prospective repeated measure ANOVA. To handle missing data, hierarchical linear models were
applied by which non-randomly missing data were handled by including indicators of missing data patterns. States all analyses
were adjusted for baseline differences but no detail of which were included as statement made reporting no differences in
baseline noted
Sample size/power calculation: based on previous studies estimated that a total of 170 participants (85 in each intervention
group) provided power of 80% for detecting a medium between-group effect size on HbA1c (reference given). They
oversampled by 30% to help account for attrition
Attrition/drop-out: numbers reported but no reasons given
General comments
Generalisability: high HbA1c at baseline, culturally referenced to Mexican-Americans
Conflict of interests: unknown: funded by research award from National Institute for Research Awards
ANOVA, analysis of variance.
followed by 3 support sessions at 3,
6 and 12 months
Audience: group based with family
member support
Delivery: didactic and interactive
approach
Treatment changes: not reported
Training of trainers: as above
Theory: as above 
Both interventions also received
usual care
Duration of intervention:
12 months
Were the care programmes
identical? Unknown
each cohort
reached 3, 6, 12,
24 and 36 months 
Length of
follow-up: 36
months. Data only
presented for 3
and 12 months 
(3-month data not
extracted)Health Technology Assessment 2008; Vol. 12: No. 9
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1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate 
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? Inadequate
Quality criteria for RCTs (CRD Report 4)
Reference and  Intervention Participants Outcome 
design measures
Study: Campbell
et al., 199651
Source: Journal
article
Country: Australia
Setting: Unclear
Language: English
Trial design: RCT
Treatment intervention:
4 programmes: minimal instruction
(1), individual education (2), group
education (3), behavioural
programme (4). All encouraged to
bring a support person
Provider: programmes 1, 2 and 3
were delivered by staff in the
diabetes education service, including
5 nurse educators and 3 dieticians. 
A single nurse delivered the
programme 4
Treatment intervention 1 (apparently
individual) = minimal education:
Sessions: two 1-h sessions within
2 weeks of referral
Topics: (same topics but less detail
than others); the portion exchange
dietary system, exercise, use of oral
hypoglycaemics, practical instruction
in urine testing, foot care and
recommendations to consult an
ophthalmologist and podiatrist
Treatment intervention 2 = individual
education: 
Sessions: 2 sessions for 1 h within
2 weeks of referral, then 30-minute
sessions approximately monthly until
12 months
Topics: same but more detail than for
intervention 1 and included
information on the causes,
symptoms, mechanisms and
complications of diabetes 
Treatment intervention 3 = group
education: 
Sessions: at least 2 individual sessions
and a 3-day small group education
course. (Individual monthly sessions
were continued until a course could
be scheduled)
Mode: Course involved lectures,
small group exercises, practical
sessions
Eligibility/exclusion criteria: 
Inclusion: <80 years, Type 2 for <5 years,
speak and write English, had received no
previous formal instruction, not taking
>75% of the maximum dose OHAs, had
no terminal illness
How selected: patients referred by GP
Numbers involved: total N = 238; 
group (1) 59, (2) 57, (3) 66, (4) 56
Numbers on insulin: none
Tablets: group (1) 19, (2) 22, (3) 24, (4) 23
Diet alone: group (1) 40, (2) 35, (3) 42,
(4) 33
Type of diabetes?: Type 2
Duration of diabetes (mean years +
SE): group (1) 0.5 (0.1), (2) 0.9 (0.2),
(3) 0.4 (0.1), (4) 0.36 (0.1)
Baseline measurements of outcome
parameter:
HbA1: group (1) 11.9% (SE 0.6), (2) 12.2%
(0.5), (3) 12.1% (0.6), (4) 13.3% (0.6)
Knowledge: group (1) 5.7 (0.4), (2) 5.3 (0.4),
(3) 5.5 (0.4), (4) 4.6 (0.5)
Systolic BP: group (1) 136.9 (2.4), (2) 135.5
(3.0), (3) 137.5 (2.7), (4) 145.8 (3.3)
Diastolic BP: group (1) 80.7 (1.3), (2) 81.6
(1.2), (3) 81.7 (1.4), (4) 91.7 (1.7) 
Gender (M/F): group (1) 22/37, (2) 33/24,
(3) 35/31, (4) 24/32
Mean age: group (1) 58.2 (1.3), (2) 56.8
(1.5), (3) 58.4 (1.4), (4) 60.9 (1.4) years
Ethnic groups: not reported
Losses to follow-up: group (2) 40% attrition,
(3) 42%, (4) 9%
Compliance: 
Primary
outcomes used:
HbA1
Secondary
outcomes used:
BP , knowledge,
satisfaction,
uptake podiatry,
ophthalmology,
hospitalisations,
BMI 
Individual
preferred
learning style
addressed?: no
Any subgroups:
no
Normal range(s)
for outcomes:
HbA1 <8.5%,
knowledge?
How outcomes
assessed?: HbA1
laboratory,
knowledge,
satisfaction,
hospitalisations
self-report, BP
unclear
Validated?:
HbA1, knowledge
(DKNA) yes,
satisfaction
reported to have
shown good
internal
consistency and
reliability
Timing of
outcomes: same
for both groups
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Reference and  Intervention Participants Outcome 
design measures
Outcomes (mean change  Group 1  Group 2  Group 3  Group 4  Difference 
± SE unless otherwise  (minimal  (individual  (group  (behavioural) between 
noted) education) education) education) groups
HbA1 (%):  No follow-up –3.3 (0.9) –3.0 (1.1) –4.8 (0.7)
n = ?/25/19/39
Knowledge:  No follow-up 4.4 (0.6) 4.2 (0.5) 5.6 (0.6)
n = ?/29/26/35
Systolic BP (mgHg):  No follow-up –6.8 (5.8) –12.4 (6.8) –16.9 (3.8)
n = ?/16/11/37
Diastolic BP (mgHg):  No follow-up –5.3 (3.0)* –5.0 (4.0)* –7.9 (2.6) *Significant from 
n = ?/16/11/374 group 4, 
BMI: No follow-up –2.0 (0.4)  –1.4 (0.5) –2.6 (0.5) p < 0.05
n = ?/30/25/41
Cholesterol (mmol/l): No follow-up 0.12 (0.20) 0.16 (0.16) –0.33 (0.15)
n = ?/23/19/34
HDL cholesterol (mmol/l): No follow-up 0.02 (0.04) 0.18 (0.10) 0.06 (0.08)
n = ?/21/16/27
Cholesterol risk ratio No follow-up –0.25 (0.03) –0.35 (0.46) –0.59 (0.20)
(total/HDL):
n = ?/21/15/25
Treatment intensity: No follow-up % unchanged: 75 % unchanged: 70 % unchanged: 74
n = ?/29/27/42 % decreased: 17 % decreased: 22 % decreased: 17
% increased: 7 % increased: 8 % increased: 10
Satisfaction  No follow-up 74.8 (2.2) 77.9 (2.0) 77.0 (2.3)
(actual score + SE):
n = ?/25/25/30
Topics: same topics as the other
programme. 2-h follow-ups were
scheduled at 3 and 9 months
Treatment intervention 4 =
behavioural:
Sessions: series of individual visits, 3
in first month, after which differed
depending on patient’s needs with a
minimal schedule of 3, 6 and
13 months supplemented with
telephone calls
Topics: same topics as other groups 
Mode: Sessions in patient’s home 
All groups:
Treatment changes: no details
Training trainers: no details
Theory: no details except for group 4:
based on cognitive–behavioural
strategies
Participants in groups 2 and 3 also
had opportunity to attend a 2-h
lecture on diet (group)
Duration of intervention: Up to
12 months
Length of
follow-up:
12 months
(minimal
instruction only
6 months) from
inception
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Outcomes (mean change  Group 1  Group 2  Group 3  Group 4  Difference 
± SE unless otherwise  (minimal  (individual  (group  (behavioural) between 
noted) education) education) education) groups
Proportion consulting  No follow-up 97 95 89
ophthalmology (%):
n = ?/38/37/47
Proportion consulting  No follow-up 55 73 74
podiatry (%):
n = ?/31/30/42
(3- and 6-month data reported)
Methodological comments 
Allocation to treatment groups: not described
Blinding of outcome assessors?: not described
Allocation concealment?: not described
Analysis by ITT?: no
Comparability of treatment groups: significant differences in levels of education, duration since diagnosis, diastolic BP , smoking
Method of data analysis: continuous data – change scores were calculated and compared by ANCOVA with t-tests as
post hoc tests; categorical data – 2 and pair-wise comparisons, mean and SE given
Sample size/power calculation: no
Attrition/drop-outs: percentages reported but no reasons given
General comments
Generalisability: 94% patients asked to participate consented, high HbA1c at baseline
Conflict of interests: funding support not mentioned
Other:
ANCOVA, analysis of covariance; SE, standard error.
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Partially
7. Did the analyses include an ITT analysis? Unknown
8. Were withdrawals and drop-outs completely described? PartialAppendix 5
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Reference and  Intervention Participants Outcome 
design measures
Study:
Cooper et al.,
2002;56 200357,58a
Source:
Published and
unpublished
Country: UK
Setting: Multi-
centre: 2 hospitals
and 1 health
centre
Language: English
Trial design: RCT
(waiting list design)
Treatment intervention:
Diabetes Look After Yourself
(DLAY) course (for further
details of constituent patient
groups, see the next column)
Topics: self-management
[nutrition, physical activity,
relaxation, screening,
management of complications,
foot care, sick-day rules
(personal communication
author)] exploration of feelings,
how to make best use of health
service)
Provider: specialist diabetes
nurses (supported by dieticians –
personal communication by
author)
Sessions: 8 weekly sessions of
approximately 2 h each.
Delivered at staggered intervals
over 14 months
Delivery: largely interactive, small
and plenary group discussions,
problem-based learning, goal
setting, exercise, relaxation and
practice of skills in 3 centres (see
first column)
Treatment changes:
proportionally more people
(46%) in the intervention group
had their diabetes drug
treatment changed compared
with the control group (30%)
but the difference was not
significant (2, p = 0.16). Four
people (2 in each group) were
changed to insulin therapy during
the course of the trial
Training of trainers: nurse trainers
trained together and were
provided with a teaching manual
Theory: grounded in educational
and behavioural theories
associated with adult experiential
learning and health protective
behaviour, which produced a
framework of variables including
cognitive factors, and
social–environmental factors.
Central to the philosophy was an
empowerment approach to
health education
Control group: randomised but
on a waiting list for 12 months
Duration of intervention: 
8 weeks
Eligibility/exclusion criteria:
Inclusion: Type 2 diabetes diagnosed for at least
1 year, able to give written consent,
undergoing regular diabetes screening 
Exclusion: if <21 or >75 years old, persistent
defaulters, with alcohol problem, language
problem or a physical handicap which
precluded participation in the activity/exercise
programme (more details provided)
How selected: not reported
Allocation to treatments: staggered over a
14-month period with five trial courses
running over 1 year
Participants were allocated to the 8-week
intervention directly (at 0 months) (short-term
trial group; n = 30) or after a 6-month wait-
list control period (short-term control group;
n = 23). These groups were then combined to
form a long-term (12-month) trial group which
was compared with a long-term (12-month)
control group (patients on a waiting list;
n = 36). The longer-term trial groups are
reported here
Numbers involved: intervention n = 53;
control n = 36; total n = 89 (represented only
40% of the total number of people asked to
take part – characteristics of those not
recruited were not different from those
recruited in terms of age, ethnicity or gender)
Numbers on diabetes treatment: insulin:
none
Tablets: intervention 75%; control 66% 
Diet alone: intervention 25%; control 34% 
Mean (range) duration of diabetes since
diagnosis: intervention 6 (1–28) years; 
control 6 (1–30) years
Mean ± SD baseline measurements of
relevant parameters: 
HbA1c: intervention 7.9 ± 1.7% (range
4.5–11.0); control 7.0 ± 1.6% (range
4.6–10.6)
BMI: intervention 32.5 ± 6.7 kg/m2; 
control 32.1 ± 6.1 kg/m2
Self-monitoring: intervention 67%; control
47% 
Attitudes (scale 0–100%): intervention 73.1 ±
11.9; control 74.6 ± 11.0
Exercise (scale 0–100): intervention 50.8 ±
25.5; control 48.8 ± 31.6
Diet (scale 0–100%): intervention 71.6 ±
18.2; control 69.6 (15.5)
Treatment effectiveness (Likert scale 0–5): 
intervention 4.4; control 4.0
Gender (M/F): intervention 57/43%; control
58/42% 
Primary
outcomes used:
HbA1c
Secondary
outcomes used:
summary of
Diabetes Self-
Care Activities
Questionnaire. 
Diabetes
Integration
Questionnaire
(attitudes to
diabetes and its
treatment)
Personal Models
of Diabetes
Questionnaire
(treatment
effectiveness)
(qualitative
outcomes on
patient’s
perspectives
based on focus
group interviews
not reported
here) 
Individual
preferred
learning style
addressed: no
Subgroups: none
reported
Normal range(s)
for outcomes:
HbA1c: 4–6%
How outcomes
were assessed:
HbA1c by lab,
others by self-
report
Validation of
outcomes: yes.
Quantitative
measures were
validated
Timing of
outcomes same
for both groups:
yes (if allowing for
staggered design)
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Reference and  Intervention Participants Outcome 
design measures
Mean ± SD (unless stated) of outcome at 12 months
Intervention Control  Difference  between 
(n = 48) (n ≈ 30) intervention and control
HbA1c (%) 7.9 ± 2.1 7.2 ± 1.6 p = 0.84
Attitudes (scale 0–100%, ↑ = better) 75.1 ± 11.0 70.5 ± 11.0 p = 0.01
Treatment effectiveness (median on Likert scale 0–5,  4.5 4.1 NS
↑ = better)
BMI (kg/m2) 31.3 ± 5.70 30.5 ± 3.9 NS
Diet (scale: 0–100%, ↑ = better) 76.5 ± 12.2 68.0 ± 17.8 NS
Exercise (scale: 0–100%, ↑ = better) 62.5 ± 25.3 55.9 ± 25.0 NS
Self-monitoring (% blood testing) 92 63 p = 0.002
Methodological comments
Allocation to treatment groups: stated that patients were blindly and randomly assigned to the intervention using random
number generator
Blinding of outcome assessors: not reported
Allocation concealment: information from author that patients were randomly allocated to the intervention by a statistician
who was blind to the patients involved in the trial
Analysis by ITT: not reported
Comparability of treatment groups: higher mean HbA1c level in the intervention group compared with control after attrition
(7.9 vs 7.0%) – adjusted for in the analysis. Overall, groups were comparable in relation to demographic, medical and social
characteristics. Significant differences were encountered for co-morbidities only
Method of data analysis: used both quantitative and qualitative analysis. Means, SDs and p-values were reported. Regression
analysis was used in the calculation of changes in baseline HbA1c levels, to account for differences in baseline data for the
intervention and control groups
Sample size/power calculation: yes. Calculated that 48 patients would be needed to detect a 1% change in HbA1c. This would
give 95% power with significance at the 5% level
Attrition/drop-outs: 12% (details above). Reasons for drop-outs not reported
General comments
Generalisability: only about 40% of the patients asked to take part were recruited. Those refusing to take part showed no
difference in age and sex compared with those who participated. HbA1c levels were relatively good at baseline. Patients
might have been better at self-management than typical from the outset
Conflict of interests: funded by Diabetes UK
Other: possible ceiling effects in treatment effectiveness evaluation
a Cooper et al., 200265 was also screened but duplicated existing information.
Mean (range) age: Intervention 58
(30–70) years; control 58 (35–73) years
Ethnic groups: other than caucasian:
intervention 1 (2%); control 0%
Losses to follow-up: stated in the original
work56 that overall n = 11 (12%) lost to
follow-up, comprising 5 deaths (3 in
intervention, 2 in control) and 6 drop-outs
(3 in intervention, 4 in control) (note
discrepancy: n ≠ 11). Information from
author: drop-outs (2 in intervention and 4
in control)
Compliance: 76% attended 7 or more
sessions (a significant correlation between
attendance rates and reductions in HbA1c
at 12 months)
Length of
follow-up:
12 months from
inceptionAppendix 5
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1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? Partia
[AIC data removed]
[AIC data removed]
Quality criteria for RCTs (CRD Report 4)
Reference and  Intervention Participants Outcome 
design measures
Study: 
Deakin et al.,
2006;46 also
200347,48
Source: Journal
article
Country: UK
Setting:
Community 
Language: English
Trial design: RCT
Treatment intervention:
X-PERT programme
(reference available)
Topics: education and self-
management, including
weight, diet, exercise,
complications (risk,
prevention, treatment and
monitoring), goal setting and
self-monitoring
Provider: delivered by diabetes
research dietician (author)
using X-PERT programme (no
further details)
Sessions: one 2-h session per
week for 6 weeks
Audience: on average 16
subjects plus 4–8 carers in
each community venue
(number of venues not
stated)
Delivery: X-PERT programme
involving didactic and
interactive delivery to groups,
with supermarket visits,
group games, discussion
sessions and provision of an
information manual. Separate
sessions for Urdu-speaking
South Asian participants with
a translator
Treatment changes: none
reported 
Training of trainers: not
reported 
Eligibility/exclusion criteria:
Inclusion: no criteria reported
Excluded: housebound patients and those
with reduced cognitive ability
How selected: patients identified from
practice records of 16 GP clinics and invited
by letter to participate. Focused on socio-
economic deprived neighbourhoods
Numbers involved: intervention n = 157;
control n = 157; total randomised n = 314
(22 additional subjects were eligible but did
not participate due to work or holiday
commitments, or for other unreported
reasons)
Losses to follow-up: intervention n = 7
(4.5%); control: n = 16 (10.2%)
Numbers on insulin: 53 (17%)
Tablets: n = 178 (57%)
Diet alone: n = 83 (26%)
Mean ± SD duration of diabetes:
intervention 6.7 ± 6.4 years; control 6.7 ±
6.7 years; mean difference 0.0; 95% CI of
difference –1.4 to 1.5 
Gender (for overall group only):
Male: n = 162 (52%)
Female: n = 152 (48%)
Mean ± SD age: intervention: 61.3 ±
9.7 years; control: 61.8 ± 11.0 years; mean
difference: 0.5 years; 95% CI of difference:
–1.8 to 2.8
Ethnic groups: South Asian and white
caucasian but numbers of each not
Primary outcome
used: HbA1c
Secondary outcomes
used: BP (systolic and
diastolic)
Lipids (total
cholesterol, HDL,
LDL)
Triglycerides
Body weight
BMI
Body fata, waist sizea
Lifestyle outcomes:
perceived frequency of
hyper/
hypoglycaemiaa,
diabetes knowledge,
self-care activitya
(exercise, foot care,
blood testing), dieta,
nutritional intakea,
treatment satisfactiona,
diabetes
empowermenta, QoL
Individual preferred
learning style
addressed?: no
(group interventions)
Subgroups: none
reported
Normal range(s) for
outcomes: stated that
acceptable ranges of
blood lipids and BP
continuedHealth Technology Assessment 2008; Vol. 12: No. 9
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Reference and  Intervention Participants Outcome 
design measures
Theory: empowerment and
discovery learning (reference
cited)
Control intervention:
Routine care plus diabetes
education and individual
review with a dietician 
(30 minutes), practice nurse
(15 minutes) and GP 
(10 minutes)
Duration of intervention:
6 weeks
Were the care
programmes identical?:
Not reported
reported. Noted (see first column) that
Urdu-speaking South Asian subjects
received separate sessions
Compliance: not reported; no inclusion
criteria were stated. If a participant failed to
attend one session, a telephone reminder
was given; if they failed to attend two
sessions, no further contact was made (the
numbers of subjects in these categories
were not reported)
Mean ± SD baseline measurements of
relevant parameters in the
intervention (int.) and control (con.)
and the difference in means (diff., 95%
CI in parentheses): 
HbA1c: int. 7.7 ± 1.6 %; con. 7.7 ± 1.6%;
diff. 0.0 (–0.3 to 0.4 %)
Systolic BP: int. 147.5 ± 19.8 mmHg; 
con. 147.8 ± 23.7 mmHg; diff. 0.3 (–4.6 to
5.1 mmHg)
Diastolic BP: int. 82.6 ± 11.0 mmHg; 
con. 82.2 ± 12.2 mmHg; diff. –0.4 (–3.0 to
2.2 mmHg)
Total cholesterol: int. 5.1 ± 1.1 mmol/l; 
con. 4.9 ± 1.0 mmol/l; diff. –0.2 (–0.4 to
0.1 mmHg)
HDL cholesterol: int. 1.3 ± 0.3 mmol/l; 
con. 1.3 ± 0.4 mmol/l; diff. 0.0 (–0.1 to
0.1 mmol/l)
LDL cholesterol: int. 2.7 ± 0.9 mmol/l; 
con. 2.7 ± 0.8 mmol/l; diff. 0.0 (–0.2 to
0.2 mmol/l)
Triglycerides: geometric means (95% CI): 
int. 2.2 (2.0 to 2.4) mmol/l; con. 2.0 (1.9 to
2.2) mmol/l; ratio of means 0.9 (0.8 to 1.0)
Body weight: int. 83.2 ± 14.5; con. 82.8 ±
17.6 kg; diff. –0.4 (–4.0 to 3.2) kg
BMI: int. 30.8 ± 5.3 kg/m2; con. 30.6 ±
5.7 kg/m2; diff. –0.3 (–1.5 to 1.0) kg/m2
Diabetes knowledge score (0–14): int. 7.5 ±
3.5; con. 7.0 ± 3.1; diff. –0.5 (–1.3 to 0.3)
Overall ADDQoL score: int. –2.2 ± 2.2; 
con. –1.9 ± 2.2; diff. 0.3 (–0.3 to 0.8)
Perceived frequency of hypoglycaemia (score
0–6): int. 1.2 ± 1.7; con. 0.9 ± 1.5; diff.
–0.3 (–0.7 to 0.1)
Perceived frequency of hyperglycaemia (score
0–6): int. 2.8 ± 1.9; con. 2.1 ± 1.8; diff.
–0.7 (–1.2 to –0.3)
were obtained from
recent guidance reports
(data not provided)
How outcomes were
assessed: 
HbA1c: measured using
a Diabetes Control and
Complications Trial
(DCCT) aligned
method (reference
cited) 
BP: measured
conforming to
‘accepted’ methods
(reference cited)
Height (for BMI):
measured with a
portable sonic device
Body weight: measured
with calibrated
electronic scales
Diabetes knowledge:
assessed using a
validated questionnaire
with 14 multiple-choice
questions (reference
cited) 
QoL: assessed using
validated scale
(ADDQoL: audit of
Diabetes Dependent
Quality of Life;
reference cited) rated
from –9 (negative
impact) to +9 (positive
impact)
Perceived frequency of
hypo- and
hyperglycaemia: assessed
using a validated
psychosocial
questionnaire
(reference cited)
Validation of
outcomes:
yes: used validated
lifestyle, psychosocial
and QoL
questionnaires; clinical
outcomes used
standard methods
(above)
Timing of outcomes
the same for both
groups?: yes
Length of follow-up:
14 months
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Results
Outcome  Intervention group  Control group  Comparisons between groups: 
(14 months) Mean ± SD (n) Mean ± SD (n) mean difference (95% CI) and 
significance of overall change 
HbA1c (%) 7.1 ± 1.1 (150) 7.8 ± 1.6 (141) 0.7 (0.3 to 1.0) (p < 0.001)
Change from baseline in HbA1c (%) –0.6 0.1 p < 0.001
Systolic BP (mmHg) 141.3 ± 16.8 (150) 144.4 ± 23.5 (141) 3.1 (–1.6 to 7.9) (p = 0.1)
Diastolic BP (mmHg) 78.4 ± 9.6  (150) 80.2 ± 10.9 (141) 1.7 (–0.6 to 4.1) (p = 0.1)
Total cholesterol (mmol/l) 4.8 ± 1.1  (150) 4.7 ± 1.0  (141) –0.1 (–0.3 to 0.1) (p = 0.01)
Change from baseline in  –0.3 –0.2 p = 0.01
total cholesterol (mmol/l)
HDL cholesterol (mmol/l) 1.1 ± 0.4 (150) 1.1 ± 0.4 (141) 0.0 (–0.1 to 0.1) (p = 0.3)
LDL cholesterol (mmol/l) 2.7 ± 0.9 (150) 2.7 ± 0.8 (141) 0.0 (–0.3 to 0.1) (p = 0.1)
Triglycerides (geometric mean,  1.8 (1.6 to 2.0)b (150) 1.8 (1.6 to 1.9)b (141) Ratio of means:
95% CI) (mmol/l) 1.0 (0.9 to1.1) (p = 0.3)
Body weight (kg) 82.7 ± 14.8 (150) 83.9 ± 18.8 (141) 1.2 (–2.7 to 5.2) (p < 0.001)
Change from baseline in  –0.5 1.1 p < 0.00
body weight (kg)
BMI (kg/m2) 30.6 ± 5.5 (150) 31.0 ± 6.4 (141) 0.4 (–1.0 to 1.7) (p < 0.001)
Change from baseline in BMI (kg/m2) –0.2 0.4 p < 0.001
Diabetes knowledge score 9.3 ± 3.1 (100) 7.8 ± 2.7 (91) –1.5 (–2.3 to –0.7) (p < 0.001)
(0–14 scale; multiple-choice question)
Overall ADDQoL score –1.4 ± 1.7 (100) –1.7 ± 2.1 (91) –0.3 (–0.8 to 0.3) (p = 0.2)
Methodological comments 
Allocation to treatment groups: random permuted blocks (details not specified) and sealed opaque envelopes were used to
randomise participants to the intervention or control group. Patients were told that the objective was to compare the
effectiveness of an individual versus group approach, to reduce their likelihood of identifying whether they were in the
intervention or control group
Blinding of outcome assessors?: yes: carried out by a community nurse and healthcare assistant blinded to treatment
assignment (details of the blinding procedure were not given)
Allocation concealment?: yes: using opaque envelopes
Analysis by ITT?: no: the authors stated that ITT populations were analysed where possible but the outcomes presented
exclude those participants who were lost to follow-up
Comparability of treatment groups: the study reports there were no statistically significant differences between groups for
demographic or outcome variables. However, the perceived frequency of hyperglycaemia (based on a scoring system of 0–6
from questionnaires but not obviously linked to actual BG) was significantly higher in intervention than control subjects at
baseline (95% CI of the mean difference did not include zero). All other outcomes did not differ significantly between the
treatment groups at baseline
Method of data analysis: repeated measures ANOVA was used to test the effect of interaction between treatment group and
time (change from baseline), with HbA1c as the primary outcome variable. Other outcomes were interpreted as hypothesis-
generating variables (no details were given of how the analysis was adjusted for this purpose). Means, SDs and 95% CIs
were provided for all outcomes at baseline and end-point. The authors reported that they adhered to the CONSORT
statement where possible (reference cited)
Sample size/power calculation: yes: 64 patients per group required for 80% power to detect a 1% difference in HbA1c with
 = 0.05 and assuming an SD of 2%; 157 patients per group were recruited to allow for attrition
Attrition/drop-outs: yes. Intervention: n = 7 (4.5%): 2 died, 2 refused (1 because too ill), 1 in Pakistan, 1 lost contact, 
1 moved out of area. Control: n = 16 (10.2%): 5 died, 1 terminally ill, 4 refused (1 because too ill), 1 severe psychiatric
illness, 1 in Pakistan, 2 lost contact, 2 moved out of area
General comments
Generalisability: Northern England population focusing on socio-economic deprived neighbourhoods but generality of the
findings is unknown because the inclusion and exclusion criteria were not specified 
Conflict of interests: None evident (funding support stated; research foundations) 
Other: The paper by Deakin et al. (2003)47 only presents results for <1 year
a Data not extracted for these.
b The value for the intervention only (not the control) is indicated by the authors to be a geometric mean.Health Technology Assessment 2008; Vol. 12: No. 9
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1. Was the assignment to the treatment groups really random? Partial
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? No
5. Were outcome assessors blinded to the treatment allocation? Adequate
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? Adequate
Quality criteria for RCTs (CRD Report 4)
Reference and  Intervention Participants Outcome measures
design
Study:
Goudswaard et al.,
200461
Source: Journal
article
Country: The
Netherlands
Setting:
Community
Language: English
Trial design: RCT
Treatment intervention:
Described as a ‘collaborative,
mixed, education intervention’
Topics: general diabetes
information; reinforcement of
medication compliance; self-
monitoring and self-
management of exercise,
weight, diet, nutrition, and BG
(BG meters and reagents were
provided)
Provider: two diabetes nurses
Sessions: six sessions at intervals
of 3–6 weeks during a 6-month
period. Each session
15–45 minutes, giving a total
contact time of ~2.5
Audience: one-to-one sessions
between participants and
diabetes nurses
Delivery: assume mainly didactic
(no interactive component
reported). Location of the
sessions was not stated
(probably GP practice or
diabetes clinic) 
Treatment changes: there were
no changes in medication for
diabetes in either group, except
for two participants in the
control group who were
referred to secondary care
before the end of the
intervention period (for
symptomatic hyperglycaemia
and co-morbidity)
Training of trainers: not reported.
Theory: not stated 
Control group:
Usual GP care according to the
Dutch Guideline on 
Type 2 diabetes, which
recommends 3-monthly
reviews, focusing on diabetic
symptoms and measurement of
Eligibility/exclusion criteria:
Inclusion: patients receiving primary care
only, age <76 years and with HbA1c
 7.0% were eligible if, after
optimisation of oral medication, their
HbA1c remained 7.0% while taking the
maximum feasible doses of two different
OHAs (mostly sulfonylurea and
metformin)
Exclusion: severe co-morbidity, inability
to follow instructions spoken in Dutch or
short-term insulin requirement for
severe hyperglycaemic symptoms
How selected: medical records of 1810
patients who were receiving only primary
care were obtained from 57 general
practices (78 GPs) and screened against
the inclusion/exclusion criteria by two
research assistants
Numbers involved: intervention 
n = 28; control n = 30; total randomised
n = 58 [18 additional eligible patients
were excluded due to refused consent 
(n = 6), severe co-morbidity (n = 7) or
short-term insulin requirement (n = 5)].
The authors stated (without data) that
the included and excluded patient groups
had similar baseline characteristics
Losses to follow-up: intervention n = 4
(14.3%); control n = 4 (13.3%)
Diabetes treatment (in the full
population; n = 1810): insulin 12%;
tablets 66%; diet alone 22%
Mean ± SD duration of diabetes:
intervention 7.3 ± 5.0 years; control: 
7.6 ± 3.8 years
Gender: intervention 52% male;
control: 44% male
Mean ± SD age: intervention 62.6 ±
9.0 years; control 58.7 ± 11.4 years
Ethnic groups: not reported
Primary outcomes
used: HbA1c at end-
point; HbA1c change
from baseline
Secondary outcomes
used: body weight
(measured only at
6 months after
inception; not
reported here)
Individual preferred
learning style
addressed?: not
reported.
Subgroups: none
reported
Normal range(s) for
outcomes: HbA1c
4–6%
How outcomes were
assessed: HbA1c was
measured by
turbidimetric inhibition
assay (reference cited)
Validation of
outcomes: yes
(standard outcomes
used)
Timing of outcomes
the same for both
groups?: yes (except
for an HbA1c
measurement at
3 months after
inception, which was
only carried out in the
intervention group)
Length of follow-up:
18 months (following
the 6-month
intervention, both
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Reference and  Intervention Participants Outcome 
design measures
Results
Outcome  Intervention group  Control group  Comparisons between groups: 
(control – intervention)
Mean ± SD HbA1c at end-point  7.8 ± 0.9 8.2 ± 1.4 No statistics were reported for this 
(18 months) (%) comparison at end-point
HbA1c change from baseline to  –0.4 –0.6 % Mean difference (95% CI):
end-point (18 months) (%)a,b 0.2% (–0.7 to 0.4%) 
(p not significant)
Patients with HbA1c <7.0% at  17 15 Reported as not statistically significant 
end-point (18 months) (%) (no p-value given)
Patients on insulin therapy at  6 (25%) 10 (38%) Reported as not statistically significant 
end-point (18 months)  (no p-value given)
Methodological comments
Allocation to treatment groups: the authors stated that randomisation was done by a telephone call to an independent trial
centre, which used a computer-generated random assignment with blocks of eight at a time (blocks were not defined)
Blinding of outcome assessors?: not reported
Allocation concealment?: computer-generated assignment off-site
Analysis by ITT?: no: the authors stated that their analysis was by ITT using the last observation carried forward, but the
numbers of patients involved in calculating the reported statistics are not given; ineligible patients mistakenly randomised,
and patients who withdrew before the start of the intervention were excluded from analysis
Comparability of treatment groups: these were similar at baseline in terms of age, gender and educational level, but no
statistical assessment was made. (Data for duration of diabetes, BMI and HbA1c for the two groups at baseline are given
above)
Method of data analysis: comparison of HbA1c and body weight between the two groups was carried out using ANCOVA to
adjust for baseline values. Logistic regression was used to assess the proportions of patients who had HbA1c < 7.0% and
the proportions of those who were treated with insulin. Other statistical techniques (not described here) were used in
comparisons of outcomes in the short term (<1 year)
Sample size/power calculation: yes: to detect a difference in HbA1c of at least 0.8%, which was considered clinically relevant
for the patient groups, 26 patients were needed per group, based on SD = 1.0,  = 0.05 and power 80%
Attrition/drop-outs: yes. intervention: n = 4 (14.3%), comprising three withdrawals before the first session (refusal) and one
death between intervention and end-point. Control: n = 4 (13.3%), comprising one withdrawal due to inaccurate inclusion,
two deaths and one hospital admission
General comments
Generalisability: unknown due to lack of information on ethnicity. The tightly defined inclusion criteria might limit the
generality of the findings
Conflict of interests: unknown. The study was supported by a research grant from a diabetes device company
Other: This study provides limited data on outcomes at 18 months and focuses in more detail on the short-term outcomes
(<1 year)
a The authors reported a significantly larger decrease (by 0.7%) of HbA1c in the intervention compared with the control
group at 7.5 months after inception (95% CI 0.1 to 1.4; p = 0.025).
b Adjusted for baseline values in an ANCOVA model.
fasting BG, with education being
given during normal medical
appointments. The GP was
instructed not to refer the
subject to a diabetes nurse or
(except for severe
hyperglycaemic symptoms) to
alter their medication
Duration of intervention: 
6 months
Were the care programmes
identical?: 
Unknown: not stated, other
than the details above
Compliance: intervention n = 25/28
(89.3%) due to 3 refusals to take part
after randomisation; control n = 29/30
(96.7%) due to 1 inaccurate inclusion
Baseline measurements of relevant
parameters: 
Mean ± SD HbA1c: intervention 8.2 ±
1.1%; control 8.8 ± 1.5
Mean ± SD BMI: intervention 30.2 ±
4.4 kg/m2; control 29.8 ± 5.5 kg/m2
groups received usual
care until end-point)Health Technology Assessment 2008; Vol. 12: No. 9
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1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? Adequate
Quality criteria for RCTs (CRD Report 4)
Reference and  Intervention Participants Outcome 
design measures
Study: Heller
et al., 198859
Source: Journal
article
Country: UK
Setting: Hospital
Language: English
Trial design: RCT
Treatment intervention:
Group weight loss intervention of 
4–6 patients with a spouse or friend. Each
given a target weight
Topics: aim was to lose weight, what foods
to eat and those to avoid, aetiology of
diabetes, self-monitoring, self-care, diabetic
complications, the importance of eye
examinations and foot care. Self-monitoring
of urine taught (twice per day).
Provider: one of two diabetes nurses and one
dietician
Sessions: 3 × 90-minute sessions at weekly
intervals with follow-up visits (90 minutes) at
3 and 6 months
Materials: video which explained foods to
eat, etc., a board for plotting weights so the
group could see progress and a book on
diabetes for patients
Delivery: group education
Treatment changes:
Training of trainers:
Theory:
Mode:
Persistent symptoms glycosuria or random
blood glucose >15 mmol/l were withdrawn
At 3 months patients visited for 90 minutes
and lunched with nurse and dietician
followed by a group discussion with critical
discussion of food choice. At 6-month visit a
general review undertaken and watched
video again
Patients could contact nurses within
following 6 months
Control intervention:
Usual clinic care, seen by doctor and then
referred to dietician, seen individually. Clinic
appointments as necessary and mandatory at
3,6,12 months. Any patients started on
OHAs in first year were withdrawn.
Duration of intervention:
6 months
Eligibility criteria:
Included: all newly diagnosed Type 2
patients (defined), overweight
(BMI >27 kg/m2), aged
30–75 years) 
Excluded: patients with ketonuria,
those in whom diagnosis was made
as an inpatient (e.g. at time of
surgery), judged too infirm, or with
major language difficulties
How selected: from patients
referred to clinic over 18-month
period
Numbers involved: total N = 87,
intervention (int.) 40; control
(cont.) 47
Numbers on insulin: none
Tablets: none
Diet alone: assume all
Type of diabetes?: Type 2
Duration of diabetes: newly
diagnosed
Baseline measurements of
outcome parameter: HbA1
(mean + 95% CI): int. 12.3%
(11.4 to 13.2); con. 12.7% (11.9 to
13.5)
Gender (M/F): int. 20/16; 
con. 16/23
Age ranges (mean + 95% CI):
int. 56.6 (55 to 58) years; 
con. 56.4 (53 to 59.9) years
Ethnic groups: not reported
Losses to follow-up: int. 4; con. 8
(reasons given)
Compliance: 1 con. + 2 int. did
not attend 3-month follow-up, 
1 int. did not attend at 6 months
Primary
outcomes used:
HbA1
Secondary
outcomes used:
knowledge, fasting
BG, weight
Individual
preferred
learning style
addressed?: no
Any subgroups
(e.g. ethnic
groups): no
Normal range(s)
for outcomes:
HbA1 5.0–7.5%;
knowledge (max.
score 36)
How outcomes
assessed?:
knowledge self-
report, laboratory
for HbA1
Validated?: HbA1
yes; knowledge no
details of
validation
Timing of
outcomes same
for both groups:
yes
Length of
follow-up:
12 months from
inception
continuedQuality criteria for RCTs (CRD Report 4)
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Outcome (mean + 95% CI) Intervention (n = 36) Control (n = 39) Differences between groups
HbA1 9.0% (8.2 to 9.8) 9.9% (8.9 to 10.9)
Proportion of patients HbA1 <7.5% (%) 36 28
FBG (mmol/l) 9.1 (7.9 to 10.3) 10.3 (8.8 to 11.8)
Weight loss (kg) –5.5 (4 to 6.5) –3 (2 to 4) p < 0.05
Knowledge – not reported as not validated. 3- and 6-month data reported
Methodological comments
Allocation to treatment groups: not reported. Correspondence from author: randomisation using computerised random
numbers 
Blinding of outcome assessors?: not reported. Correspondence from author: HbA1c values were measured in the laboratory
by people unaware of assignment; weight was measured by co-investigators
Allocation concealment?: not reported. Correspondence from author: process was sealed opaque envelopes
Analysis by ITT?: not reported
Comparability of treatment groups: no differences reported, no statistical analysis reported
Method of data analysis: mean or median with 95% CIs. t-Tests, Mann–Whitney and 2 tests used
Sample size/power calculation: no
Attrition/drop-outs: drop-outs reported and reasons given
General comments
Generalisability: overweight population. All newly diagnosed 
Conflict of interests: Boehringer acknowledged for donation of urine testing equipment. British Diabetic Association
supported 2 authors
Other:
1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Partial
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
7. Did the analyses include an ITT analysis? Unknown
8. Were withdrawals and drop-outs completely described? AdequateHealth Technology Assessment 2008; Vol. 12: No. 9
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Reference and  Intervention Participants Outcome 
design measures
Study: Ko et al.,
200745
Source: Journal
article
Country: Korea
Setting:
Secondary care
(inpatient clinic
with patients
hospitalised by
diabetes-related
illnesses)
Language: English
Trial design: RCT
Treatment intervention:
Structured Intensive Diabetes
Education Programme (SIDEP) based
on Bucharest–Dusseldorf study and
Diabetes Prevention Programme
(DPP) (references available)
Topics: diabetes knowledge, diabetes
self-management skills, self-
monitoring, injection techniques,
sick-day care, diet and nutrition,
physical activity, foot inspection,
hypoglycaemia management
Provider: delivered by 8 professional
diabetes health providers:
diabetologist, certified diabetes
educator (nurse or dietician),
ophthalmologist, rehabilitation
therapist, pharmacist, psychologist,
family doctor, rehabilitation medicine
doctor
Sessions: 6 h per day for 5 days
during hospitalisation (total 30 h),
with free physical activity under
supervision, plus one 3-h
reinforcement outpatient session 
per year
Audience: group education with 
5–10 patients per group 
Delivery: didactic and interactive
inpatient sessions to which patients’
family members were also invited
(curriculum timetable reported)
Treatment changes: at annual
reinforcement sessions physician
assessed and adjusted glucose-
lowering agents
Training of trainers: stated only that
trainers were professional health
providers in the field of diabetes
Theory: cognitive-behavioural therapy
(references cited)
Control intervention:
Patients received the same first 4 h
of group education as the
intervention group. Control patients
were offered 30 minutes of diet and
also nutritional advice and also
introductory education and
introductions to insulin injection,
physical activity, self-monitoring and
diabetes management (but unclear if
these were within or additional to
the initial 4-h session). Follow-up
was at 3-month intervals without
education reinforcement (focus on
BG monitoring and drug adjustment
only)
Eligibility/exclusion criteria:
Inclusion: hospital inpatients with Type 2
diabetes who had been admitted with
symptoms related to poor glycaemic
control and who had no previous
experience of systematic diabetes education
Exclusion: patients who were aged
>70 years, mentally ill, unable to undertake
recommended physical activity or had any
severe illness (e.g. sepsis, severe infection,
hypoglycaemia or shock).
How selected: consecutive recruitment of
inpatients in a hospital-based university-
affiliated diabetes centre
Numbers involved: intervention n = 219;
control n = 218; total randomised n = 437
(64 additional subjects were eligible but of
these 48 refused to participate and 16 did
not participate for other, unspecified,
reasons)
Losses to follow-up:
intervention/control: 
In total: n = 59 (27%)/n = 70 (32%)
By individual year:
Year 1: n = 26 (11.9%)/n = 30 (13.8%)
Year 2: n = 17 (7.8%)/n = 19 (8.7%)
Year 3: n = 7 (3.2%)/n = 19 (8.7%)
Year 4: n = 9 (4.1%)/n = 2 (0.9%)
Numbers on insulin: intervention n = 36
(16.4%); control n = 31 (14.2%)
(difference p = 0.520)
Numbers on tablets: intervention n = 111
(50.7%); control n = 127 (58.3%)
(difference p = 0.112)
Numbers on tablets + insulin: intervention
n = 72 (32.9%); control n = 60 (27.5%)
(difference p = 0.223)
Numbers on diet alone: none
Mean ± SD duration of diabetes:
intervention 6.0 ± 6.0 years; control 6.2 ±
5.5 years (difference p = 0.838)
Gender (M/F): intervention n = 92/127
(44/56%); control n = 100/118 (46/54%)
(difference, p = 0.665)
Mean ± SD age: intervention 53.3 ±
9.3 years; control 54.1 ± 7.4 years
(difference p = 0.307)
Ethnic groups: none stated; due to
location assumed most or all patients were
Korean
Compliance: not reported
Primary
outcome used: 
mean value of
HbA1c and
changes in HbA1c
during follow-up
Secondary
outcomes used: 
Dieta
SMBGa
Physical activitya
Frequency of
admissions related
to diabetic
complications
(BMI, FBG and BP
were also
monitored but no
data provided for
follow-up)
Individual
preferred
learning style
addressed?: no
(group
interventions)
Subgroups: two
subgroups were
analysed
retrospectively,
according to the
mean of all HbA1c
values over the 
4-year follow-up
period: group 1,
HbA1c < 7.0
(well-controlled);
group 2, HbA1c >
7.9% (not well
controlled) (data
not extracted)
Normal range(s)
for outcomes:
not stated, but
reference range
for HbA1c given
(see below)
How outcomes
were assessed:
HbA1c measured
using HPLC
(laboratory name
reported) with
reference range
4.6–6.4%. Diet,
exercise and
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Reference and  Intervention Participants Outcome 
design measures
Results
SIDEP group Control group Comparison 
Mean ± SD (n = 219)b Mean ± SD (n = 218)b between groups 
Mean (± SD) HbA1c (%)  n = 174 n = 187 Mean difference (95% CI) 
at 12 months 7.9 ± 1.7 8.1 ± 1.5 0.14 (–0.20 to 0.47), p = 0.420
Mean (±S D) HbA1c (%)  n = 168 n = 169 Mean difference (95% CI)
at 24 months 7.9 ± 1.5 8.2 ± 1.5 0.28 (–0.04 to 0.61), p = 0.089
Mean (± SD) HbA1c (%)  n = 167 n = 148 Mean difference (95% CI)
at 36 months 7.8 ± 1.5 8.4 ± 1.6 0.51 (0.17 to 0.85), p = 0.004
Mean (± SD) HbA1c (%)  n = 161 n = 147 Mean difference (95% CI)
at 48 months 7.9 ± 1.2 8.7 ± 1.6 0.8 (0.49 to 1.12), p < 0.0001
Median frequency per patient  n = 160 n = 148 p = 0.005c
of admissions due to any  1.0 (range 0–4) 0.8 (range 0–3)
diabetic complications 
over 4 years
Duration of intervention:
30 h over 5 days followed by annual
3-h reinforcement sessions
Were the care programmes
identical?:
Not reported
Mean ± SD baseline measurements of
relevant parameters (95% CI in
parentheses): 
HbA1c: intervention: 9.4 ± 2.0 %
(n = 219); control: 9.2 ± 1.9 % (n = 211);
difference –0.24 (–0.62 to 0.14 %)
(p = 0.213)
BMI: intervention 25.5 ± 3.5 kg/m2; control
25.3 ± 3.2 kg/m2 difference p = 0.650
Fasting plasma glucose: intervention 9.8 ±
3.8 mmol/l; control 9.9 ± 3.6 mmol/l;
difference p = 0.712
Total cholesterol: intervention 4.9 ±
1.1 mmol/l; control 4.9 ± 1.0 mmol/l;
difference p = 0.752
Triglycerides: intervention 1.96 ±
1.4 mmol/l; control 1.91 ± 1.5 mmol/l;
difference p = 0.726
HDL cholesterol: intervention 1.16 ±
0.3 mmol/l; control 1.18 ± 0.4 mmol/l;
difference p = 0.558
Smoking: intervention n = 50 (22.9%);
control n = 57 (26.0%); difference 
p = 0.452
Alcohol: intervention n = 62 (28.3%);
control n = 53 (24.3%); difference
p = 0.343
Numbers hypertensive (140 mmHg systolic,
90 mmHg diastolic, or on treatment):
intervention n = 81 (37%); control n = 94
(43.1); difference p = 0.191
Diabetes family history: intervention n = 64
(29.2%); control n = 58 (26.6%);
difference p = 0.542
SMBG were
monitored by
annual
questionnaires and
scored on a 
5-point scale
Validation of
outcomes:
unclear if the
questionnaires for
diet, exercise and
SMBG (data not
extracted) were
validated, but
references cited
Timing of
outcomes the
same for both
groups?: yes
Length of follow
up: data
presented for 6,
12, 24, 36 and
48 months, but
actual follow-up in
intervention group
was 51.7 ±
7.4 months
(2 weeks after
discharge then
every 3 months
thereafter when
diabetes nurse
checked
adherence to
lifestyle
modifications)
continuedQuality criteria for RCTs (CRD Report 4)
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Methodological comments 
Allocation to treatment groups: randomisation using a random number table
Blinding of outcome assessors: yes 
Allocation concealment: used sealed, sequentially numbered envelopes given to participants. Unclear if the allocation within
these envelopes was concealed from the investigator
Analysis by ITT?: not reported
Comparability of treatment groups: there were no significant differences in baseline characteristics of the two groups
Method of data analysis: unpaired t-tests with 0.05 significance level. Subgroup analysis of the intervention group to
determine any differences in glycaemic control (data not extracted)
Sample size/power calculation: yes: sample size was determined to be large enough to detect a difference of 0.6% in HbA1c
between SIDEP and control groups with 80% power at the two-tailed significance level  = 0.05, assuming 20% loss to
follow-up
Attrition/drop-outs: number given but no reasons reported
General comments
Generalisability: Korean population of people admitted to hospital with complications of diabetes and HbA1c in the region of
9%
Conflict of interests: none declared or evident
Other: 
a Data not extracted for this review.
b The mean HbA1c dropped after 6 months in the intervention group and the control group. The intervention group change
from baseline was statistically significantly different compared with the control group (SIDEP n = 205, 7.1 ± 1.5; control
group n = 187, 7.9 ± 1.4 [mean difference 0.87 (95% CI 0.58 to 1.16), p < 0.0001].
c Text reports that frequency was significantly lower in the intervention group than the control group; however, data are
presented showing the control group significantly lower than the intervention group. Possible error in the data presented.
The most common cause of hospitalisation in both groups was infection.
1. Was the assignment to the treatment groups really random? Adequate 
2. Was the treatment allocation concealed? Inadequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were the eligibility criteria specified? Yes 
5. Were outcome assessors blinded to the treatment allocation? Adequate 
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate 
7. Did the analyses include an ITT analysis? Unknown 
8. Were withdrawals and drop-outs completely described? PartialAppendix 5
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Reference and  Intervention Participants Outcome 
design measures
Study:
Raz et al., 198862
Source: Journal
article
Country: Israel
Setting: Hospital
Language: English
Trial design: RCT
after stratification
by pre- and post-
prandial glucose
and HbA1c
Treatment intervention:
Topics: explanation of the disease, the
main mode of treatment, explanation
and demonstration of self-care and
treatment techniques, the logic and
practice of diet, and home exercise
Provider: physicians, a nurse, dietician
and physical therapist each providing
different topics
Sessions: three lessons within
3 weeks, repeated every 4 months.
Patients were encouraged to interact
between the sessions and were also
individually followed in the diabetic
clinic every 2 months
Delivery: assume didactic, group
education
Treatment changes: diet and exercise
could be manipulated, but drug
therapy unchanged
Training of trainers:
Theory:
Control intervention: Control
group were followed up every
2 months
Duration of intervention:
12 months
Eligibility/exclusion criteria:
Inclusion: Type 2 diabetes, aged
30–65 years, 1 year since diagnosis, clinic
record of uncontrolled diabetes (defined) in
last 12 months, no late diabetic
complications or concurrent psychiatric or
terminal illnesses
How selected: states patients were
selected from the clinic, no details.
Numbers involved: total N = 51, int 25;
cont. 26
Numbers on insulin: none
Tablets: 20
Diet alone: 31
Type of diabetes: Type 2
NB: baseline characteristics based on those
completing study
Duration of diabetes: (intervention) (int.)
9.0 years (SD 4.5); (control) (con.)
9.2 years (SD 5.3)
Baseline measurements of outcome
parameter (mean ± SD):
HbA1c: int. 10.0% ± 2.7; con. 9.6% ± 2.6
Fasting glucose: int. 200.1 ± 55.1; con.
200.8 ± 59.9
Postprandial glucose: int. 234.3 ± 68.6; 
con. 238.5 ± 69.3
Cholesterol: int. 226.1 ± 42.6; con. 220.3 ±
55.4
Triglyceride: int. 232 ± 32; con. 211 ± 34
HDL cholesterol: int. 47.0 ± 4.2; con. 45.8
± 4.5
Weight: int. 75.4 ± 11.7 kg; con. 73.4 ±
11.5 kg
Gender (M/F): int 7/16; con. 10/16
Age ranges: int. 51.1 (SD 8.1) years; 
con. 53.7 (SD 12.8) years
Ethnic groups (Israel/Asia +
Africa/Europe + America): int. 8/7/8;
con. 3/10/13 
Losses to follow-up: 2 int. patients did not
participate in the education programme or
keep appointments
Compliance: 23 patients participated in
the first meetings, 21 in the second and 18
in the third and fourth
Primary
outcomes used:
HbA1c
Secondary
outcomes used:
knowledge (not
reported here),
BP , weight (kg –
not reported
here), pre- and
postprandial blood
glucose (not
reported here),
blood cholesterol,
HDL cholesterol
blood triglyceride
Individual
preferred
learning style
addressed?: no
Any subgroups
(e.g. ethnic
groups): no
Normal range(s)
for outcomes:
not reported
How outcomes
assessed?: HbA1c
laboratory,
knowledge by
self-report
Validated?:
knowledge not
validated
(prepared for this
study)
Timing of
outcomes same
for both groups:
yes
Length of
follow-up:
12 months from
inception
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Outcomes (many  Intervention (n = 23) Control (n = 26) Difference between 
approximations from figure) groups
HbA1c (%) (from Figure 3) 8.25 9.6 Interaction between
intervention and time, 
p < 0.05a
Preprandial BG  162 210 Interaction between 
(mg/dl) (from Figure 1) intervention and time, 
p < 0.01a
Postprandial BG (mg/dl) (from Figure 2) 190 225 Interaction between
intervention and time, 
p < 0.05a
BP Not reported
Mean blood cholesterol (mg/dl) 213.8 ± 37.7 226.1 ± 60.8 NS
Blood triglycerides (mg/dl) 214 ± 24 204 ± 31 NS
HDL cholesterol (mg/dl) 49.6 ± 4.3 45.2 ± 4.4 NS
Weight (kg) (from Figure 4) 73 73 Interaction between
intervention and time, 
p < 0.05a
Methodological comments
Allocation to treatment groups: patients stratified according to mean values of pre- and postprandial glucose and HbA1c and
randomised. No detail of method
Blinding of outcome assessors?: laboratories unaware
Allocation concealment?: not reported
Analysis by ITT?: not reported
Comparability of treatment groups: no differences reported in baseline characteristics
Method of data analysis: ANOVA for repeated measures (over time) and t-tests and 2 between groups. No point estimates
given or CIs
Sample size/power calculation: not given
Attrition/drop-outs: drop-outs reported and reasons given
General comments
Generalisability:
Conflict of interests: funding support not mentioned
Other:
NS, not significant.
a This interaction represents the difference between groups in the change from baseline to end-point.
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Adequate
6. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
7. Did the analyses include an ITT analysis? Unknown
8. Were withdrawals and drop-outs completely described? Adequate
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Reference and  Intervention Participants Outcome 
design measures
Results
Outcomes Intervention  (n = 39) Control (n = 38) Differences between 
groups
Mean (95% CI) HbA1c (%) at 1 year  6.2 (5.7 to 6.7)a 6.4 (5.8 to 7.0)a Not significant 
(intervention end) (no p-value provided)
Mean (95% CI) HbA1c (%) 6.1 (5.5 to 6.7)a 6.6 (6.0 to 7.2)a p < 0.01
at 2 years (follow-up end)
Study: Sarkadi and
Rosenqvist, 200460
Source: Journal
article
Country: Sweden
Setting:
Pharmacies 
Language: English
Trial design: RCT
Treatment intervention: 
Topics: self-management, including
diet, exercise and other lifestyle
changes, complications and self-
monitoring BG (not reported in
detail)
Provider: specially trained
pharmacists, initially also with a
diabetes nurse specialist (numbers
and allocation among groups and
pharmacies not stated)
Sessions: once monthly (length not
stated)
Audience: groups (size, composition
and allocation among pharmacies 
and pharmacists not stated)
Delivery: pilot-tested programme
(reference available) comprising
interactive and didactic education: 
a diabetes education video and
booklet, interactive group game,
diabetes management booklet and
continuous back-up support from
pharmacists
Treatment changes: subjects were
referred to a medical team if 
glucose control was unsatisfactory
Training of trainers: pharmacists
trained by one of the authors in a 
3-day intensive course
Theory: experience-based learning
with a pedagogical principle that any
questions raised should be solved by
the group, not by the group leader
Control group:
Patients assigned to 2-year waiting
list (no other details reported)
Duration of intervention: 1 year
Were the care programmes
identical?: Not reported
Eligibility/exclusion criteria:
Inclusion: diagnosed with Type 2 diabetes
and, if treated with insulin, for 2 years
Exclusion: insulin use >2 years, or did not
provide an initial HbA1c measurement or
did not complete an initial questionnaire
How selected: self-referrals responding to
advertisements in local newspapers, GP
clinics and office of Stockholm Diabetes
Association
Numbers involved (excluding losses to
follow-up): intervention n = 39; 
control n = 38; total randomised n = 77 
(7 additional subjects eligible but not
randomised as no baseline HbA1c and/or
questionnaire – see Exclusion criteria)
Losses to follow-up: intervention n = 6;
control n = 7
Diabetes treatment: numbers on insulin,
tablets, or diet only: not reported
Duration of diabetes (mean ± SD):
intervention 5.9 ± 5.8 years; control 2.6 ±
2.2 years (significance of this difference
stated, without explanation, as a range:
p = 0.007 to p = 5.6)
Gender: not reported
Age (mean ± SD): intervention 66.4 ±
7.9 years; control: 66.5 ± 10.7 years
Ethnic groups: not reported
Compliance: not reported
Baseline measurements of relevant
parameters: 
HbA1c estimated from Figure 2 by
reviewer: intervention and control both
close to 6.5%; the difference between
them not statistically significant (no p-value
provided)
Mean ± SD BMI: intervention 27.2 ± 3.6;
control 28.6 ± 5.8 (units not stated;
assumed kg/m2)
Primary
outcomes used:
HbA1c at end-
point; HbA1c
changes from
baseline
Secondary
outcomes used:
none reported
Individual
preferred
learning style
addressed?: no
(group education)
Subgroups: none
reported
Normal range(s)
for outcomes:
not reported
How outcomes
were assessed:
not reported
Validation of
outcomes: not
reported
Timing of
outcomes the
same for both
groups?: yes
Length of follow
up: 2 years
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Methodological comments:
Allocation to treatment groups: unmarked envelopes containing patient information were drawn randomly from a box then
assigned to the two groups (inadequate details provided) by an assistant who was witnessed by another assistant, with the
latter deciding which of the groups would be the intervention and the control
Blinding of outcome assessors?: none stated
Allocation concealment?: envelopes were unmarked but it was not reported whether they were opaque
Analysis by ITT?: no (but unclear): numbers analysed were not stated but appear to exclude losses to follow-up
Comparability of treatment groups: the control group had a lower duration of diabetes; this difference between groups may
have been statistically significant, but this is unclear due to ambiguous reporting. Four participants were missing from the
control group on this measure (randomised n = 31; actual n = 27)
Method of data analysis: the authors report that one-way ANOVA was used but no data are presented, only p-values and a
chart (Figure 2). They also used regression models to enable the analyses to be adjusted for baseline differences in diabetes
duration and HbA1c. However, the models are poorly and ambiguously reported. Accordingly, the adjusted outcomes are
excluded from this data extraction
Sample size/power calculation: yes: the authors reported that 18 subjects per group would be needed to detect a 1%
decrease in HbA1c with  = 0.05 and  = 0.1. The authors recruited additional patients to allow for 20% drop-out and for
testing of other variables. However, the reported calculation provides only 10% power with 18 subjects per group, whereas
no power calculation is given for >18 subjects per group
Attrition/drop-outs: yes: intervention n = 6 (15%); control n = 7 (18%)
General comments
Generalisability: unknown: the populations were not described (no indication given of ethnicity, gender, etc.)
Conflict of interests: none evident (funding support stated; research foundations)
Other: overall, the poor standard of reporting and lack of empirical data limit data extraction
a Estimated from chart (Figure 2) by reviewer; an assumption is made that the bars shown in the chart each represent half
of a symmetrical CI.
1. Was the assignment to the treatment groups really random? Partial
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Partial
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? PartialAppendix 5
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Reference and  Intervention Participants Outcome 
design measures
Study: Trento
et al., 2001;53
2002;54 200455
Source: Journal
articles
Country: Italy
Setting:
University clinic
Language: English
Trial design: RCT
Treatment intervention:
Topics: observation phase,
educational diagnosis,
definition of goals and
development of plan including
methods and setting in which
to deliver. Data collected on
patient baseline education,
health beliefs, undesirability of
being overweight, meal
planning, improving and
checking metabolic control
and preventing complications
(more detail provided).
Homework diaries for weight
and food intake were given
out at the end of each
meeting, and discussed at the
beginning of the next
Provider: 1 or 2 physicians and
an educationalist. Also GP , 2
postgraduate medical students,
clinical psychologist and
psychometrist helped design
the programme
Sessions: 4 sessions, over 1 h
each, repeated every 3
months in years 1 and 2. Then
spread over 7 sessions in years
3 and 4. Patients in
need/wishing to have clinical
attention were seen on a one-
to-one basis at the end
Audience: 6 groups of 9–10
patients 
Delivery: Both didactic and
interactive (hands-on activities,
group work, problem-solving
activities, real-life simulations
and role play)
Treatment changes: none
reported
Training of trainers: not
reported
Theory: not reported
Control group:
Traditional consultations every
3 months in the diabetes clinic,
unless intercurrent problems.
Seen by same physicians as
intervention who were
unaware that patients were in
the control group. Also had
weekly diaries of body weight
and nutrition. Individual
education sessions from same
educationalist, with special
Eligibility/exclusion criteria: 
Inclusion: Type 2 diabetes treated with either
diet alone or diet and OHAs, who had
attended clinic for at least 1 year and aged
<80 years
How selected: not reported
Numbers involved: total 112 (56 intervention;
56 control)
Numbers on diabetes treatment: insulin
none; tablets 50 intervention, 46 control; diet
alone 6 intervention, 10 control
Mean (range) duration of diabetes:
intervention 9.4 (1–23) years; control 9.8
(1–39) years
Gender M/F: intervention 27/29; control 34/22
Mean (range) age: intervention 62 (35–80)
years, control 61 (43–78) years
Ethnic groups: not reported
Mean ± SD baseline measurements of
relevant parameters: 
1. Reported by Trento et al.53 in their
comparison with 2-year follow-up:
HbA1c: Intervention (int.) 7.4% ± 1.4;
control (con.) 7.4% ± 1.4 
QoL (DQOL): int. 67.6 ± 19; con. 66.7 ± 25 
Retinopathy (none/mild/more severe): 
int. 42/8/6; con. 38/13/5 
Knowledge: int. 14.9 ± 7.9; con. 20.2 ± 7.4
BMI: int. 29.7 ± 4.5; con. 27.8 ± 4.1
No. hypertensive: int. 34; con. 25
Weight (kg): int. 77.4 ± 13.1; con. 78.2 ±
14.6
Fasting BG (mmol/l): int. 9.8 ± 2.6; con. 10.0
± 3.1
Total cholesterol (mmol/l): int. 5.8 ± 1.1; 
con. 5.5 ± 0.9
HDL cholesterol (mmol/l): int. 1.2 ± 0.3; con.
1.3 ± 0.3
Triglyceride (mmol/l): int. 2.6 (0.7–11.5); 
con. 1.7 (0.5–5.2)
Creatinine (mol/l): int. 91.6 ± 14.2; 
con. 90.0 ± 14.0
Albuminuria (none/micro or macro): int. 32/24;
con. 37/19
Foot ulcers (never/past/active): int. 54/0/2;
con. 53/2/1
Hypoglycaemic treatment (int./cont.): diet
only 6/10, sulfonylureas 27/21, metformin
5/6, sulfonylureas + metformin 18/19,
insulin 0/0
Primary
outcomes used:
body weight,
fasting BGa,
HbA1c, diabetic
retinopathy, blood
lipids, knowledge
of diabetes, health
behaviour
(Contact and
Disorder Rating)a,
QoL (DQOL)
Secondary
outcomes used:
hypoglycaemic
medicationa,
microalbuminuria,
systolic and
diastolic BP
Individual
preferred
learning style
addressed?: no
(group
interventions)
Subgroups: none
reported.
Normal range(s)
for outcomes:
not reported
How outcomes
were assessed:
not reported
Validation of
outcomes: HbA1c
yes. QoL with
Diabetes Quality
of Life (DQOL)
(slightly modified
with 6 qualities
omitted from the
worry,
social/vocational
section as
pertinent to young
Type 1 patients).
Retinopathy: yes.
Knowledge by
education study
group of the
Italian Society of
Diabetes
(reported to be
valid); Health
Conduct assessed
by CdR validated
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Reference and  Intervention Participants Outcome 
design measures
reference to eating habits,
home monitoring of glucose
and prevention of
complications
Duration of intervention: 
Varied among patients; up to
5 years
2. Reported by Trento et al.54 in their
comparison with 4-year follow-up:
HbA1c: int. 7.4% ± 1.4; con. 7.4% ± 1.4
QoL (DQOL): int. 67.6 ± 19; con. 70.5 ±
21.7
Retinopathy (none/mild/more severe): 
int. 33/12/0; con. 28/14/0
Knowledge: int. 14.9 ± 7.9; con. 20.4 ± 7.8
BMI: int: 29.8 ± 4.5; con. 27.9 ± 4.5
Weight (kg): int 77.8 ± 13.6; con. 77.8 ±
15.0
Fasting BG (mmol/l): int. 9.8 ± 2.6; con. 10.2
± 3.2
Total cholesterol (mmol/l): int. 5.84 ± 1.11;
con. 5.46 ± 0.93
HDL cholesterol (mmol/l): int. 1.27 ± 0.31;
con. 1.32 ± 0.31
Triglyceride (mmol/l): int. 2.54 (0.66–11.49); 
con. 1.81 (0.51–5.22)
Creatinine (µmol/l): int. 91.94 ± 14.14; 
con. 91.05 ± 14.14
Microalbuminuria: int. 31.79; con. 4.96
Hypoglycaemic treatment (int./con.): diet
only: 6/10; OHAs: 0/46
Systolic BP (mmHg): int. 160 ± 26; 
con. 151 ± 19
Diastolic BP (mmHg): int. 95 ± 11; 
con. 92 ± 10
3. Reported by Trento et al.55 in their
comparison with 5-year follow-up:
HbA1c: int. 7.4% ± 1.4; con. 7.4% ± 1.4
QoL (DQOL): int. 67.4 ± 19; con. 70.0 ±
21.4
Knowledge: int. 15.5 ± 7.9; con. 21.4 ± 7.2
BMI: int. 30.0 ± 4.7; con. 27.7 ± 4.6
Weight (kg): int. 79.6 ± 13.7; con. 77.5 ±
16.0
Fasting BG (mmol/l): int. 9.8 ± 2.6; con. 9.9
± 3.2
Total cholesterol (mmol/l): int. 5.84 ± 1.11;
con. 5.46 ± 0.93
HDL cholesterol (mmol/l): int. 1.27 ± 0.31;
con. 1.32 ± 0.31
Triglyceride (mmol/l): int. 2.54 (0.66–11.49); 
con. 1.81 (0.51-5.22)
Creatinine (µmol/l): int. 91.94 ± 14.14; 
con. 91.05 ± 14.14
Losses to follow-up: 
At 2 years: int. 13 (3 deaths, 10 moved); con. 9
(1 death, 5 moved, 3 lost to follow-up)
At 4 years: int. 11 [3 deaths, 8 moved (2 moved
in year 1 and returned in year 3)], con. 11 
[2 deaths, 17 moved (10 returned for year 4
assessment), 2 lost to follow-up]
At 5 years: int. 14 (3 deaths, 10 moved, 1 not
traced), con. 14 (3 deaths, 9 moved, 2 not
traced)
Timing of
outcomes the
same for both
groups: yes
Length of
follow-up:
5 years from
inception, with
reporting at 2, 4
and 5 years
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Mean ± SD of outcomes at 2-year follow-up
Intervention Control  Differences 
(n = 43) (n = 47) between groups
HbA1c (%) 7.5% ± 1.4 8.3% ± 1.8 p < 0.002
DQOL score 55.6 ± 15.9 80.8 ± 31.5 p < 0.001
Diabetic retinopathy (none/mild/more severe) 35/5/3 33/7/7 NS
GISED (knowledge) score 24 ± 6.6 17.4 ± 8.6 p < 0.001
BMI (kg/m2) 29.0 ± 4.4 27.6 ± 4.2 p = 0.06
Number hypertensive 26 22 NS
Weight (kg) 76.0 ± 13.4 77.1 ± 14.7 NS
Fasting BG (mmol/l) 9.9 ± 2.6 9.2 ± 2.9 NS
Total cholesterol (mmol/l) 5.7 ± 1.2 5.6 ± 1.2 NS
HDL cholesterol (mmol/l) 1.4 ± 0.4 1.3 ± 0.3 p < 0.05
Triglycerides (mmol/l) (range) 2.1 (0.7–6.9) 1.7 (0.6–3.9) p = 0.53
Creatinine (mol/l)  88.8 ± 16.5 87.8 ± 17.2 NS
Albuminuria (none/micro or macro) 20/21 19/22 NS
Number with foot ulcers (never/past/active) 42/1/0 45/1/1 NS
SMBG 10 14 NS
Hypoglycaemic treatment:
Diet only 2 5 NS
Sulphonylureas 18 13 NS
Metformin 3 6 NS
Sulfonylureas + metformin 18 25 NS
Insulin 2 5 NS
Mean ± SD of outcomes and mean changes from baseline 
at 4 years follow-up
Intervention (n = 45) Control (n = 45)
At 4 years Change from  At 4 years Change from 
baseline baseline
HbA1c (%) 7.0 ± 1.1 –0.3 (NS) 8.6 ± 2.1 1.3 (p < 0.001)
DQOL score 44.0 ± 7.5 –23.6 (p < 0.001) 89.8 ± 28.1 19.2 (p < 0.001)
Diabetic retinopathy (none/mild/more severe) 35/10/0 19/20/3
GISED (knowledge) score 27.1 ± 6.6 12.2 (p < 0.001) 17.2 ± 8.7 –3.2 (p < 0.05)
BMI (kg/m2) 28.7 ± 4.0 –1.0 (p < 0.001) 27.6 ± 4.7 –0.3 (NS)
Weight (kg) 75.2 ± 13.0 –2.6 (p < 0.001) 76.9 ± 16.1 –0.9 (NS)
Fasting BG (mmol/l) 9.3 ± 2.6 –0.5 (NS) 11.0 ± 4.6 0.8 (NS)
Total cholesterol (mmol/l) 5.77 ± 1.34 –0.07 (NS) 5.59 ± 1.29 0.13 (NS)
HDL cholesterol (mmol/l) 1.42 ± 0.31 0.15 (p < 0.001) 1.37 ± 0.28 0.05 (NS)
Triglycerides (mmol/l) (range) 2.11 (0.45 – 10.93) –0.43 (NS) 1.64 (0.43–3.47) –0.17 (NS)
Creatinine (mol/l) 86.63 ± 15.91 –5.31 (NS) 97.24 ± 25.64 6.19 (NS)
Microalbuminuria 6.26 –25.52 (NS) 6.15 1.18 (NS)
Systolic BP (mmHg) 154 ± 21 –5.9 (NS) 149 ± 15 –1.9 (NS)
Diastolic BP (mmHg) 88 ± 7 –7.1 (p < 0.001) 86 ± 9 –6.3 (p < 0.001)
Urea nitrogen (mmol/l) 13.67 ± 3.82 –0.75 (NS) 15.74 ± 5.78 2.18 (p < 0.05)
Hypoglycaemic treatment (diet  2/38/4/1 2/37/3/3
only/oral agents/oral agents and 
insulin/insulin alone)
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Mean ± SD of outcomes and mean (95% CI) changes from baseline 
at 5-year follow-up
Intervention (n = 42) Control (n = 42) Difference in change
from baseline 
At 5 years Change from At 5 years Change from between intervention
baseline baseline and control
HbA1c (%) 7.3 ± 1.0 –0.1 9.0 ± 1.6 1.7 p < 0.001
(–0.5 to 0.4) (1.1 to 2.2)
DQOL score 43.7 ± 7.2 –23.7 89.2 ± 30.1 19.2 p < 0.001
(–30.0 to –17.3) (8.4 to 29.9)
GISED (knowledge) score 27.9 ± 5.7 12.4 18 ± 8.5 –3.4 p < 0.001
(9.7 to 15.2) (–1.1 to –5.7)
BMI (kg/m2) 28.6 ± 4.1 –1.4 27.6 ± 4.4 –0.10 p = 0.067
(–2.0 to –0.7) (–0.7 to 0.5)
Weight (kg) 76.1 ± 12.9 –3.5 77.3 ± 16.0 –0.24 p = 0.015
(–5.2 to –1.8) (–1.9 to 1.5)
Fasting BG (mmol/l) 9.4 ± 2.3 –0.4 10.2 ± 2.9 0.3 NS
(–1.52 to 0.70) (–0.99 to 1.51)
Total cholesterol (mmol/l) 5.50 ± 1.06 –0.32 5.27 ± 1.13 –0.43  NS
(–0.68 to 0.03) (–0.54 to 0.10)
HDL cholesterol (mmol/l) 1.39 ± 0.33 0.14 1.42 ± 0.31 0.10  NS
(0.07 to 0.22) (–0.02 to 0.23)
Triglycerides (mmol/l) 2.17 ± 2.30 –0.48 1.52 ± 0.75 –0.28 NS
(–1.15 to 0.20) (–0.60 to 0.03)
Creatinine (mol/l)  75.14 ± 25.63 –16.79  78.67 ± 47.73 –12.37
(–25.63 to –10.60) (–26.52 to 2.65) NS
Methodological comments
Allocation to treatment groups: random number tables
Blinding of outcome assessors: not reported
Allocation concealment: not reported
Analysis by ITT: no: narrative indicates ITT, but in reality not analysed that way
Comparability of treatment groups: control participants had higher levels of education and better knowledge of diabetes 
Some differences observed in baseline measurements between the three publications may be due to rounding; for others
the explanation is unclear
Method of data analysis: means, with SD, range or CIs given with significance (p < 0.05 significant). Paired Student’s t-test or
Wilcoxon rank-sum test. Generalised linear model. ANCOVA was used to test for differences between groups in changes
from baseline to 5 years and adjust for baseline differences. Between-group comparisons were not made at 4 years
Sample size/power calculation: not reported
Attrition/drop-outs: reported as above
General comments
Generalisability: unknown [ethnicity not stated; different baseline data reported in each paper (see above)]
Conflict of interests: none evident; Turin University research grant
Other: three related publications
a Data not extracted.
1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Inadequate
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? AdequateAppendix 5
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Reference and  Intervention Participants Outcome 
design measures
Study: Domenech
et al., 199564
Source: Journal
article
Country:
Argentina
Setting:
Community
Language: English
Trial design: CCT
Patients had previously received
dietary advice from their physicians
and/or had been treated with 
OHAs
Treatment intervention: 
Group intervention of up to 8
patients incorporating group
discussion and teaching
Provider: physicians who had
previously participated in a 2-day
instruction of the teaching
programme
Sessions: 4 teaching units
(90–120 minutes each) carried out
once per week for 1 month
Topics: normal physiological range 
for serum glucose, symptoms of
hypoglycaemia, hyperglycaemia, 
the renal threshold for glucose, self-
monitoring of glycosuria, the effect
of obesity, planning of an individual
meal plan, foot care, physical activity
and basic rules to be applied on sick
days
Delivery: group education. Materials:
flip charts, teaching files,
photographs of different food
representing 1000 cal, question cards
to verify knowledge, an individual log
book, a patient booklet including the
main contents, a questionnaire
Each patient was encouraged to
attend accompanied by spouse
After session 1, a very low-calorie
diet (600 cal) was recommended for
alternative days for 1 week and to
stop the intake of OHA, thereby
giving an opportunity to test the
effect of diet upon glucose levels.
Testing for glycosuria was
recommended for twice per day 
2 h after food
Control intervention:
Usual care
Duration of intervention:
1 month
Eligibility/exclusion criteria: 
Exclusion: excluded if newly diagnosed Type
2 diabetes, aged over 60 years, presence of
advanced microangiopathic complications
and presence of other severe diseases (e.g.
cancer)
How selected: the first 6–7 patients
consulting each physician were selected for
inclusion. In the control groups a larger
number were included as were expecting a
larger drop-out and in order to obtain a
better match by age, gender and duration
of diabetes
Numbers involved: total N = 124,
intervention (int.) 53; control (con.) 71
NB: Baselines based on those completing
study
Numbers on insulin: not reported,
assume none. Tablets: int. 29; con. 32. 
Diet alone: assume int. 11; con. 7
Type of diabetes?: Type 2
Duration of diabetes: int. 6.9 (±0.7);
con. 6.3 (±1.3) years
Baseline measurements of outcome
parameter: HbA1 int. 9% (± 2.6); 
con. 9% (± 2.2)
Gender (M/F): int.18/22; con. 17/22 
Age ranges: int. 52.7 (SE 3.1); con. 53.1
(SE 1.1) years
Ethnic groups: not reported
Losses to follow-up: int. 13; con. 32
(details given for intervention group only)
Primary
outcomes used:
HbA1
Secondary
outcomes used:
knowledge weight
in kg, daily intake
of OHAs
Individual
preferred
learning style
addressed?: no
Any subgroups
(e.g. ethnic
groups): no
Normal range(s)
for outcomes:
HbA1 <7.5%
How outcomes
assessed?:
laboratory,
knowledge by
self-report
Validated?: HbA1
yes, knowledge no
Timing of
outcomes same
for both groups:
yes
Length of
follow-up:
12 months from
inception
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Outcome changes  Intervention (n = 40) Control (n = 39) Differences between groups
(mean difference ± SD)
HbA1 –0.2 (0.4) +0.8 (0.4)
Weight in (kg) –2.4 (0.5) –0.4 (0.5) p < 0.01
Daily intake OHA (no. of tablets) –1.4 (0.2) +0.9 (0.2) p < 0.01
Knowledge not reported as not a valid measure
Also reports percentage of patients who showed an improvement of more than 0.5% which was not significant between
groups (data in figure only)
Also reports that within groups a significant correlation in those who exhibited a significant decrease in HbA1 (>0.5%) was
associated with significant weight loss and a reduction in OHAs.
Methodological comments
Allocation to treatment groups: non-randomised trial
Blinding of outcome assessors?: not reported
Allocation concealment?: non-randomised trial
Analysis by ITT?: no
Comparability of treatment groups: reported to be comparable in socio-economic levels and matched for age, gender and
duration of diabetes. Also strict criteria were adopted to standardise between the two groups the level of dietary caloric
intake and OHA prescription
Method of data analysis: method not reported, assume ± = SD
Sample size/power calculation: no
Attrition/drop-outs: percentages reported
General comments
Generalisability: few baseline data reported
Conflict of interests: course materials were provided by Boehringer Mannheim
Other: unsure of control group intervention; patients in intervention groups all had different tutors
Were the groups similar at baseline in terms of prognostic factors? Reported
Were the eligibility criteria specified? Yes
Were outcome assessors blinded to the treatment allocation? Unknown
Were the point estimates and measure of variability presented for the primary outcome measure? Partial
Did the analyses include an ITT analysis? Unknown
Were withdrawals and drop-outs completely described? Adequate 
Were participants likely to be representative of the intended population? YesAppendix 5
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Reference and  Intervention Participants Outcome 
design measures
Study: Kronsbein,
et al., 198863
Source: Journal
article
Country:
Germany
Setting: general
practices
Language: English
Trial design: CCT,
conditions
implemented by
practice
Treatment intervention: 
Provider: specially trained physicians’
assistants
Topics: basic information, metabolic
self-monitoring, reasons for raised
BG levels, OHAs, diet, foot care,
physical activities, sick-day rules, late
complications
Sessions: 90–120 minutes each week
for 4 weeks; groups of 4–6 patients;
focus on group interaction with each
session including experiential,
theoretical and practical aspects
Treatment changes: unknown
Training trainers: unknown
Theory: unknown
Mode: unknown
Control intervention:
Usual care within general practices;
all patients before trial had been
given unstructured dietary advice by
physicians and/or were treated with
oral sulfonylureas
Duration of intervention: 4 weeks
Eligibility:
WHO criteria for NIDDM
Exclusion: physical or mental handicaps that
prevented them from following the
intervention programme
How selected:
8 GPs attending teaching programme
volunteered to introduce programme – 
5 practices immediately, 3 after 1 year.
Intervention participants: all consecutive
patients who participated in first three
courses
Numbers involved: starting total: 127,
intervention (int.) 65; control (con.) 62
Total (those completing follow-up) 99, 
int. 50; con. 49
Type of diabetes: Type 2
Duration of diabetes (year ± SD):
int. 7 ± 5; con. 7 ± 6
Baseline measurements of outcome
parameter (mean ± SD):
HbA1c: int. 7.1 ± 1.6%; con. 6.5 ± 1.6%
Weight (kg): int. 76.5 ± 12.6; con. 75.1
+ 12.9
Knowledge: int. 9 ± 3; con. 9 ± 3
No. without glucose-lowering
medication: int. 32%; con. 39%
Gender (M/F): int. 42/58%; con. 39/61%
Age ranges (mean ± SD): int. 65 ±
9 years; con. 63 ± 8 years
Ethnic groups: not reported
Losses to follow-up: int. 15; con. 13
Primary
outcomes used:
HbA1c
Secondary
outcomes used:
knowledge score,
no. on BG-
lowering
medications,
treatment with
insulin, frequency
self-monitoring
urine, body
weight
Individual
preferred
learning style
addressed?: no
Any subgroups
(e.g. ethnic
groups): no
Normal range(s)
for outcomes:
HbA1c up to 5.6%
How outcomes
assessed: HbA1c
by laboratory,
knowledge by
specially designed
questionnaire, no.
on medication not
reported, self-
report glycosuria
testing
Validated:
knowledge
questionnaire
assumed
validated,
reference
provided
Timing of
outcomes same
for both
groups?:
unknown
Length of
follow-up: 1 year
from inception
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Outcome (mean and SD) Intervention  Control  Difference between groups
(n = 50) (n = 49) (95% CI)
HbA1c 7.1 ± 1.6 6.7 ± 1.5 NS
Knowledge 13 ± 4 10 ± 4 3 (16 to 48)a
% without BG-lowering medication 62 39 23 (3 to 43)b
Treatment with insulin 0 10 10 (2 to 18)b
Body weight (kg) 73.8 ± 12.6 74.8 ± 13.2 2.3 (1.0 to 3.6)a
Self-monitoring glycosuria (%) 72 2 70 (57 to 83)a
Methodological comments 
Allocation to treatment groups: group formed by treatment within participating practices or not, all GPs received programme
training
Blinding of outcome assessors: not reported
Allocation concealment: not randomised
Analysis by ITT: no
Comparability of treatment groups: reported that baseline characteristics of those completing and not completing follow-up
did not differ
Method of data analysis: hypothesis tests with CIs for within-group and between-group differences
Sample size/power calculation: reported power required ~55 patients per group
Attrition/drop-outs: yes
General comments
Generalisability: both patient groups started with relatively low HbA1c and therefore may not be representative
Conflict of interests: none reported
Other: none
a Difference between groups p < 0.0001.
b Difference between groups, p < 0.05.
Were the groups similar at baseline in terms of prognostic factors? Reported
Were the eligibility criteria specified? Yes
Were outcome assessors blinded to the treatment allocation? Unknown
Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
Did the analyses include an ITT analysis? Unknown
Were withdrawals and drop-outs completely described? Partially
Were participants likely to be representative of the intended population? No
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Reference and  Intervention Participants Outcome 
design measures
Study: Kaplan
et al., 198767
Source: Journal
article
Country: USA
Setting: Unclear
Language: English
Trial design: RCT
Four groups: diet education 
(group 1), exercise education 
(group 2), diet and exercise
education (group 3) and control
education (control)
All given the exchange diet (1200 cal)
recommended by ADA and each
received an exercise prescription
based on baseline exercise test. A
deposit of US$40 was requested
with return if attend and meet
predetermined goals. Treatment
interventions incorporated
behavioural modification (stretching
and walking and target heart rate)
and strategies to increase
compliance. The control did not
Sessions:
Groups 2 h once per week for
10 weeks 
Treatment intervention:
Group 1 (diet):
Provider: dietician explained the diet
Topics: identification of goals, used
principles of modern learning theory.
Diary monitoring of eating behaviour.
Identification of external cues that
lead to over/inappropriate eating
Theory: used positive reinforcement.
Also recorded own cognitions
(positive and negative self-
statements) and discussed in group.
Also brief relaxation. Ref. 11 for
fuller details
Treatment changes:
Training trainers:
Mode:
Group 2 (exercise):
Provider:
Topics: goal setting, planning for
exercise, self-monitoring introduced,
completion of diary, question
answering and group exercise
sessions. Used positive feedback and
gave suggestions for managing
problems
Treatment changes:
Training trainers:
Theory:
Mode:
Group 3 (diet and exercise):
Provider:
Topics: modified dietary intervention
for 5 weeks, then focused on
Eligibility/exclusion criteria: 
Inclusion: confirmed diagnosis, fasting
plasma glucose >3.62 mmol/l
How selected: radio and newspaper
advertisements and physicians
Numbers involved: total N = 87, unsure
of group numbers
Numbers on insulin: 19
Tablets: 29
Diet alone: 28
Type of diabetes?: Type 2
Duration of diabetes: not recorded
Baseline measurements of outcome
parameter: HbA1c: group 1 8.97% 
(SD 2.82), group 2 8.16% (SD 3.44), 
group 3 9.18% (SD 2.46), control 8.21 
(SD 1.54)
Gender (M/F): 32/44
Age ranges: group 1 54.87 (SD 12.32),
group 2 53.81 (8.04), group 3 56.96 (SD
8.95), control 54.5 (8.83) years
Ethnic groups: not reported
Losses to follow-up: 11 (reasons given)
Compliance: average attendance >80%
for all groups
Primary
outcomes used:
HbA1c, QoL
Secondary
outcomes used:
weight in (kg)
Individual
preferred
learning style
addressed?: 
Any subgroups
(e.g. ethnic
groups): no
Normal range(s)
for outcomes:
see Appendix in
text
How outcomes
assessed?: HbA1c
laboratory, QoL
self-report
questionnaire
Validated?: QoL
yes
Timing of
outcomes same
for all groups:
yes
Length of
follow-up:
18 months from
inception
continued
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Reference and  Intervention Participants Outcome 
design measures
Outcomes (18 months) Group 1 (diet) Group 2 (exercise) Group 3  Group 4 (control – 
(diet+ exercise) education)
HbA1c
a 8.51 9.46 7.70b 8.57
QoL (change scores)a +0.03b No improvement +0.06b –0.04
Weight Data not reported,  Data not reported,  Data not reported,  Data not reported, 
no changes no changes no changes no changes
Methodological comments 
Allocation to treatment groups: states randomly chosen otherwise no details
Blinding of outcome assessors?: not reported
Allocation concealment?: not reported
Analysis by ITT?: not reported
Comparability of treatment groups: no significant differences reported
Method of data analysis: change scores compared with ANOVA, no estimate of variance given
Sample size/power calculation: post hoc power analysis
Attrition/drop-outs: percentages given
General comments
Generalisability: minimal eligibility criteria, baseline characteristics suggest generalisable
Conflict of interests: funding support not mentioned
Other: unsure of N in each group
a Overall marginally significant difference between groups (p < 0.10). 
b Significant from group 4, p < 0.05. 
There were significant correlations between improvements in QoL and decreases in HbA1c (r = –0.22, p < 0.05). Some
costs–utility analysis reported.
exercise, self-monitoring, foot care
and stretching, then followed
exercise and behaviour modification
format 
Treatment changes:
Training trainers:
Theory:
Mode:
Control intervention:
Education: 
Provider: exposed to healthcare
specialists including an
endocrinologist, podiatrist,
ophthalmologist, psychologist,
dietician, official from ADA,
representative from company that
manufactures home glucose
monitoring equipment and
physiologist 
Session: each provider presented for
1 session (2 h) in form of lecture
providing diabetes care
Treatment changes:
Training trainers:
Theory:
Mode:
Duration of intervention:
10 weeksAppendix 5
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1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
7. Did the analyses include an ITT analysis? Unknown
8. Were withdrawals and drop-outs completely described? Reported
Quality criteria for RCTs (CRD Report 4)
Reference and  Intervention Participants Outcome measures
design
Study: Ridgeway,
et al., 199969
Source: Journal
article
Country: USA
Setting:
community –
ambulatory clinic
Language: English
Trial design: RCT
Treatment intervention:
Topics: dieting and exercise
were emphasised as
important in the control of
diabetes. Diet and exercise
prescriptions and goals set
individually. Contracts made
to emphasise patient
participation and personal
responsibility
Provider: registered nurse and
a dietician
Sessions: 1.5 h per month × 6
Delivery: group intervention,
didactic and interactive
Treatment changes: both
groups seen by physicians in
the usual manner
Training of trainers: certified
diabetes educators
Theory: didactic based on life
skills programme
Control intervention:
assume normal care with
clinic visits
Duration of intervention:
6 months
Treatment changes: OHA
medication started or
increased intervention (int.)
1; control (con.) 4, stopped
or decreased int. 1; con. 0,
insulin increased int. 2; con.
2, OHA replaced by insulin,
int. 0; con. 3
Eligibility/exclusion criteria:
Inclusion: Type 2 diabetes (defined), at least
20% over ideal weight, able to travel to clinic
monthly, judged by physician to be able to
comprehend dietary and diabetic teaching,
had inadequately controlled diabetes (fasting
BG >150 mg/dl and HbA1c above normal
range)
How selected: computerised audit was
conducted and yielded 150 patients, of whom
56 met inclusion criteria
Numbers involved: N = 56, int. 28; con. 28. 
Numbers on insulin: int. 3; con. 3, tablets
int. 12; con. 13, diet alone: int. 3; con. 4
Type of diabetes: Type 2
Duration of diabetes: int. 10 years; 
con. 13 years
Baseline measurements of outcome
parameter (mean ± SD): 
GHb: int. 12.3 + 2.2%; con. 12.3 ± 3.0% 
Knowledge: int. (n = 17) 74.2; 
con. not reported
QoL: not reported 
Diabetes symptoms: int. 43.8 ± 14.7; 
con. 44.5 ± 19
Fasting BG: int. 215; con. 210
Total cholesterol: int. 259; con. 224
HDL-cholesterol: int. 40; con. 40
Triglyceride: int. 634; con. 381
LDL-cholesterol: int. 133; con. 119
Gender (M/F): int. 6/12; con. 5/15 
Mean age: int. 62 years; con. 65 years
Ethnic groups: not reported
NB: baseline characteristics based on those
completing study
Losses to follow-up: int. 10; cont. 8 (reasons
given)
Compliance: int. at least 5 classes
Primary outcomes
used: GHb, QoL
(MOS SF-36 and DRP
questionnaires),
symptoms
Secondary
outcomes used:
knowledge (life skills
test), fasting BG, total
cholesterol, HDL
cholesterol,
triglyceride, LDL
cholesterol
Individual preferred
learning style
addressed?: no
Any subgroups (e.g.
ethnic groups): 
Normal range(s) for
outcomes: GHb
4.8–7.8%. Knowledge
scored as percentage
of correct answers.
No values for QoL 
How outcomes
assessed?: GHb by
laboratory. Others by
questionnaire,
presume self-report 
Validated: GHb yes,
MOS SF-36 unclear
whether validated;
unclear whether DRP
and life skills tests
validated
Timing of outcomes
same for both
groups: assume yes
Length of follow-up:
12 months from
inception
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Outcome (12 months) Intervention group Control group  Differences 
(n = 18) (n = 20) between groups
GHb (%) 11.52 11.64 NS
QoL No data presented No 12-month 
Knowledge 85.7 data presented
Symptoms No data presented
Weight (lb) 186 186 NS
Fasting BG 205 185 NS
Total cholesterol 219 234 p = 0.09
HDL cholesterol 36 37 NS
Triglyceride 485 336 NS
LDL cholesterol (in patients with  130 125 NS
triglyceride <400)
Methodological comments
Allocation to treatment groups: states randomly assigned in text but no details of method of any randomisation; also states
that education was recommended to patients after ‘randomisation’ which all in education group accepted
Blinding of outcome assessors?: not reported
Allocation concealment?: not reported
Analysis by ITT?: no
Comparability of treatment groups: groups similar on baseline characteristics
Method of data analysis: t-Tests. Standard error (difference within groups) given. No other measure of variance reported. 
No CIs 
Sample size/power calculation: not calculated, reported to be likely numbers available in a small general internal medicine
group practice
Attrition/drop-outs: yes
General comments
Generalisability: small group, large proportion of drop-outs, GHb poor at outset in both groups, patients judged to be able
to comprehend teaching by physicians
Conflict of interests: funding by Department of Medicine
Other: cost estimate for programme is US$95 for educational materials and salaries, excluding laboratory costs
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? AdequateAppendix 5
100
Reference and  Intervention Participants Outcome 
design measures
Study: Samaras
et al., 199772
Source: published
Country: Australia
Setting:
Community –
hospital outpatient
clinic
Language: English
Trial design: RCT
Treatment intervention:
Topics: initially a needs
assessment undertaken using
focus groups of outpatients
where contributing factors
for exercise non-compliance
were identified and classified.
Strategies to overcome
barriers, build self-esteem
and motivation and provide
professional and peer
support. Safe exercise,
exercise-specific education to
improve confidence, coping
with diabetes and exercise,
self-esteem issues, decision-
making, goal setting and
achieving mastery and
enjoyment in exercise
Provider: designed and
undertaken by nurse
educator, also involved
exercise physiologist,
dietician, group facilitator and
physician
Sessions: monthly sessions for
1 h followed by a moderately
paced aerobic exercise
session
Delivery: group intervention,
in person
Treatment changes: unclear
Training of trainers:
Theory: health promotion
model ‘proceed–precede’
(reference given)
Control intervention: 
usual treatment with
assessment visits at baseline,
6 and 12 months and routine
clinic visits 
Duration of intervention:
6 months (after programme
exercise sessions still
available to int. group)
Eligibility/exclusion criteria: 
Inclusion: Type 2 diabetes, aged 40–70 years,
performing less than 1 h of exercise per week
Exclusion: if history or signs of ischaemic heart
disease, current smoker, poor comprehension
of English
How selected: endocrinologists completed
questionnaires on all their patients
40–70 years old at routine clinic for 2 months
Numbers involved: N = 26 [(intervention
(int.) 13; control (con.) 13)]
Numbers on insulin: int. 3; con. 4;
Sulfonylurea: int. 5; con. 5; metformin or 
diet alone: int. 5; con. 4
Type of diabetes: Type 2
Duration diabetes: not reported
Baseline measurements of outcome
parameter (mean ± SE): 
HbA1c: int: 5.6% ± 0.3; con. 6.8% ± 0.6 
(not significant)
BMI: int. 32.3 ± 1.1; con. 35.7 ± 1.6
Weight: int. 83 ± 3.6; con. 98.2 ± 3.4
Skinfolds: int. 99.4 ± 6.0; con. 119.4 ± 9.4
% body fat: int. 40.3 ± 1.7; con. 40.3 ± 2.4
Waist:hip: int. 0.94 ± 0.1; con. 0.94 ± 0.08
Activity score: int. 164 ± 28; con. 168 ± 16
Total cholesterol: int. 5.6 ± 0.3; con. 5.6 ± 0.2
HDL cholesterol: int. 1.1 ± 0.1; con. 1.1 ± 0.1
Triglycerides: int. 3.1 ± 1.1; con. 2.3 ± 0.3
Fasting glucose: int. 9.3 ± 1.0; con. 7.9 ± 0.7
Fasting insulin: int. 22.4 ± 4.1; con. 21.4 ± 2.2
Gender (M/F): int. 4/9; con. 6/7 
Age ranges: int. 60.5 years (SE 7.8); 
con. 60.5 years (SE 2.1)
Ethnic groups: not reported, varied cultural
backgrounds
Losses to follow-up: assume none
Compliance: full
Primary outcomes
used: HbA1c, QoL
(SF-36)
Secondary
outcomes used: BMI 
Individual preferred
learning style
addressed?: no
Any subgroups (e.g.
ethnic groups): those
managed with
metformin or diet
alone and those taking
sulfonylurea or insulin
therapy
Normal range(s) for
outcomes: not
reported
How outcomes
assessed:
physiological measures
laboratory, QoL self-
report, activity =
meter
Validated?: HbA1c
yes, QoL by SF-36 –
validated.
Timing of outcomes
same for both
groups: yes
Length of follow-up:
12 months from
baseline
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Outcome (values are changes  Intervention group Control group Differences between groups
from baseline, mean ± SE)
HbA1c % +0.86 (0.29) +0.86 (0.27) NS
QoL No data presented
BMI –0.1 (0.5) +0.29 (0.45) NS
Weight (kg) +0.14 (1.09) +0.79 (1.09) NS
Skinfolds +6.18 (2.2) –3.7 (4.8) NS
% body fat +1.2 (0.5) +1.1 (0.9) NS
Waist:hip –0.02 (0.02) +0.01 (0.001) NS
Activity score (metabolic equivalents or task) +1 (12) –23 (11) NS
Total cholesterol (mmol/l) –0.22 (0.27) –0.33 (0.18) NS
HDL cholesterol (mmol/l) –0.01 (0.04) –0.07 (0.04) NS
Triglycerides (mmol/l) –0.46 (1.02) –0.23 (0.23) NS
Fasting glucose (mmol/l) +0.97 (0.64) +1.5 (0.98) NS
Fasting insulin –3.3 (3.5) +1.5 (2.2) NS
Subgroup: metformin or diet-alone HbA1c +0.4 ± 0.3 +1.5 ± 0.14 p = 0.02
(changes from baseline)
Subgroup: metformin or diet-alone FBG 
(changes from baseline) +1.1 ± 0.3 +3.1 ± 0.4 p = 0.003
Methodological comments
Allocation to treatment groups: no details of method of randomisation
Blinding of outcome assessors?: not reported
Allocation concealment?: not reported
Analysis by ITT?: no drop-outs reported
Comparability of treatment groups: weight significantly higher, BMI and skinfolds marginally significantly higher in control group
at baseline
Method of data analysis: ANOVA and Mann–Whitney statistics employed. SD given in some cases. No CIs given
Sample size/power calculation: not reported
Attrition/drop-outs: not reported
General comments
Generalisability: small sample size, smokers excluded 
Conflict of interests: funding support not mentioned
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Partial
7. Did the analyses include an ITT analysis? Unknown
8. Were withdrawals and drop-outs completely described? Unknown
Quality criteria for RCTs (CRD Report 4)Appendix 5
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Reference and  Intervention Participants Outcome measures
design
Study: 
Uusitupa, et al.,
1992–9668,86–90
Source: Journal
article
Country: Finland
Setting: Hospital
outpatient
Language: English
Trial design: RCT
Basic education to both groups:
prior to randomisation for
3 months, both groups received
basic education (basic knowledge of
NIDDM, dietary advice to lose
weight, reduce intake of saturated
fat and cholesterol and increase the
use of unsaturated fat and unrefined
carbohydrates)
Both groups, after the 1-year
intervention period: were advised
to visit local health centres at 
3-month intervals and the research
centre at 21 and 27 months
Treatment intervention: 
Topics:
1. Individualised intensified dietary
education: principles of the
diabetic diet, fat, carbohydrate,
fibre, sweeteners, special diabetic
products, behaviour modification,
review of important things in
diet, food preparation:
recommended an individually
tailored diet, compliance
measured by food records and
fatty acids of serum lipids
2. Exercise training: oral and written
instructions – proposed walking,
jogging, cycling, swimming, cross-
country skiing. Recommended
heart rate during sessions
110–140 beats per minute.
Recommended 3–4 times per
week for 30–60 minutes 
Provider: physician, DSN(s), clinical
nutritionist
Length and number of sessions: six
visits to the clinic (at 
2-month intervals).
Recommended frequency of
exercise training 3–4 sessions per
week of 30–60 minutes each
Mode: given in person at the local
health centre
Treatment changes: no
Training of trainers:
Theory:
Control intervention: usual
education given at the local health
centres that originally referred
them. They visited at 2–3-month
intervals, plus twice visited the
outpatient clinics
Duration of intervention:
12 months
Eligibility criteria: 
Inclusion: obese, newly diagnosed 
Type 2 patients aged 40–64 years, 
FBG levels of 6.7 mmol/l
How selected: physicians working in
five rural and one urban health centre
in Kuopio, referred all newly diagnosed
patients from 1987 to 1989
Numbers involved: total n = 86,
intervention (int.) 40; control (con.) 46
Numbers on insulin: none. Tablets: 7
(int. = 2; con. = 5) (1 in trial 2283);
diet alone: assume 79 (85 in trial 2283)
Type of diabetes: Type 2
Duration of diabetes: all newly
diagnosed 
Baseline measurements of
outcome parameters – mean (SD): 
Weight (kg): int. 88.3 (14.1); con. 88.8
(14)
BMI: int: 32.0 (5.2); con. 31.6 (4.8)
FBG (mmol/l): int. 6.6 (1.9); con. 7.5
(2.9)
FBG adjusted (mmol/l): int. 7.0; con. 7.2 
% patients with FBG 6.7 mmol/l: 
int. 37.5; con. 26.1
HbA1c (%): int. 7.1 (1.8); con. 7.8 (2.0) 
HbA1c adjusted (%): int. 7.4; con. 7.8
% patients with HbA1c 7.0%: no data
reported
Total cholesterol (mmol/l): int. 6.1 (1.2);
con. 6.3 (1.0)
HDL cholesterol (mmol/l): int. 1.07
(0.25); con. 1.17 (0.29)
Non-HDL cholesterol (mmol/l): int. 5.1
(1.3); con. 5.1 (1.0)
Triglycerides (mmol/l): int. 2.50 (1.44);
con. 2.26 (1.33)
Systolic BP (mmHg): int. 140 (16); 
con. 137 (16)
Diastolic (mmHg): int. 87 (11); cont. 83
(9)
Gender (M/F): int. 21/19; con. 28/18
Age ranges: 40–64 years. Mean (SD)
ages at diagnosis: int: 52.2 (6.5); 
con. 54.2 (6.5).
Ethnic groups: not reported
Losses to follow-up: at 2-year 
follow-up 2 lost in each group. 
Reasons not given
Primary outcomes
used: HbA1c
Secondary
outcomes used: BP ,
FBG, weight, BMI,
cholesterol, HDL
cholesterol, non-HDL
cholesterol,
triglycerides, food
intake, apolipoproteins
A1 and B, HDL
cholesterol/
cholesterol, drug
treatment, aerobic
capacity
Individual preferred
learning style
addressed: no
Any subgroups (e.g.
ethnic groups): no
Normal range(s) for
outcomes: not
reported
How outcomes
assessed: body weight
measured with electric
scale; physiological
measures by
laboratory, BP nurse
measured (mean of 
3 measurements),
food intake self-report
Validated: yes, except
self-report measures
Timing of outcomes
same for both
groups: yes
Length of follow-up:
after the 1-year
intervention period,
patients followed up
for a further
12 months
continuedHealth Technology Assessment 2008; Vol. 12: No. 9
103
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Outcome (24 months: int. N = 38,  Intervention Control Differences 
con. N = 44), mean ± SD between groups
HbA1c (%)
12 months 6.6 (1.6) 7.5 (1.7)
24 months 7.2 (1.9) 8.0 (1.6)
HbA1c (%) adjusted
12 months 6.7 7.3
24 months 7.4 7.9
% patients with HbA1c  7.0%
12 months 74.4a 47.8 a p = 0.005
24 months 55.3b 31.8 b p = 0.016
BMI
12 months 31.4 (5.0) 31.9 (4.6)
24 months 31.9 (5.0) 32.2 (4.5)
Systolic BP (mmHg)
12 months 137 (16) 144 (18)
24 months 146 (19) 150 (22)
Diastolic BP (mmHg) 
12 months 83 (9) 85 (9)
24 months 88 (10) 87 (9)
Total cholesterol (mmol/l)
12 months 6.0 (1.0) 6.4 (1.0)
24 months 6.4 (1.3) 6.5 (1.1)
HDL cholesterol (mmol/l)
12 months 1.20 (0.29) 1.21 (0.28)
24 months 1.17 (0.24) 1.19 (0.29)
Non-HDL cholesterol (mmol/l)
12 months 4.8 (1.0)
24 months 5.2 (1.0)
Triglycerides (mmol/l)
12 months 1.96 (0.89) 2.33 (1.19)
24 months 2.34 (1.19) 2.25 (1.25)
Weight (kg)
12 months 86.5 (13.7) 90.2 (14.3)
24 months Men (n = 20) 91.8 (10.7);  Men (n = 26) 95.1 (10.3); 
women (n = 18) 83.1  women (n = 18) 84.8 
(14.2) (18.1)
FBG (mmol/l)
12 months 6.2 (1.8) 7.5 (2.2)
24 months 7.1 (2.4) 8.2 (2.3)
FBG (mmol/l) adjusted
12 months 6.4a 7.3 a p < 0.02
24 months 7.4 8.0
% patients with FBG  6.7 mmol/l
12 months 75a 52.2 a p = 0.005
24 months 55.3b 31.8 b p = 0.016
Apolipoprotein A1
12 months 1.38 (0.19) 1.41 (0.18)
Apolipoprotein B
12 months 1.13 (0.24)a 1.26 (0.27) a p < 0.02
HDL cholesterol/total cholesterol
12 months 0.20 (0.05) 0.19 (0.05)
Drug treatment (% taking)
24 months 12.5a 34.8 a Significant from 
control, p = 0.005
Most of the comparisons reported were within groups. Only comparisons between groups are reported below.
Self-report outcomes not reported here.
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Methodological comments
Allocation to treatment groups: unclear, only reports ‘randomised’
Blinding of outcome assessors: not relevant
Allocation concealment: not reported
Analysis by ITT: not reported
Comparability of treatment groups: intervention group lower for FBG and HbA1c – difference not tested statistically. Values
were adjusted as covariates into MANOVA procedures and into the two-way ANCOVA
Method of data analysis: MANOVA, ANCOVA, t-tests. ANOVA used to test differences between groups. p-Values reported.
Variables expressed as mean (SD)
Sample size/power calculation: no
Attrition/drop-outs: numbers reported, but no reasons given.
General comments
Generalisability: 108 patients were recruited and 86 randomised – 11 did not fulfil selection criteria and 11 refused
Conflict of interests: funding from Finnish Medical Council, Academy of Finland, Finnish Ministry of Education, Finnish
Foundation for Diabetes Research
Other: Significant decrease for both groups for body weight, FBG and HbA1c during 3 months of basic education before
randomisation
ANCOVA, analysis of covariance; ANOVA, analysis of variance; MANOVA, multivariate analysis of variance.
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? UnknownHealth Technology Assessment 2008; Vol. 12: No. 9
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Reference and  Intervention Participants Outcome measures
design
Results
No physiological measures differed between groups, therefore results were reported for all 3 groups combined 
Outcome Behaviour group Nutrition group Standard care Differences between groups
Weight (kg) –1.78 –3.03 –3.43 NS
Methodological comments 
Allocation to treatment groups: method of randomisation not reported
Blinding of outcome assessors: BP assessment blinded, others not reported
Allocation concealment: not reported
Analysis by ITT: no
Comparability of treatment groups: reported that there were no differences in groups in pretreatment physiological measures
Method of data analysis: hypothesis tests (ANOVA), no CIs
Sample size/power calculation: not reported
Attrition/drop-outs: 3/53, not reported from within groups
General comments
Generalisability: participants self-selected to participate on basis of advertisements or suggestion from physician, therefore
may be more motivated than average patient; however, this would be true across conditions
Conflict of interests: no mention
Other: none
Study: Wing et al.,
198570
Source: Journal
article 
Country: USA
Setting:
Community
Language: English
Trial design: RCT
3 groups
Treatment intervention: 
Behaviour modification:
Provider: behavioural psychologist and
nutritionist
Topics: information on nutrition, exercise,
diabetes, behavioural strategies. Self-
monitor diet. Caloric goal for exercise and
group exercise. Contingency contract
refunded US$3 per lb of weight loss.
Changing eating environment. Changing
cognitions
Sessions: weekly for 16 weeks in groups 
Treatment changes:
Training trainers:
Theory:
Mode: lecture + discussion on topic related
to diet and exercise
Nutrition education
Provider: as above
Topics: diet – follow exchange list eating
plan closest to caloric goal. Nutrition topics.
Importance of exercise. No requirement to
self-monitor either diet or exercise. No
contingency contract for weight loss
Sessions: weekly for 16 weeks in groups
Treatment changes: 
Training trainers: 
Theory: 
Mode: as above 
Control intervention: 
Treatment programme identical in content
with nutrition education except only
4 monthly meetings
Duration of intervention:
Intervention for 16 weeks and follow-up 
for 1 year after intervention
Eligibility criteria:
Inclusion: 30–70 years of age,
20% or more above ideal
weight for height, diabetes
being treated by diet only or
by OHA medication, Type 2
diabetes by criteria specified
by National Diabetes Data
Group
How selected: recruited via
newspaper advertisements
and articles and letters to
physicians
Numbers involved:
Total: 53. No. in each group
not reported
Numbers on insulin: 0.
Tablets 75%; diet alone 25%
Type of diabetes: Type 2
Duration of diabetes:
5.9 years
Baseline measurements of
outcome parameter:
HbA1: 9.3 ± 0.3 (mean ±
SEM)
BMI: 34.8 ± 7
BDI: 11.2
Gender (M/F): 20/33
Age (mean ± SEM): 
55.1 ± 1
Ethnic groups: not reported
Losses to follow-up: 3
Primary outcomes
used: HbA1
Secondary outcomes
used: BP , Beck
Depression Inventory
(BDI), BMI, insulin, total
cholesterol, total
triglycerides, HDL
cholesterol, FBG,
activity, food frequency,
eating behaviour
inventory
Individual preferred
learning style
addressed?: no
Any subgroups (e.g.
ethnic groups): no
Normal range(s) for
outcomes: not reported
How outcomes
assessed: laboratory
nurse measure and self-
report 
Validated: yes, except
activity, food frequency,
eating behaviour
inventory
Timing of outcomes
same for both groups:
yes
Length of follow-up:
12 months post-
intervention (16 months
from inception)Appendix 5
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1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Were the point estimates and measure of variability presented for the primary outcome measure? Partially
7. Did the analyses include an ITT analysis? Unknown
8. Were withdrawals and drop-outs completely described? Partial
Quality criteria for RCTs (CRD Report 4)
Reference and  Intervention Participants Outcome measures
design
Study: Wing et al.,
198671
Source: Journal
article
Country: USA
Setting:
Community and
home
Language: English
Trial design: RCT
Common treatment
components: 
All sessions: individual weigh-in,
BG measurement, discussion of
behaviour modification for weight
control. Given a standard
behavioural weight control
programme. A daily calorie goal
set. Calorie books and self-
monitoring diaries were
distributed. Patients asked to self-
monitor their food intake and to
walk to exercise. Behaviour
modification techniques were
presented. All patients deposited
US$85, which could be earned
back for meeting treatment
contingencies
Treatment intervention =
glucose monitoring group
Providers:
Topics: Focused on the relationship
between weight loss and BG
control. Taught to monitor BG and
values recorded on a self-
monitoring form; both the form
and used strips were returned to
the office at each meeting. Patients
encouraged to keep BG levels
normal by adjusting caloric intake
and expenditure
Sessions: weekly meeting for
12 weeks, monthly meetings for
the next 6 months and follow-up
sessions at 9 and 12 months
Treatment changes:
Training trainers:
Theory:
Mode:
Control intervention = weight
control group:
Focused on weight reduction. 
BG levels checked at each meeting
so adjustments could be made to
Eligibility:
Inclusion: Type II diabetes, aged
35–65 years; 20% over more above
ideal weight for height; use of OHA or
insulin for control of BG; diagnosis
30 years 
Exclusion: patients having prior
experience with home monitoring of
BG
How selected: About two-thirds
were self-referred, one-third referred
by their physicians
Numbers involved: N = 50 (25
weight control group, 25 glucose
monitoring group)
Numbers on insulin: weight control
group 48%, glucose monitoring group
52%
Type of diabetes: all Type 2
Duration of diabetes: not given
Baseline measurements of
outcome parameter: 
FBG: weight control group (N = 22)
207 ± 70.5, glucose monitoring group
(N = 22) 209.2 ± 69.7
HbA1 (%): weight control group 
(N = 21) 10.86 ± 2.00, glucose
monitoring (N = 22) 10.19 ± 2.51
Weight (kg), mean ± SD: weight
control group (N = 22) 96.35 ± 23.57
Gender (% male): weight control
group 20%, glucose monitoring group
24%, overall 39 women/11 men
Age (years): overall average 54 years,
weight control group 54.0, glucose
monitoring group 53.5
Ethnic groups: not given
Losses to follow-up: 5 (10%) –3
from weight control group and 3 from
glucose monitoring group
Primary outcomes
used: HbA1
Secondary
outcomes used: 
self-reported
depression, weight in
kg, FBG, BP ,
triglyceride levels,
total cholesterol levels,
HDL cholesterol,
decreases in
medication (others
reported only for
12 weeks)
Individual preferred
learning style
addressed?: no
Any subgroups (e.g.
ethnic groups):
Normal range(s) for
outcomes: FBG levels
60–120 mg/dl
HbA1 6.5 ± 0.5%
How outcomes
assessed: Beck
Depression Inventory
Scale for depression
(self-report), BP nurse,
laboratory
physiological
measures, self-report
compliance
Validated: yes
Timing of outcomes
same for both
groups: yes
Length of follow-up:
12 months from
inception
continuedHealth Technology Assessment 2008; Vol. 12: No. 9
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Reference and  Intervention Participants Outcome 
design measures
Outcomes Weight control group  Glucose monitoring group Differences 
(n = 22) (n = 23) between groups
HbA1 (%) 10.44 ± 2.16 10.19 ± 2.29
Beck Depression Inventory No data provided
FBG (n = 22) 210 ± 73.1 216.2 ± 58.7
Decreases in medication (%) Oral agents: 64 Oral agents: 73 NS
Insulin: 64 Insulin: 83
Serum lipids did not differ between groups. Analysis for BP , triglyceride levels, total cholesterol levels and HDL cholesterol
only tested before and after
Methodological comments
Allocation to treatment groups: randomisation blocked according to sex and % overweight, no other details
Blinding of outcome assessors: nurse unaware BP , HbA1 not applicable, others unclear
Allocation concealment: not stated
Analysis by ITT: no
Comparability of treatment groups: no significant differences between groups reported
Method of data analysis: Repeated-measures ANOVA used to compare physiological changes in patients in two groups. 
p-Values given
Sample size/power calculation: no
Attrition/drop-outs: reports 10%; however, numbers for outcomes also reduced but no details
General comments:
Generalisability: approximately two-thirds of patients were self-referred (and perhaps more motivated), so may not be
generalisable to all patients
Other:
medication, but no praise or
reinforcement was given for BG
control. Sessions as intervention
group. 
Duration of intervention:
12 weeks
Compliance: Assessed by self-report
records and by a ‘marked item’
technique. Patients used 89.1% of the
assigned strips during treatment and
70.2% during the follow-up period.
They detected 86.7% of the marked
items during treatment and 62.8%
during follow-up
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Adequate
6. Were the point estimates and measure of variability presented for the primary outcome measure? Partially
7. Did the analyses include an ITT analysis? Unknown
8. Were withdrawals and drop-outs completely described? Reported
Quality criteria for RCTs (CRD Report 4)Appendix 5
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Reference and  Intervention Participants Outcome 
design measures
Study: Wing et al.,
198873
Source: Journal
article
Country: USA
Setting: Unclear
Language: English
Trial design: RCT
Common procedure to both groups: 
Weight control programme. Participated in a
lecture-discussion on behavioural weight control,
given individualised calorie goals and recorded all
intake. Taught about caloric values of food groups
and trained in portion size estimation. Exercise
(walking) was stressed, and given gradually
increasing exercise goals. Other lessons focused on
behavioural strategies for controlling cues for eating,
dealing with social situations involving food,
changing cognitions about food, motivation and self-
reinforcement and problem solving. Deposited
money at start and refunded for every pound of
weight lost and for attending 
Both groups given free glucometers and asked to
monitor BG 12 times/week. Trained in its use
Intervention 1: self-regulation education:
Topics: extensive training in how to use SMBG
information; this information was given gradually
over the course of the programme. Meetings 1–5
given homework tasks to demonstrate the effect of
diet and exercise on BG control, and given
examples; these were then discussed at later group
meetings. Meetings 6–9 given goals for BG which
were ‘good’ and ‘fair’. Monitored how many within
each range. Then taught to use the readings to self-
regulate their behaviours using reinforcement.
Meetings 10–13 refunded deposit money for
behaviour changes and other criteria used in
previous phases. Not asked to adjust treatments in
response to SMBG.
Provider:
Sessions: 13 sessions
Delivery: in person
Treatment changes: treatment changes in both
groups monitored by physician and followed
standard algorithm
Training of trainers:
Theory:
Intervention 2: self-monitoring education
No additional training in using SMBG information 
(as int. 1 had) 
Duration of both interventions: 
13 meetings over 16 weeks (held weekly for
10 weeks and every 2 weeks for the following
6 weeks). Follow-up meetings held every 2 weeks
for the next 3 months and at monthly intervals for
the following 3 months. 10 months total 
Were care programmes identical: unclear
Eligibility criteria: 
Inclusion: >20%
overweight, 30–65 years
old, met NDDG (1979)
criteria for Type 2 diabetes
How selected: newspaper
advertisements used to
recruit
Numbers involved: total
N = 20, int. 1 = 10, 
int. 2 = 10
Numbers on insulin: 0.
Tablets 16; diet alone 4
Type of diabetes: Type 2
Duration of diabetes: 
not reported
Baseline measurements
of outcome parameter
(mean ± SE): 
HbA1: int. 1 10.57% ±
0.44, int. 2 10.54% ± 0.55
BMI: 35.4 ± 1.05
Gender (M/F): 7/13
Age ranges: average
53.3 years (range 38–60)
Ethnic groups: not
reported
Losses to follow-up: 
3 in total, 1 in int. 1, 2 in
int. 2 (1 death, 2 refusal)
Compliance: all attended
all 16 weeks
Primary
outcomes used:
HbA1
Secondary
outcomes used:
BMI
Individual
preferred
learning style
addressed?: no
Any subgroups
(e.g. ethnic
groups): no
Normal range(s)
for outcomes:
HbA1 6.1 ± 0.5%
How outcomes
assessed?:
laboratory
Validated?: yes
Timing of
outcomes same
for both groups:
yes
Length of 
follow-up: week
68 from inception
continuedQuality criteria for RCTs (CRD Report 4)
Health Technology Assessment 2008; Vol. 12: No. 9
109
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Outcome (mean ± SE) Intervention 1  Intervention 2 Differences between groups
(n = 9) (n = 8)
HbA1 (%) 10.8 ± 0.8 9.71 ± 0.78 Time × condition interaction, 
NS (based analysis on baseline of
those attending for follow-up)
Weight (BMI not reported at follow-up) (kg) 86.6 ± 5.6 94.8 ± 5. 9 Time × condition interaction, NS 
(based analysis on baseline of
those attending for follow-up)
Methodological comments 
Allocation to treatment groups: not described
Blinding of outcome assessors?: not described – not relevant for HbA1
Allocation concealment?: not described
Analysis by ITT?: no
Comparability of treatment groups: no report of any differences in baseline, many characteristics reported per total N only
Method of data analysis: ANOVA for repeated measures of the two treatment groups pretreatment and 1 year. Standard
error of mean reported
Sample size/power calculation: not reported
Attrition/drop-outs: percentages reported
General comments
Generalisability: self-selected sample 
Conflict of interests: biodynamics supplied glucometers and strips for SMBG
Other:
NDDG, National Diabetes Data Group. 
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Yes
5. Were outcome assessors blinded to the treatment allocation? Not applicable
6. Were the point estimates and measure of variability presented for the primary outcome measure? Partial
7. Did the analyses include an ITT analysis? Inadequate
8. Were withdrawals and drop-outs completely described? PartialAppendix 5
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Reference and  Intervention Participants Outcome 
design measures
Study: Gilliland
et al., 200274
Source: Journal
article
Country: USA
Setting:
Community
Language: English
Trial design: CCT
(3 groups)
Intervention 1: family and
friends (FF):
Topics: culturally appropriate
diabetes education materials, skill
building, social support. Three core
areas: exercise, diet and support.
Sessions named: get more exercise;
eat less fat; eat less sugar; together
we can (how to get/receive
support); staying on the path
(maintenance of lifestyle changes)
Intervention used Native American
values, Native American foods,
information on diet and exercise
and videos featuring Native
Americans. Consistent with Native
American learning, stories and
prayers were used. There were
written materials, in addition to
food and physical activity
demonstrations. Activities to
encourage discussion and sharing of
stories about living with diabetes.
Group physical activities and shared
healthy meal
Provider: mentor led
Sessions: 5 sessions, approximately
6 weeks apart for approximately 2 h
Delivery: in person in groups with FF
Treatment changes: 
Training of trainers: bilingual
community mentors trained on
each session
Theory: social learning theory 
Intervention 2: one-on-one
(OO)
Same written materials as given to
FF but in individual sessions for
~45 minutes
Control: usual care (UC)
Usual schedule of clinic visits and
activities. All participants received
comprehensive diabetes care
including professional and patient
education. This group did not
receive culturally specific
intervention materials
Duration of both interventions:
Sessions conducted during 
10-month period 
Were care programmes
identical: yes
Eligibility criteria: 
Inclusion: all Native American women
and men in local diabetes registries
18 years old, mentally and physically
able and resided in one of 8
communities
How selected: placed into groups by
community of residence 
Numbers involved: 104 evaluable
patients provided both baseline and
follow-up data (see below); 32 in FF,
39 in OO, 33 in usual care.
Numbers on insulin: total = 19: 2 FF,
10 OO, 7 UC. Tablets: total = 63: 25
FF, 23 OO, 15 UC. Diet alone: total =
22: 5 FF, 6 OO, 11 UC
Type of diabetes: Type 2
Duration of diabetes (mean ± SD):
FF 8.1 (5.3), OO 8.3 (6.4), UC 10.0
(6.6)
Baseline measurements of
outcome parameter (mean ± SD): 
HbA1: FF 8.3 (1.9), OO 9.2 (2.3), 
UC 7.9 (2.0)
BMI: FF 31.0 (5.6), OO 31.2 (6.8), 
UC 32.0 (6.1)
Weight (lb): FF 174.6 (35.4), OO 172.2
(37.2), UC 168.9 (33.8)
Diastolic BP (mmHg): FF 80 (9), OO 81
(12), UC 78 (10)
Cholesterol (mg/dl): FF 199 (51), 
OO 218 (50), UC 193 (43)
Triglycerides (mg/dl): FF 224(147), 
OO 290 (214), UC 214 (154) 
Gender (M/F): FF 9/23, OO 10/29, 
UC 3/30
Age (mean ± SD) (years): FF 60.2
(12.1), OO 59.9 (13.4), UC 60.2 (11.8) 
Ethnic groups: all participants Native
American
Losses to follow-up: 206 volunteered
to participate, 47 withdrew before
receiving intervention, 42 dropped out
during intervention, 13 did not have
information on covariates, 104 were
evaluable
Compliance: all evaluable patients
received full intervention
Primary outcomes
used: HbA1c, weight
Secondary
outcomes used:
diastolic BP ,
cholesterol,
triglycerides
Individual preferred
learning style
addressed?: no
Any subgroups (e.g.
ethnic groups): no
Normal range(s) for
outcomes: HbA1 not
reported
How outcomes
assessed: laboratory 
Validated: yes
Timing of outcomes
same for both
groups: yes 
Length of follow-up:
~1 year from
inception
continuedHealth Technology Assessment 2008; Vol. 12: No. 9
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Outcome groups  FF intervention OO intervention Control – usual care Differences between 
(mean ± SD) (across 3 arms)
HbA1 adjusted mean change +0.5 (0.3) +0.2 (0.3) +1.2 (0.4) p < 0.05
Combined
interventions vs
control, p < 0.05
Weight (lb) –2.0 (1.5) –1.8 (1.5) +1.7 (1.8) NS
Combined
interventions vs
control, p = 0. 05
Diastolic BP (mmHg) –6.5 (2.0) –0.4 (1.7) –0.3 (2.1) p < 0.05
Combined
interventions vs
control, NS
Cholesterol (mg/dl) –22 (11) –20 (11) –10 (16) NS
Combined vs control,
NS
Triglycerides (mg/dl) –178 (78) –48 (48) –69 (63) NS
Combined vs control,
NS
Methodological comments
Allocation to treatment groups: by community
Blinding of outcome assessors: not reported, not of concern for laboratory measures
Allocation concealment: not applicable
Analysis by ITT?: no
Comparability of treatment groups: at baseline groups differed in HbA1c, in number of patients receiving oral agents, in
hypertension. These differences were incorporated into statistical analyses
Method of data analysis: ANOVA for continuous variables, 2 or Fisher’s exact tests for discrete variables. Analysis of
covariance for intervention differences in HbA1c and weight. Covariates were sex, age, duration of diabetes, medication use,
two preintervention determinations of annual change in HbA1c and factors significantly different at baseline
Sample size/power calculation: none reported. Study size likely underpowered to detect differences in two interventions
Attrition/drop-outs: More women than men and more obese than non-obese participants were evaluable. Participants in
usual care were more likely to drop-out
General comments
Generalisability: Compared with the overall population of diabetic patients in the included communities, the patients who
were evaluable seem generally representative. However, the evaluable patients were more likely to be women and older.
Relatively high drop-out rate is a concern for generalisability
Conflict of interests: none reported
Other:
Were the groups similar at baseline in terms of prognostic factors? Reported
Were the eligibility criteria specified? Yes
Were outcome assessors blinded to the treatment allocation? Unknown
Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
Did the analyses include an ITT analysis? Inadequate
Were withdrawals and drop-outs completely described? Partially
Were participants likely to be representative of the intended population? No
Quality criteria for CCTs (CRD Report 4)T
his is a supplement to the list of excluded
studies by Loveman and colleagues.37
Trials excluded owing to study
design (i.e. not RCT or CCT, or
inappropriate comparator)
Albisser AM, Harris R, I, Albisser JB, Sperlich M. 
The impact of initiatives in education, self-management
training, and computer-assisted self-care on outcomes in
diabetes disease management. Diabetes Technol Ther
2001;3:571–9.
Gagliardino JJ, Etchegoyen G. A model educational
program for people with type 2 diabetes: a cooperative
Latin American implementation study (PEDNID-LA).
Diabetes Care 2001;24:1001–7.
Vallis TM, Higgins-Bowser I, Edwards L, Murray A,
Scott L. The role of diabetes education in maintaining
lifestyle changes. Can J Diabetes 2005;29:193–202.
Wendel I, Durso SC, Zable B, Loman K, Remsburg RE.
Group diabetes patient education. A model for use in a
continuing care retirement community. J Gerontol Nurs
2003;29:37–44.
Trials excluded owing to
inappropriate patient populations
(i.e. not adults with Type 2
diabetes)
Dijkstra R, Braspenning J, Huijsmans Z, Akkermans R,
van Ballegooie E, ten Have P, et al. Introduction of
diabetes passport involving both patients and
professionals to improve hospital outpatient diabetes
care. Diabetes Res Clin Pract 2005;68:126–34.
Ellis SE, Speroff T, Dittus RS, Brown A, Pichert JW,
Elasy TA. Diabetes patient education: a meta-analysis
and meta-regression. Patient Educ Couns 2004;52:
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Simmons D, Gamble GD, Foote S, Cole DR, 
Coster G. The New Zealand Diabetes Passport Study: 
a randomized controlled trial of the impact of a
diabetes passport on risk factors for diabetes-related
complications. Diabet Med 2004;21:214–17.
Steed L, Cooke D, Newman S. A systematic review of
psychosocial outcomes following education, self-
management and psychological interventions in
diabetes mellitus. Patient Educ Couns 2003;51:5–15.
Tankova T, Dakovska G, Koev D. Education and quality
of life in diabetic patients. Patient Educ Couns 2004;
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Trials excluded owing to the nature
of the educational intervention 
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provided or not reproducible)
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(i.e. no reports of diabetic control,
QoL or end-points)
Kirk AF, Mutrie N, MacIntyre PD, Fisher MB.
Promoting and maintaining physical activity in people
with type 2 diabetes. Am J Prev Med 2004;27:289–96. 
Appendix 6
114Psychometric instruments
A few studies used measures that were constructed
for the purposes of the study about which no
validation information was provided. Unfortunately,
the studies’ failure to use validated instruments or
to validate their own instrument means that these
results cannot be clearly interpreted. The use of
unvalidated psychometric instruments represents a
lost opportunity to collect valuable information.
Quality of life (QoL)
[AIC data removed]
The ADDQoL (Audit of Diabetes-Dependent
Quality of Life) questionnaire was used by Deakin
and colleagues.46 This is a 13-item questionnaire
in which questions have the format “if I did not
have diabetes, my [employment/social life/etc.]
would be [a great deal better – a great deal
worse]”. Each QoL item is scored by the
respondent on a seven-point scale (–3 to +3) and
the respondent then indicates which items are very
important (score 3), important (2), quite
important (1) or not important (0). To obtain the
final ADDQoL score, the item scores and
importance scores are multiplied for each of the
applicable items and the results averaged.
ADDQoL has been reported to have relatively
high internal consistency (Cronbach’s  = 0.85)
and an independent review found good evidence
for reliability and internal and external construct
validity. ADDQoL has not been tested specifically
on elderly or minority patient groups. 
A modified version of the Diabetes Quality of Life
(DQoL) measure was used by Trento and
colleagues.53–55 The DQOL measure was originally
designed for use in the DCCT (Diabetes Control
and Complications Trial). The original intent was
to evaluate the burden of an intensive diabetes
treatment regimen. However, it was also designed
for broader application in diabetes as the scale
items cover a range of issues relevant to diabetes
and its treatment. The instrument addresses
satisfaction with treatment, impact of treatment,
worry about the future effects of diabetes and
worry about social/vocational issues in addition to
an overall well-being scale. The items are
answered on a five-point scale. Test–retest
reliability ranges from 0.78 to 0.92. The test has
also been shown to have good internal consistency
in patients with either Type 1 or Type 2 diabetes.
QoL was tested by Kaplan and colleagues67 using a
previously validated scale used in chronic obstructive
pulmonary disease. The index conceptualises health
as two components: current state of health and
prognosis. The measure has three scales: mobility,
physical activity and social activity. Patients are also
classified as having any of 36 symptoms or problems
that might inhibit function. Levels of well-being are
the social preferences that society associated with
observable levels of functioning. 
Knowledge
Deakin and colleagues46 used a validated diabetes
knowledge questionnaire with 14 multiple-choice
questions and nine further optional questions for
patients using insulin. The questionnaire had been
previously validated on two separate populations,
one of which received diabetes care in their
community from a variety of providers and plans
whilst the other received diabetes care from a local
health department. The questionnaire was
considered reliable (Cronbach’s  > 0.70) and valid
for a variety of settings and patient populations
(although it could not clearly discriminate between
Type 1 and Type 2 diabetic patients).
Brown and colleagues52 used a diabetes knowledge
instrument developed specifically for the
population as part of a graduate nursing thesis
project but did not report any other details.
The Diabetes Knowledge scale – form A (DKNA)91
is a 15-item scale with Cronbach’s  > 0.82. 
The scale was used by Campbell and colleagues.51
The multiple-choice questions include questions
on the normal range for BG, the causes of
hypoglycaemia, insulin requirements during illness
and the status of rice as a carbohydrate food.
Additional items test basic survival information
and other valid content.
Knowledge of diabetes was tested by Trento and
colleagues53–55 using the GISED. This
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Appendix 7
Psychological instruments used in included trialsquestionnaire was developed by the Education
Study Group of the Italian Society for Diabetes.
The 38-item questionnaire was slightly modified to
clarify the meaning of some terms. The internal
consistency was found to be acceptable and
internal validity was checked by cluster analysis.
Kronsbein and colleagues63 used a knowledge
questionnaire that was designed for the trial
(DTTP–NIDDM). The questionnaire consisted of
21 multiple-choice items. Additional information
was not evaluated as it was in a German
publication.
Other validated instruments used
Additional instruments were used in various
studies. These instruments are not described here,
because the studies in which they were used did
not report the results of these measures at a 
12-month or later evaluation. 
The SF-36 was used to measure QoL in the trial by
Samaras and colleagues.72 An apparent variation
of this scale was also used by Ridgeway and
colleagues.69
The Beck Depression Inventory was used by Wing
and colleagues.70,71 Although this is a valid
psychometric instrument, the use of the
instrument has been questioned in patients who
are not depressed.
Ridgeway and colleagues69 used the Life Skills
cognitive knowledge of diabetes test provided by
the Diabetes Education Society and approved by
the American Diabetes Association.
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